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growing number of cancer survivors
With the ongoing improvements in early detecti on and treatment of cancer along with the 
ageing of the populati on, the number of cancer survivors is rapidly increasing in the Western 
world. In 2010, there were about 600,000 cancer survivors in The Netherlands, expected 
to increase to 915,000 in 2020 1. Cancer has increasingly been referred to as a chronic 
disease since the majority (59%) of the pati ents survive relati vely long-term (>5 years aft er 
diagnosis) 2. 
defi niti on of a ‘cancer survivor’
The concept of cancer survivorship and the populati on which the defi niti on covers has been 
widely discussed and interpreted over the last decades 3. Since the 1960’s, when treatments 
started to improve, health care practi ti oners defi ned “cancer survivors” as those persons 
who had survived at least 5 years since initi al diagnosis or treatment 4. The number of 
cancer survivors increased further in the 1970’s and 1980’s and the US Nati onal Coaliti on for 
Cancer Survivorship (NCCS), a ‘survivor-led advocacy organizati on’ was founded. One of the 
founders of the NCCS, Fitzhugh Mullan, describes his personal experience as follows (1985): 
‘Actuarial and populati on-based fi gures give us survival esti mates for various cancers, but 
those fi gures do not speak to the individual pati ent, whose experience is unique and not 
determined or described by aggregate data. Many pati ents are “cured” long before they 
pass the fi ve-year mark, and others go well beyond the fi ve-year point with overt or covert 
disease that removes them from the ranks of “cured”, no matt er how well they feel. Survival is 
a much more useful concept, because it is a generic idea that applies to everyone diagnosed 
as having cancer, regardless of the course of illness. Survival, in fact, begins at the point of 
diagnosis, because that is the ti me when pati ents are forced to confront their own mortality 
and begin to make adjustments that will be part of their immediate, and to some extent, 
long-term future ’ 5. 
The NCCS therefore defi nes a person diagnosed with cancer a survivor from the moment 
of diagnosis through the balance of his or her life 6. This defi niti on was also used by the 
Insti tute of Medicine (IOM) in their report “Lost in transiti on” 4 and was adapted by The 
Nati onal Cancer Insti tute’s Offi  ce of Cancer Survivorship. The latt er however also included 
family members, friends, and caregivers since they are also impacted by the survivorship 
experience 4. In this thesis we use the defi niti on of the NCCS and IOM, focusing only on 
the cancer survivor, and not including relati ves or caregivers. This defi niti on shows that 
potenti ally anyone with a diagnosis of cancer can be a survivor. This defi niti on also raises the 
awareness of the need to consider issues of  survival from the start of cancer treatment 4. 
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Why study the fate of (long-term) cancer survivors?
Scientific evaluations of new treatments and care protocols for cancer patients are 
traditionally based on biological outcomes, specifically disease-free and overall or relative 
survival 7. Although improving survival is an important issue in cancer treatment, evaluating 
(long-term) sequelae of treatment will finally determine the functional effectiveness of the 
treatment 8. Health-related quality of life (HRQoL) and other patient reported outcomes 
(PROs) are more and more recognized to be of importance 9, especially since many new 
treatments have only a marginal impact on survival rates, and many survivors face continuing 
physical and psychosocial problems after completion of primary treatment 7. Achieving and 
maintaining optimal well-being must be an important objective of current cancer treatment, 
cancer rehabilitation and aftercare.
In the past decade a growing number of studies has documented the high prevalence of 
short-term effects (e.g. hair loss, pain, nausea and vomiting, anemia), long-term effects 
(e.g. fatigue, pain, memory problems and sexual dysfunction) and late effects (e.g. 
second malignancies, cardiovascular disease and osteoporosis) of cancer treatment 10, 11. 
Furthermore, research shows that many survivors experience a decline in HRQoL, fear of 
recurrence, high levels of anxiety and depression, employment, insurance and financial 
problems and relationship difficulties 10, 12, 13. Due to these research findings concerns about 
long-term physical, psychosocial and economic effects of cancer and its treatment are 
increasingly being recognized and new therapies not only focus at maximizing cure but also 
at minimizing long-term effects. Up to now, most of these survivorship studies focused on 
survivors of common types of cancer like breast, colorectal and prostate cancer.
Thyroid cancer survivors: an underexposed group
Although the knowledge about cancer survivorship has grown in the past decade, survivors 
of rare tumours, like thyroid cancer, so far received little attention in the cancer survivorship 
literature. Each year 500-600 patients are diagnosed with thyroid cancer in The Netherlands 
2. Due to the increasing incidence and good prognosis of papillary and follicular thyroid 
cancer (exceeding >90% 5-year survival) 14 the number of thyroid cancer survivors is 
increasing rapidly. In 2000, 3800 people survived thyroid cancer diagnosed in the past 20 
years vs. 5500 in 2010, an increase of 45% 1. Treatment of thyroid cancer involves surgery, 
predominantly (near-) total thyroidectomy with or without lymphadenectomy, followed 
by radioiodine (iodine-131) therapy to ablate the remaining thyroid tissue. Depending 
on type and size of the tumour hemithyroidectomy could suffice. The removal of the 
whole thyroid gland is accompanied by a lifelong dependence on supplement therapy 
with exogenous thyroid hormone (levothyroxine), in the first years with dosing regimens 
suppressing thyroid stimulating hormone (TSH) production 15, 16. Despite the efficacy of 




distant metastases, even decades later 17. Therefore, intensive long-term periodical follow-
up is necessary. Given the longevity of thyroid cancer survivors and the radical surgery and 
aggressive postoperati ve radioiodine treatment accompanied by a lifelong dependence on 
exogenous thyroid hormone, possible (long-term) physical and psychosocial problems are 
of considerable concern. However, the number of studies focusing on quality of life of (long-
term) thyroid cancer survivors is limited. 
Cancer survivorship care: Informati on provision
Survivorship care includes four components: (1) preventi on and detecti on of new cancers 
and recurrent cancer; (2) surveillance for cancer spread, recurrence, or second cancers; (3) 
interventi on for consequences of cancer and its treatment; and (4) coordinati on between 
specialists and primary care providers to ensure that all of the survivor’s health needs 
are met 4. An essenti al factor of supporti ve cancer care across all four components is the 
provision of informati on. The goals of informati on provision are to assist pati ents in making 
treatment decisions, prepare pati ents for their treatment, increase treatment adherence 
and abiliti es to cope with the illness as well as to promote recovery 18, 19. Unti l the 1980s 
most doctors disclosed only selected informati on about cancer. With the introducti on of the 
concept of cancer survivorship in 1986, more att enti on has been paid to the informati on 
needs of cancer pati ents and their right to be fully informed, parti cularly in the Western 
world 20.  
Previous research showed that informati on needs are prevalent among cancer survivors 
and the majority (>80%) of cancer survivors even want to be fully informed 21-23.  The nature 
of informati on needs is associated with the stage across the cancer conti nuum. During 
diagnosis and treatment the most prominent informati on needs are informati on about 
disease stage, treatment opti ons and side-eff ects of treatment. Post-treatment, pati ents 
report a conti nued need for treatment related informati on and also informati on about 
rehabilitati on is important 22. Other studies showed that socio-demographic and clinical 
factors like age, sex, disease stage, marital status, educati onal level and ethnicity, may also 
infl uence informati on needs 18. For example, younger age has been associated with more 
informati on needs and female survivors have reported more psychosocial informati on needs, 
while males have reported more informati on needs related to treatment 24. Furthermore, 
informati on needs might also vary as a functi on of adjustment to cancer and it is suggested 
that personality traits may inhibit or assist informati on seeking behavior 25, 26.
A systemati c review showed that 6–93% of the cancer survivors report adequate informati on 
provision as an unmet need throughout the cancer conti nuum 27. Especially the informati on 
needs of cancer survivors post-treatment are unmet 22. This may be because health 
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care providers do not have enough time and resources to inform patients appropriately. 
Furthermore, patients may have difficulty understanding the often complex information or 
have problems with processing the potentially upsetting information 25. In addition, there is 
a discrepancy between the actual information needs of cancer patients and the perception 
of health care providers about the needs of cancer patients 28. It is important that this 
discrepancy disappears, since the provision of tailored information, that is congruent with 
patients’ needs, is an important determinant for patient satisfaction 29. Additionally, unmet 
information needs and dissatisfaction have been linked to negative PROs like increased 
emotional distress (anxiety and depression) and HRQoL 30, 31. However, the number of studies 
that investigated these associations is limited and inconclusive because of methodological 
flaws such as cross-sectional designs and use of self-developed and not yet validated 
questionnaires or single questions to assess information provision. 
aIms and OrganIzaTIOn Of THIs THesIs
The current thesis can be subdivided into two parts. Part I addresses the perceived level of, 
and satisfaction with, information received by cancer survivors in different stages of their 
disease and how this is related to PROs like HRQoL, distress (anxiety and depression) and 
illness perception. Part II addresses the (long-term) health-related quality of life of thyroid 
cancer survivors.
Part I - Information provision and patient reported outcomes
In the past decade, the role of information provision in (supportive) cancer care has been 
acknowledged. Throughout this thesis information provision is defined as all cancer-related 
information provided by the health care provider in oral, written or other form. Part I of this 
thesis is guided by the conceptual model presented in Figure 1. 
Investigating the current state of information provision and degree of satisfaction with 
information provision of cancer survivors is necessary to determine whether the information 
provision is sufficient, or whether improvements are necessary (centre of conceptual 
model). Therefore the aim of Chapter 2 was to assess the perceived level of and satisfaction 
with information received by melanoma cancer survivors with an internationally validated 
questionnaire 32. Furthermore, possible associations between clinical and socio-demographic 
characteristics and the perceived level of and satisfaction with received information were 
explored (left part of conceptual model). 
Furthermore individual differences in personality might be related to the perception of 
received information. Recently, a large amount of studies focused on the effects of Type 
D personality on clinical and psychological outcomes in different patient populations 33-35. 




the tendency to experience negati ve emoti ons (negati ve aff ecti vity) and to inhibit self-
expression in social interacti on (social inhibiti on) 36. The combinati on of the two personality 
traits possibly makes Type D pati ents vulnerable for inadequate informati on provision, since 
they probably experience more negati ve emoti ons associated with medical informati on 
and will probably not ask for further informati on if their needs are not met. Therefore, 
diff erences in the perceived level of, and sati sfacti on with, informati on received by Type D 
and non-Type D cancer survivors of diverse cancer types were described in Chapter 3. 
Next to the clinical, socio-demographic and psychological factors that might infl uence the 
perceived level of and sati sfacti on with the received informati on, some PROs might have 
a bidirecti onal relati onship with informati on provision (right part of conceptual model). 
Several studies have investi gated the relati onship between informati on provision and 
HRQoL, anxiety and depression, Chapter 4 gives an overview of these studies. 
Pati ents respond to their illness by forming cogniti ve and emoti onal representati ons of the 
illness that lead to coping responses 37. These illness percepti ons are a major determinant 
of HRQoL 38 and are possibly associated with informati on provision. Therefore, the aim of 
Chapter 5 was to examine the associati on between illness percepti ons and informati on 
provision among a diverse group of 3080 cancer survivors. 
The studies included in our systemati c review focused on cancer survivors without advanced 
disease. Pati ents with metastasized cancer might have diff erent informati on needs and 
percepti ons compared to pati ents with non-metastati c cancer. The objecti ve of Chapter 6 
was to measure the perceived level of, and sati sfacti on with, informati on received by pati ents 
with metastati c (stage IV) colorectal cancer as compared with pati ents with non-metastati c 
(stage I,II,III) colorectal cancer. Furthermore, associati ons of informati on provision with 
HRQoL, anxiety and depression, and illness percepti ons were examined for pati ents with 
metastati c disease only.
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satisfaction with, 
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Patient (including personality), 
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treatment and hospital 
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Chapters 5, 6 
Background characteristics Information provision Outcomes 
figure 1: Conceptual model of informati on provision and pati ent reported outcomes. The numbers 
indicate the chapter numbers of this thesis where the relati onship is discussed.
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Most studies described in the systematic review (Chapter 4) had a cross-sectional design 
and determination of causal associations was therefore difficult. The relationship between 
information provision and prospectively assessed HRQoL, anxiety and depression among a 
large group of lymphoma and multiple myeloma survivors was examined in Chapter 7. 
Part II - Thyroid cancer survivors: an understudied group
The first aim of Part II of this thesis was to assess trends in incidence, mortality, and survival of 
thyroid cancer in The Netherlands between 1989 and 2009 (Chapter 8). This chapter shows 
that the prevalence of thyroid cancer is rising. Given the longevity of thyroid cancer survivors 
and the radical surgery and aggressive postoperative radioiodine treatment accompanied by 
a lifelong dependence on supplemental exogenous thyroid hormone, possible (long-term) 
physical and psychosocial problems are of considerable concern. In Chapter 9 the existing 
literature on HRQoL of thyroid cancer survivors was systematically reviewed. The studies 
included in the review showed contradictory results and there were several methodological 
issues that impede drawing strong conclusions on the HRQoL of (long-term) thyroid cancer 
survivors. The main problem was the lack of a valid, thyroid cancer specific instrument to 
assess HRQoL. Most studies only used a general HRQoL questionnaire, which cannot capture 
the specific complaints associated with thyroid cancer and its treatment. The development 
of a thyroid cancer specific HRQoL questionnaire applicable in combination with the core 
questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC 
QLQ-C30) 39 was described in Chapter 10.
Since long-term thyroid cancer survivorship studies were lacking, the aim of Chapter 11 
was to assess (thyroid cancer specific) HRQoL among long-term thyroid cancer survivors 
and to compare this with the HRQoL of an age- and sex-matched normative population. The 
second objective was to investigate which clinical and socio-demographic characteristics 
and thyroid cancer specific problems were associated with HRQoL.
Fatigue is a common problem among patients with (subclinical) hyperthyroidism 40, as is the 
case for thyroid cancer survivors with suppressing doses of levothyroxine in the first years 
after surgery. It can therefore be expected that short-term thyroid cancer survivors (<5 years 
since diagnosis) report higher levels of fatigue compared to a normative population or long-
term thyroid cancer survivors (≥5 years since diagnosis) who have returned to a euthyroid 
state. Up to now, no study has focused on the level of fatigue among thyroid cancer survivors. 
Therefore, the aim of Chapter 12 was to obtain insight into the prevalence of fatigue among 
short-term (<5 years) and long-term (≥5 years) thyroid cancer survivors, by comparing a 
sample of thyroid cancer survivors with an age- and sex-matched normative population. 
Furthermore, associations between clinical and socio-demographic characteristics and 




In Chapter 13 the main fi ndings of this thesis will be discussed and implicati ons for future 
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INFORMATION PROVISION AMONG MELANOMA SURVIVORS
21
madam, The incidence of melanoma is rapidly rising which can lead to an increasing burden for 
health care providers 1. Informati on provision is one of the most important aspects of supporti ve 
cancer care. Providing informati on that is congruent with pati ents’ needs may lead to lower levels 
of distress, bett er quality of life, improved pati ent sati sfacti on and sense of control 2, 3. More disease 
knowledge can result in informed decision making and can have positi ve eff ects on treatment- and 
follow-up adherence leading to reduced follow-up visits 1. However, one of the most frequently 
reported unmet needs by cancer pati ents is informati on disclosure 4. There is a discrepancy between 
the actual informati on needs of cancer pati ents and the percepti on of health care providers about 
the needs of cancer pati ents 5. Health care providers are oft en sti ll reluctant to give the full amount 
of informati on about cancer and its treatment. Melanoma pati ents would appreciate especially more 
informati on concerning their diagnosis, treatment and skin conditi on 6.
We conducted a cross-secti onal study to measure the perceived level of, and sati sfacti on with, 
informati on received by melanoma pati ents 7. Pati ents diagnosed with melanoma between January 1st 
1998 and August 1st 2007 from three regional hospitals were selected. Melanoma was defi ned using 
the ICD-O codes: C44.0-C44.9 with morphology 8720-8790. Medical specialists sent their (former) 
pati ents a lett er to inform them about the study and a questi onnaire. The EORTC-QLQ-INFO26 
questi onnaire was used to evaluate the informati on received by melanoma pati ents 8.
Of the 699 melanoma survivors, 562 (80.4%) returned a completed questi onnaire. There were no 
demographic or clinical diff erences between respondents and non-respondents. Demographics and 
clinical characteristi cs of parti cipati ng pati ents are presented in Table 1. A large percentage of pati ents 
indicated the absence of informati on about diff erent aspects of melanoma, treatment and aft ercare 
(Table 2).
In multi variate linear regression analysis, none of the pati ent characteristi cs were signifi cantly 
associated with perceived informati on provision about the disease. More informati on about medical 
tests was associated with shorter ti me since diagnosis (ß = -0.10; p < 0.05) and a higher stage 
melanoma (ß = 0.19; p<0.01). More perceived informati on provision about treatment was signifi cantly 
independently associated with younger age (ß = -0.15; p<0.05), higher stage of disease (ß = 0.20; 
p<0.01) and higher educational level (ß = -0.10; p<0.05). Logistic regression analysis showed that 
satisfaction with information was independently associated with hospital of treatment (odds rati o, 
OR = 0.49 (95% CI 0.32-0.76), p<0.01), high educati onal level (OR = 0.63 (95% CI 0.41-0.99), p<0.05) 
and less frequent use of the internet for additi onal informati on (OR = 0.60 (95% CI 0.39-0.92), p<0.05).
Pati ents with a higher disease stage are more likely to undergo more medical tests and/or treatments 
due to the increased risk of recurrence and metastasis. Therefore these pati ents might get more 
att enti on and informati on from their health care providers compared to pati ents with stage I melanoma. 
Also, the majority of melanoma pati ents receive most informati on immediately aft er diagnosis. Aft er 
the completi on of treatment the contacts of the pati ents with their doctor will diminish 3, while the 
informati on need of the melanoma survivor may sti ll exist. Pati ents diagnosed and treated shortly 
before the completi on of the questi onnaire, might have a clearer picture of the informati on they 
received and therefore reported to have received more informati on. 
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Table 1: Demographics and clinical characteristics of participating patients (N = 562)
Total
n (%)











≤ 1.0 mm 275 (49%)
1.01-2.0 mm 149 (27%)
2.01-4.0 mm 100 (18%)
>4.0 mm 32 96%)
Treatment
Surgery 556 (99%)
Sentinal Node 113 (20%)
Lymphadenectomy 27 (5%)
Radiotherapy 3 (0.5%)





Two or more 174 (32%)
Hospital
Hospital A 168 (30%)
Hospital B 255 (45%)
Hospital C 139 (25%)
marital status
Married 416 (74%)
Never married 55 (10%)
Divorced/widowed 89 (16%)
education level
Higher education 161 (29%)
Intermediate education 242 (43%)
Secondary school 103 (19%)
2
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Table 1: Demographics and clinical characteristi cs of parti cipati ng pati ents (N = 562) (Conti nued)
Total
n (%)




















Younger and higher educated melanoma pati ents are more likely acti vely involved in decision-making 
processes and ask more questi ons. Older pati ents are reported to be less interested in detailed 
informati on and leave the provision of details up to the doctor 9.  Likewise, doctors can be prejudiced 
against older pati ents. Furthermore, older and less educated pati ents may have more diffi  culti es 
processing and remembering informati on they receive and may compensate for their reduced 
cogniti ve capacity by asking fewer questi ons to their specialist 9.
The observed variati on in informati on sati sfacti on levels between pati ents treated in diff erent 
hospitals can be explained by the variati on in pati ent-centred informati on giving, which is strongly 
related to informati on recall and understanding. Our fi nding that only 25% of the melanoma survivors 
wanted more informati on could be explained by the increasing internet use of melanoma pati ents 10. 
When pati ents are not sati sfi ed with the informati on received from their health care provider, they will 
search for additi onal informati on on the internet. 
Health care providers oft en have limited ti me and resources to provide the informati on that melanoma 
pati ents require. With growing evidence that well-informed pati ents are more sati sfi ed with their 
care, and do bett er clinically, eff orts are needed to improve the informati on provision to melanoma 
pati ents. Explorati on of the pati ents personal informati on needs must lead to a more pati ent-tailored 
approach of informing melanoma pati ents.  A good opportunity would be the implementati on of a 
survivorship care plan, which aims at providing a cancer survivor with a summary of their course of 
treatment, management of late eff ects, and strategies for health promoti on.
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Table 2: Perceived information provision characteristics (N (%))
received no 
information







Diagnosis 47 (9%) 309 (56%) 154 (28%) 41 (7%)
Spread disease 104 (19%) 271 (49%) 135 (25%) 37 (7%)
Cause disease 203 (37%) 226 (41%) 103 (19%) 17 (3%)
Under control 76 (14%) 258 (47%) 164 (30%) 48 (9%)
medical tests
Purpose test 134 (25%) 220 (41%) 157 (29%) 29 (5%)
Course test 125 (23%) 237 (44%) 144 (27%) 32 (6%)
Results test 74 (14%) 237 (44%) 188 (35%) 38 (7%)
Treatment 
Medical treatment 201 (38%) 162 (30%) 137 (26%) 30 (6%)
Non-medical
treatment
496 (94%) 26 (5%) 5 (1%) 2 (0%)
Expected result 182 (34%) 202 (38%) 122 (23%) 25 (5%)
Side effects 333 (62%) 131 (25%) 56 (10%) 14 (3%)
Expected results on 
disease symptoms
288 (54%) 163 (31%) 65 (12%) 14 (3%)
Expected results on
social life
423 (80%) 84 (16%) 18 (3%) 7 (1%)
Expected results on
sexual life
487 (92%) 32 (6%) 6 (1%) 5 (1%)
Other services
Additional help 484 (92%) 36 (7%) 6 (1%) 2 (0%)
Rehabilitation 481 (91%) 28 (5%) 14 (3%) 4 (1%)
Cope with cancer  
at home
441 (84%) 68 (13%) 16 (3%) 2 (0%)
Psychological
assistance
492 (94%) 29 (5%) 3 (1%) 2 (0%)
single items
Different care locations 472 (91%) 38 (7%) 9 (2%) 3 (0%)
Things to do to 
get better
399 (76%) 92 (18%) 25 (5%) 7 (1%)
not satisfied a little satisfied Quite satisfied satisfied
Satisfaction with       
information
72 (13%) 259 (48%) 164 (30%) 46 (9%)
not useful a little useful Quite useful Very useful




279 (52%) 259 (48%)
Received information 
on video or cd-rom
4 (1%) 538 (99%)
Wanted more information 135 (25%) 402 (75%)
Wanted less information 10 (2%) 518 (98%)
2
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CHaPTer 3
sati sfacti on with informati on provision in cancer 
survivors and the moderati ng eff ect 
of Type d personality
O. Husson, J. Denollet, S. Oerlemans, F. Mols




Objective: Optimal information provision is important in cancer survivorship, but satisfaction 
with this provision may depend upon individual differences in personality. We examined the 
effect of personality traits negative affectivity and social inhibition and their combined effect 
(Type D personality) on satisfaction with information received.
methods: Four population-based, cross-sectional surveys were conducted through the 
Eindhoven Cancer Registry (ECR). All individuals diagnosed with lymphoma, multiple 
myeloma, endometrial cancer or colorectal cancer (1998-2008) as registered in the ECR 
were eligible for participation. In total, 4446 patients, received questionnaires including the 
EORTC QLQ-INFO25 and the Type D personality scale (DS14); 69% responded (n=3080).
results: Nineteen percent of patients (n=572) had a Type D personality. On the information 
provision subscales of the EORTC QLQ-INFO25 (scale 0-100), the perceived receipt of disease 
specific (mean 46 vs. 51), medical test (56 vs. 63) and treatment information (37 vs. 42) was 
significantly lower for Type D patients compared to non-Type Ds (all Ps<0.01). Type D cancer 
patients were less satisfied with the received information (49 vs. 58;p<0.01) and found the 
received information less useful (55 vs. 61;p<0.01) compared to non-Type Ds. Multivariate 
linear regression analyses showed that Type D personality was independently associated 
with information about the disease (Beta=-0.09), medical tests (Beta=-0.12) and treatment 
(Beta=-0.08) and with satisfaction with information received (Odds ratio=0.54; 95%CI=0.44-
0.66;all Ps<0.01).
Conclusions:  This study showed that patients with a Type D personality perceived to receive 
less information and reported less satisfaction with the amount of received information as 
compared to non-Type D patients. 
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InTrOduCTIOn
Providing cancer pati ents with appropriate informati on is one of the most important aspects 
of cancer care across the whole cancer conti nuum. Informati on provision is defi ned as all 
cancer-related informati on provided by the health care provider/nurse in oral, writt en or 
other form 1. Adequate informati on provision can result in informed decision making, bett er 
treatment adherence, bett er health-related quality of life (HRQoL), lower levels of distress, 
improved sati sfacti on with care and sense of control 1, 2. However, one of the most frequently 
reported unmet needs by cancer pati ents in all phases of the disease is informati on 
provision 3. This indicates that health care providers and pati ents diff er in their percepti ons 
of informati on needs 4 and diff erences between health care providers in communicati on 
skills 5. Informati on provision can be diffi  cult since medical informati on is oft en complex and 
someti mes emoti onally charged (e.g. likelihood of survival) 6. The majority of cancer pati ents 
want as much informati on as possible about their disease, treatment and rehabilitati on 7. 
However, informati on needs vary by sex, age, cultural background, ti me since diagnosis, 
educati onal level, disease stage and as a functi on of adjustment to cancer 6, 8.
There also may exist substanti al diff erences in the informati on needs of cancer pati ents as 
a functi on of underlying individual diff erences in personality. It has been suggested that 
personality characteristi cs may inhibit or assist informati on seeking 9. Studies have shown 
that personality characteristi cs such as high internal locus of control, self-esteem and self-
effi  cacy are shown to contribute positi vely to informati on seeking 10-12, while nervousness 
formed an obstacle for seeking informati on for 20% of cancer pati ents 13. Informati on 
seeking is frequently described as a coping mechanism, where pati ents with a monitoring 
style tend to require more informati on and pati ents with a blunti ng style feel bett er with 
less informati on 14. However, litt le research to date has focused on the area of personality 
and informati on provision in cancer survivorship. 
Recently, a large amount of studies focused on the eff ects of Type D personality on clinical 
and psychological outcomes in diff erent pati ent populati ons 15-17. A distressed personality 
(Type D) is defi ned by the combinati on of two personality traits; the tendency to experience 
negati ve emoti ons (negati ve aff ecti vity) and to inhibit self-expression in social interacti on 
(social inhibiti on) 18.  Studies showed that cancer pati ents with a Type D personality 
experience a lower quality of life and mental health status 19, report higher rates of comorbid 
conditi ons and to report to feel more bothered by these conditi ons 20. Also, pati ents with a 
Type D personality had more negati ve percepti ons about their illness, were more concerned 
about their illness and felt that their disease more oft en infl uenced them emoti onally 21.  A 
possible explanati on for these negati ve illness percepti ons is that there might be a diff erence 
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in the perceived receipt of information between cancer patients with and without a Type D 
personality, however research on this topic is lacking. 
Therefore, the aim of this study was to evaluate differences in the perceived level of, and 
satisfaction with, information received by Type D and non-Type D cancer patients. We 
hypothesized that Type D patients would indicate to receive less information and to be less 
satisfied with it as compared to non-Type D patients, since they probably experience more 
negative emotions (for example anxiety, sadness, anger, depression, guilt) associated with 
medical information (negative affectivity) and will probably not ask for further information 
if their needs are not met (social inhibition).
meTHOds
setting and Participants
For this study, data from four large population-based cross-sectional surveys on patients 
of endometrial cancer, colorectal cancer, lymphoma and multiple myeloma was used 22-
26. These surveys were set up between 2008 and 2009 with the goal to evaluate various 
patient-reported outcomes among cancer patients. Data collection was done within 
PROFILES (Patient Reported Outcomes Following Initial treatment and Long term Evaluation 
of Survivorship). PROFILES is a registry for the study of the physical and psychosocial impact 
of cancer and its treatment from a dynamic, growing population-based cohort of both short- 
and long-term cancer survivors 22. PROFILES contains a large web-based component and is 
linked directly to clinical data from the Eindhoven Cancer Registry (ECR), which compiles 
data of all individuals newly diagnosed with cancer in the southern part of the Netherlands, 
an area with 10 hospitals serving 2.3 million inhabitants 27. Data from the PROFILES registry 
will be available for non-commercial scientific research, subject to study question, privacy 
and confidentiality restrictions, and registration (www.profilesregistry.nl).
All individuals diagnosed with Hodgkin lymphoma, non-Hodgkin lymphoma or multiple 
myeloma between 1999-2008 or with endometrial cancer or colorectal cancer between 
1998-2007 as registered in the ECR were eligible for participation. However due to the 
large number of colorectal cancer patients (n=5399) a weighted random selection of 2219 
patients based on tumour, sex, and year of diagnosis was made 25, 26. We excluded those 
patients who had cognitive impairment (based on medical records and advice attending 
specialist), had unverifiable addresses or had died prior to start of study (according to the 
ECR, hospital records, and the Central Bureau for Genealogy which collects information on 
all deceased Dutch citizens via the civil municipal registries). All the studies were approved 
by the certified Medical Ethics Committee of the Maxima Medical Centre in the Netherlands.
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data collecti on
Details of the PROFILES data collecti on method have been described previously 22. In 
summary, pati ents were informed about the study via a lett er from their (ex)-att ending 
specialist. The lett er explained that by completi ng the questi onnaire (online or by pencil-
and-paper), pati ents consented to parti cipate and agreed to the linkage of the questi onnaire 
data with their disease history in the ECR. Non-respondents were sent a reminder lett er and 
questi onnaire within two months.
sociodemographic and clinical characteristi cs
Pati ents’ sociodemographic and clinical informati on were available from the ECR. The ECR 
routi nely collects data on tumour characteristi cs, including date of diagnosis, tumour grade 
according to the Tumour-Node-Metastasis clinical classifi cati on 28, clinical stage 28, treatment, 
and pati ent background characteristi cs including date of birth and comorbidity at the ti me 
of diagnosis. Questi ons on marital status, educati onal level, and current occupati on were 
added to the questi onnaire.
Informati on provision
To evaluate the informati on received by cancer pati ents, the 25-item EORTC QLQ-INFO25 
questi onnaire was used 29. This questi onnaire incorporates four informati on provision 
scales and eight single items. The scales are as follows: 1) perceived receipt of informati on 
about the disease (four items regarding diagnosis, spread of disease, cause(s) of disease 
and whether the disease is under control), 2) medical tests (three items regarding purpose, 
procedures and results of tests), 3) treatment (six items regarding medical treatment, 
benefi ts, side-eff ects, eff ects on disease symptoms, social life and sexual acti vity) and 4) 
other care services (four items regarding additi onal help, rehabilitati on opti ons, managing 
illness at home, psychological support). The questi on format was as follows: “During your 
current disease or treatment, how much informati on have you received on”. The single 
questi ons concerned the perceived receipt of writt en informati on or informati on on CDs 
or tape/video, wanti ng to receive more or less informati on, and the sati sfacti on with the, 
amount of, and helpfulness of informati on. The answer categories of the items were ‘‘not at 
all’’, ‘‘a litt le’’, ‘‘quite a bit’’, and ‘‘very much’’, except for four items which had a dichotomous 
(yes/no) scale. Aft er linear transformati on, all scales and items range in scores from 0 to 100, 
with higher scores indicati ng bett er perceived informati on provision 2. The questi onnaire 
has been internati onally validated, and internal consistency for all scales is good (a > 0.70), 
as is test–retest reliability (intraclass correlati ons > 0.70) 29. Apart from the EORTC-QLQ-
INFO25 questi onnaire, two single questi ons about the use of Internet for seeking additi onal 
informati on were added (i.e., ‘‘Do you make use of the Internet?’’ and ‘‘Have you used the 
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Internet to look for information about cancer?’’), which could be answered with either yes 
or no.
Type d Personality
Type D personality was measured with the 14-item Type D Personality Scale (DS14) 18. The 
DS14 is self-administered and takes only a few minutes to complete. The 14 items of this 
scale are answered on a 5-point response scale ranging from 0 (false) to 4 (true). Seven 
of these items refer to “Negative Affectivity” (NA) or the tendency to experience negative 
emotions in general. The remaining 7 items refer to the patient’s level of “Social Inhibition” 
(SI) or the tendency to inhibit the expression of emotions in social relationships. Patients 
were categorized as having a Type D personality using a standardized previously established 
cut-off score of ³10 on both the NA and SI subscales 18, item response theory analyses 
showed that the DS14 has the highest information around this point 30. The DS14 is a valid 
and reliable scale with Cronbach’s α of 0.87/0.88 in our study sample and a test-retest 
reliability over a 3-month period of r = 0.72/0.82 for the two subscales, respectively 18. 
statistical analyses 
Routinely collected data from the ECR on patient and tumour characteristics enabled us 
to compare the group of respondents, non-respondents and patients with unverifiable 
addresses, using analysis of variance (ANOVA) for continuous variables and chi-square 
analyses for categorical variables. Furthermore, differences in sociodemographic, clinical 
characteristics and single items of the EORTC QLQ-INFO25 between patients with and 
without a Type D personality were also analyzed using ANOVA for continuous variables and 
chi-square analyses for categorical variables.  
The mean subscale scores of the EORTC QLQ-INFO25, stratified by 1) Type D personality, 2) 
non-Type D personality, were compared by analysis of covariance (ANCOVA). Confounding 
background variables included for adjustment in these analyses were determined a 
priori  31 and chosen to be age, sex, years since diagnosis, comorbidity, primary treatment 
(radiotherapy/chemotherapy) and educational level since previous studies have shown that 
these factors are related to information provision 23, 24, 32, 33. Also, the EORTC QLQ-INFO25 
subscale mean scores, stratified by 1) Type D personality (NA+/SI+), 2) SI only (NA-/SI+), 3) 
NA only (NA+/SI-) 4) the reference group (NA-/SI-), were compared with ANCOVA adjusted 
for the same variables as described above.
Four multiple linear regression analyses were carried out to investigate the independent 
association of Type D personality with the EORTC QLQ-INFO25 subscales and one logistic 
regression analysis was performed to investigate the independent association of Type D 
personality with satisfaction with the amount of received information (dichotomized item). 
For the logistic regression analysis, patients were categorized into two groups: (a) patients 
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who were unsati sfi ed or only a litt le sati sfi ed, classifi ed as unsati sfi ed; and (b) pati ents who 
were quite sati sfi ed or very sati sfi ed, classifi ed as sati sfi ed. All regression analyses were 
adjusted for clinical (years since diagnosis, tumour type treatment, comorbiditi es) and 
demographic (age, sex, educati onal level and marital status) variables and internet use for 
additi onal informati on since previous studies have shown that these factors are related to 
informati on provision 23, 24, 32, 33. 
All stati sti cal tests were two-sided and considered signifi cant if p < 0.05. All analyses were 
conducted using SPSS version 17.0 (Stati sti cal Package for Social Sciences, Chicago, IL, USA).
resulTs
respondents and non-respondents
Three thousand and eighty (69.3%) pati ents returned a completed questi onnaire. A 
comparison of respondents, non-respondents and pati ents with unverifi able addresses 
indicated that pati ents with unverifi able addresses were younger, with more years since 
diagnosis, and they were less oft en treated with surgery, and less oft en diagnosed with 
colorectal cancer. Non-respondents were more oft en female, and were less oft en treated 
with radiotherapy or chemotherapy 19.
Type d, sociodemographic and clinical characteristi cs
Nineteen percent (n=572) of the respondents could be classifi ed as having a Type D 
personality, 13% (n=406) scored above the cut-off  for NA only (NA+/SI-) and 17% (n=512) for 
SI only (NA-/SI+). Sociodemographic and clinical characteristi cs of cancer pati ents, strati fi ed 
by pati ents with 1) Type D personality (NA+/SI+), 2) SI only (NA-/SI+), 3) NA only (NA+/SI-) 
4) the reference group (NA-/SI-) are presented in Table 1. Pati ents with high NA only were 
more oft en female compared to the other three groups. Type D cancer pati ents and pati ents 
with high NA only more oft en reported comorbid diseases compared to cancer pati ents 
with high SI only and the reference group. No signifi cant diff erences between the groups 
were found in age, years since diagnosis, stage of disease, marital status, educati onal level, 
current occupati on.
Perceived informati on provision 
The single questi ons of the EORTC QLQ-INFO25 showed that most pati ents (69%) indicated 
that they received quite a bit or very much informati on about the diagnosis (Table 2). 
Around a third (31%) of the cancer pati ents stated that they were not or a litt le informed 
about the medical treatment of their cancer, almost half (47%) of the pati ents were not or 
a litt le informed about the expected results of treatment and 55% of the pati ents indicated 
that they did not receive any informati on on the possible side eff ects of their treatment.  
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Colorectal cancer 595 (42) 185 (46) 226 (44) 262 (46)
Endometrial cancer 308 (22) 118 (29) 119 (23) 141 (25)
Hodgkin lymphoma 80 (6) 18 (4) 23 (5) 25 (4)
Non-Hodgkin lymphoma 365 (26) 74 (18) 124 (24) 122 (21)
Multiple Myeloma 60 (4) 11 (3) 20 (4) 22 (4)
age at time of survey (mean ± SD) 65.7 (11.8) 66.1 (11.2) 66.3 (11.1) 65.3 (11.4) 0.49
age at time of survey 0.34
<50 years 129 (9) 28 (7) 45 (9) 47 (8)
50-70 years 718 (51) 210 (52) 258 (50) 320 (56)
>70 years 559 (40) 168 (41) 209 (41) 205 (36)
Years since diagnosis (mean ± SD) 4.6 (2.5) 4.6 (2.6) 4.6 (2.5) 4.4 (2.5) 0.55
Years since diagnosis 0.73
1-5 years 908 (65) 258 (64) 331 (65) 382 (67)
>5 years 498 (35) 148 (37) 181 (35) 190 (33)
sex <0.001
Male 651 (46) 133 (33) 251 (49) 238 (42)
Female 757 (54) 273 (67) 261 (51) 334 (58)
stage at diagnosis 0.08
I 447 (50) 163 (54) 178 (52) 202 (50)
II 238 (26) 71 (23) 108 (31) 117 (29)
III 191 (21) 54 (18) 50 (15) 69 (17)
IV 27 (3) 15 (5) 9 (3) 15 (4)
Primary treatment
Surgery 898 (64) 303 (75) 344 (67) 399 (70) <0.001
Chemotherapy 528 (38) 135 (33) 164 (32) 182 (32) 0.03
Radiotherapy 373 (27) 110 (27) 144 (28) 145 (25) 0.75
Comorbidity+ <0.001
None 474 (34) 86 (21) 154 (30) 136 (24)
One 412 (29) 109 (27) 153 (30) 146 (26)
Two or more 522 (37) 211 (52) 205 (40) 290 (51)
marital status 0.89
Partner 1047 (75) 310 (77) 387 (77) 427 (76)
No partner 341 (25) 92 (23) 118 (23) 137 (24)
education level 0.72
University 305 (22) 85 (21) 121 (19) 128 (20)
Intermediate 413 (30) 130 (33) 161 (32) 170 (31)
Secondary 429 (31) 131 (33) 147 (29) 169 (31)
Primary or none 234 (17) 54 (14) 72 (14) 85 (15)
Current occupation 0.35
Employed 285 (21) 69 (18) 99 (20) 102 (19)
Unemployed 1066 (79) 326 (83) 396 (80) 448 (82)
+ adapted Self-administered Comorbidity Questionnaire49
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Other treatment related informati on was scarce. Only a few cancer pati ents (8-18%) 
indicated that they received quite a bit or very much informati on about other services (e.g. 
psychological support, additi onal help outside the hospital) or things to do to improve their 
health (23%).
Overall, 41% of the pati ents were unsati sfi ed or just a litt le sati sfi ed with the informati on 
they received and 35% found the informati on a litt le or not useful at all. Almost a quarter 
of the pati ents wanted to receive more informati on regarding the cause of their cancer, 
complicati ons and long-term eff ects of treatment, aft er care and coping with the disease, 
and overall informati on on cancer. More than two-thirds of the pati ents (71%) stated that 
they received writt en informati on. The internet was used by 1512 parti cipants (52%) of 
which 1090 parti cipants (72%) had used it to search for additi onal informati on about their 
cancer. 
Type d and perceived informati on provision
Type D cancer pati ents indicated that they received less informati on on all single items 
of the EORTC QLQ-INFO25 compared to non-Type D cancer pati ents (p<0.01), except for 
expected results of treatment on social and sexual life, psychological assistance and other 
care locati ons. There were no signifi cant diff erences between Type D pati ents and non-Type 
D pati ents in the receipt of writt en informati on (69% vs. 71%), wanti ng less informati on (5% 
vs. 3%) and use of internet for additi onal informati on (39% vs. 36%). A greater percentage 
of Type D cancer pati ents wanted more informati on compared to non-Type D pati ents (30% 
vs. 22%; p<0.01).
The ANCOVA revealed a signifi cant eff ect of Type D personality on the subscales disease 
specifi c informati on, medical test informati on, treatment informati on, sati sfacti on with 
received informati on, and usefulness of informati on, aft er adjustment for diff erences in age, 
sex, years aft er diagnosis, comorbidity, primary treatment (radiotherapy/chemotherapy) 
and educati onal level (all p<0.01). There was no signifi cant diff erence between Type D and 
non-Type D cancer pati ents on the subscale informati on about other services. 
Additi onally, we compared mean EORTC QLQ-INFO25 subscale scores, strati fi ed by pati ents 
with 1) Type D personality (NA+/SI+), 2) SI only (NA-/SI+), 3) NA only (NA+/SI-) 4) the 
reference group (NA-/SI-) (Table 3). Results showed that Type D cancer pati ents perceived 
to receive less informati on about medical tests and score lower on sati sfacti on with the 
amount of received informati on and usefulness of the informati on compared to the three 
other groups (all p<0.01). The perceived receipt of disease and treatment informati on was 
lower for Type D cancer pati ents compared to the reference group and pati ents with NA only 
(all p<0.01). Pati ents with SI only perceived to receive less disease informati on compared to 
pati ents with NA only (p<0.05). 
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Diagnosis 113 (4) 786 (27) 1422 (49) 578 (20)
Spread disease 306 (11) 877 (31) 1190 (42) 450 (16)
Cause disease 1574 (55) 784 (28) 343 (12) 142 (5)
Under control 168 (6) 761 (27) 1286 (45) 641 (22)
medical tests
Purpose test 214 (8) 754 (26) 1334 (47) 544 (19)
Course test 150 (5) 749 (26) 1406 (49) 549 (19)
Results test 87 (3) 614 (22) 1512 (53) 624 (22)
Treatment
Medical treatment 295 (10) 580 (21) 1289 (46) 665 (23)
Expected result 575 (21) 730 (26) 1099 (40) 346 (13)
Side effects 798 (28) 768 (27) 929 (33) 314 (11)
Expected results on disease
symptoms
714 (26) 814 (29) 946 (34) 302 (11)
Expected results on social life 1274 (45) 959 (34) 437 (16) 150 (5)
Expected results on sexual life 1634 (58) 708 (25) 319 (11) 143 (5)
Other services
Additional help 1609 (57) 763 (27) 326 (12) 126 (5)
Rehabilitation 1866 (67) 565 (20) 269 (10) 90 (3)
Cope with cancer at home 1423 (50) 892 (32) 407 (14) 101 (4)
Psychological assistance 2032 (73) 521 (19) 177 (6) 66 (2)
single items
Different care locations 1557 (56) 764 (27) 370 (13) 111 (4)
Things to do to get better 1138 (40) 1036 (37) 513 (18) 128 (5)




Satisfaction with information 156 (6) 1002 (35) 1251 (44) 444 (16)
not helpful a little helpful Quite a bit 
helpful
Very helpful
Helpfulness of information 100 (4) 849 (31) 1318 (48) 506 (18)
Yes no
Received written information 2064 (71) 849 (29)
Received information on video 
or cd-rom
147 (5) 2760 (95)
Wanted more information 659 (23) 2228 (77)
Wanted less information 98 (4) 2700 (97)
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Multi variate linear regression analyses showed that Type D personality was independently 
and negati vely associated with perceived receipt of informati on about the disease, 
informati on about medical tests and informati on about treatment, but not with perceived 
receipt of informati on about other services. Logisti c regression analysis showed that Type D 
personality was negati vely associated with sati sfacti on with informati on (Table 4).
Younger age, less years since diagnosis and undergoing chemotherapy were also associated 
with more perceived informati on about the disease, medical tests and treatment. Higher 
educati onal level and internet use for additi onal informati on were associated with more 
informati on about the disease and medical tests, while having one or more comorbid 
diseases was associated with less informati on about the disease and treatment. Undergoing 
radiotherapy was associated with more informati on about the treatment. Finally, less 
years since diagnosis, chemotherapy, no comorbiditi es and higher educati onal level were 
associated with more sati sfacti on with the received informati on (Table 4). 
dIsCussIOn
To our knowledge, this is the fi rst study that reported on the relati onship between Type 
D personality and informati on provision among cancer pati ents. The perceived receipt of 
informati on, and the sati sfacti on with and usefulness of the received informati on were low 
in general and even lower for cancer pati ents with a Type D personality. The perceived receipt 
of informati on was lower for Type D cancer pati ents compared to pati ents with high scores 
on NA or SI only and pati ent with low scores on both NA and SI, also aft er controlling for 
demographical and clinical variables.  The results were in agreement with our hypotheses. 
Table 3: Mean EORTC QLQ-INFO25 subscale scores for those with a Type D personality, those with a 
high score (≥10) on SI only, those with a high score (≥10) on NA only, and those with a low score (<10) 



















medical test informati on 65.0 (a) 62.2 (b) 60.1 (c) 56.3 (a)(b)(c) <0.01
sati sfacti on with informati on 61.3 (a) 52.9 (b) 56.5 (c) 49.1 (a)(b)(c) <0.01
Helpfulness informati on 63.9 (a) 58.7 (b) 58.9 (c) 55.0 (a)(b)(c) <0.01 
disease informati on 52.4 (a) 51.3 (b) 47.5 46.2 (a)(b) <0.01 
Treatment informati on 43.3 (a) 41.4 (b) 38.8 36.6 (a)(b) <0.01 
Other services 18.7 20.3 17.4 17.6 0.17
a = Type D pati ents signifi cantly diff erent from reference group (at least p<0.05);
b = Type D pati ents signifi cantly diff erent from pati ents with NA only (at least p<0.05);
c = Type D pati ents signifi cantly diff erent from pati ents with SI only (at least p<0.05)
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Non-Type D Reference Reference Reference Reference Reference Reference
Type D -0.09** -0.12** -0.08** -0.02 0.54 (0.44-0.66)** 0.58 (0.47-0.72)**
age -0.10** -0.07* -0.14** -0.12** 0.99 (0.98-1.00) 0.99 (0.97-0.99)**
Years since diagnosis -0.07** -0.08** -0.07** -0.12** 0.93 (0.90-0.96)** 0.94 (0.91-0.98)**
Tumour type
Colorectal cancer Reference Reference Reference Reference Reference Reference 
Endometrial cancer 0.09** 0.01 0.10** -0.04 1.49 (1.18-1.88)** 1.03 (0.80-1.32)
Hodgkin lymphoma 0.02 0.01 0.01 -0.02 1.49 (0.93-2.37) 2.14 (1.18 -3.90)*
Non-Hodgkin lymphoma 0.03 0.01 0.02 -0.04 1.37 (1.09-1.71)** 1.25 (0.98-1.60)
Multiple Myeloma 0.01 0.01 0.01 -0.01 1.21 (0.78-1.86) 0.78 (0.49 – 1.23)
sex
Male Reference Reference Reference Reference Reference Reference
Female 0.02 0.03 -0.01 0.01 0.88 (0.73-1.07) 1.07 (0.87-1.32)
radiotherapy
Yes Reference Reference Reference Reference Reference Reference
No -0.02 -0.04 -0.11** -0.04 0.96 (0.80-1.15) 0.87 (0.71-1.06)
Chemotherapy
Yes Reference Reference Reference Reference Reference Reference
No -0.07** -0.06* -0.26** -0.17** 0.71 (0.58-0.88)** 0.74 (0.59-0.93)*
Co morbidity
None Reference Reference Reference Reference Reference Reference
One -0.06* -0.04 -0.05* 0.02 0.94 (0.75-1.19) 0.92 (0.71-1.18)
 Two or more -0.07** -0.04 -0.06* 0.05* 0.68 (0.55-0.84)** 0.76 (0.61-0.96)*
educational level
University Reference Reference Reference Reference Reference Reference
Intermediate -0.03 -0.07* -0.05 -0.01 0.89 (0.69-1.14) 0.92 (0.70-1.20)
Secondary -0.08** -0.11** -0.07* -0.01 0.71 (0.55-0.91)** 0.63 (0.49-0.83)**
Primary or none -0.07* -0.09** -0.04 0.05 0.78 (0.60-1.02) 0.84 (0.63-1.12)
marital status
Partner Reference Reference Reference Reference Reference Reference
No partner 0.04* 0.03 0.04** -0.04* 0.95 (0.78-1.15) 0.85 (0.69-1.04)
employment
Unemployed Reference Reference Reference Reference Reference Reference
Employed -0.02 0.01 0.01 -0.03 0.95 (0.74-1.23) 1.06 (0.81-1.40)
Internet use for information
Internet Reference Reference Reference Reference Reference Reference
No internet -0.09** -0.08** -0.06 -0.02 0.91 (0.75-1.09) 0.70 (0.58-0.86)**
*p<0.05; **p <0.01
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Type D cancer pati ents perceived to receive less informati on compared to non-Type 
D’s. Individuals with a Type D personality tend to use more maladapti ve, passive coping 
strategies such as resignati on, denial, avoidance or withdrawal 34-36 and will not seek for 
support and informati on acti vely 36. Even if the doctor gives a large amount of informati on, it 
might be possible that the passive coping style leads to inadequate informati on processing, 
whereby the relevant informati on will not be picked up. Previous research showed that 
people experiencing higher levels of negati ve aff ect had diffi  culty with their att empts 
to access, obtain, and understand cancer informati on 37. Individuals with high scores on 
neuroti cism, who might also have high scores on NA 18, have a preference for informati on 
that reassures them 38 and will probably not seek out other informati on. Cancer related 
informati on might be judged as threatening by pati ents with high scores on NA and this will 
probably be accompanied by the experience of more negati ve emoti ons. The experience of 
negati ve emoti ons requires energy and can distract att enti on and diminish concentrati on. 
The recall of the received informati on could therefore be hindered. The perceived receipt of 
less informati on by Type D cancer pati ents could have resulted in lower levels of sati sfacti on 
with the received informati on and their indicati on that they wanted to receive more 
informati on as compared to non-Type D cancer pati ents.
Furthermore, pati ents with a Type D personality tend to be more socially withdrawn than non-
Type D’s, resulti ng in less social support 39.  Social support of a companion during the doctor-
pati ent conversati on has been found to increase pati ent understanding and involvement in 
consultati on 40, and will possibly also aff ect the recall of informati on. Previous studies also 
showed that one aspect of SI is feeling insecure and less competent when communicati ng 
with others 35, 41. These feelings might result in a lower willingness to ask questi ons during 
a consultati on. Type D pati ents may not follow through to get the informati on from their 
health care provider when their informati on needs are not met. Another interesti ng 
observati on in this context is that the perceived receipt of writt en informati on and the use 
of internet to search for additi onal informati on did not diff er between Type D and non-
Type D cancer pati ents in our study. This supports the idea that Type D cancer pati ents are 
less competent in acti vely communicati ng with their health care provider. In additi on, the 
informati on needs of cancer pati ents with a Type D personality might diff er from the needs 
of non-Type Ds, since a recent study showed that Type D cancer pati ents experienced worse 
illness percepti ons and found their illness less comprehensible compared to non-Type Ds 20. 
Future research should try to identi fy the specifi c informati on needs of cancer pati ents with 
a Type D personality. The Type D scale can probably be used as a screening tool in cancer 
pati ents to identi fy subgroups at risk for inadequate informati on provision. Type D cancer 
pati ents may benefi t from behavioural interventi ons that are aimed towards reducing 
maladapti ve coping strategies such as withdrawal 15. Such an interventi on should focus on 
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the empowerment of Type D patients to increase their health control and to reduce negative 
emotions 36. Giving special attention to patients with a Type D personality is important 
because both inadequate information provision and Type D personality are independently 
associated with worse health outcomes 1, 17, 42-44. It would also be interesting to investigate 
in future research whether health care practitioners identify Type D patients as a difficult 
group to work with.
This study has some limitations that should be noted. Although information was present 
concerning the demographic and clinical characteristics of the non-respondents and patients 
with unverifiable addresses, whether non-respondents more often had a Type D personality 
remains unknown. In addition, although Type D personality is a stable construct 45, the 
cross-sectional study design limits the determination of causal associations between the 
study variables. Furthermore, the validity of the cut-off scores used for the dichotomization 
of Type D personality has not been tested in cancer patients. Recent taxometric analyses 
have suggested that Type D may be better represented as a dimensional construct 46. This 
does not necessarily imply that dichotomization is inappropriate. The Type D construct has 
never inferred a true taxon that is defined by discontinuity between groups on an underlying 
dimension, and individuals belong only probabilistically to Type D and non Type D categories 
16. Rather, Type D refers to similar patterns of standing along the NA and SI dimensions that 
do occur across patients, and dichotomization helps to identify Type D patients who are 
more similar to their subgroup’s personality profile than non-Type D patients. Dimensional 
and categorical approaches to Type D do not need be to mutually exclusive, but rather 
represent two different ways of capturing psychological tendencies of individuals that 
warrant more research 47. 
Also, this study relies on self-report measures of information provision and it is not clear 
how much information was actually provided. The passive coping style of Type D cancer 
patients, including denial and avoidance, could lead to underreporting of the received 
information. It would therefore also be interesting to compare data on actual information 
provision with self-report data from questionnaires. Furthermore, the mean time since 
diagnosis was 4.6 years, which could hinder the recall of information received. Patients often 
forget a substantial amount of the information given because the information is complex 
and emotionally charged 48. Since the patients in the current study can be described as 
patients who are out of the acute phase of medical treatment and decision making, the 
results cannot be generalized to patients who are in the midst of their treatment phase or 
shortly after treatment completion. For future research, it would be interesting to compare 
the responses of patients in the midst of their treatment to determine possible differences 
between Type D and non-Type D’s in recall bias.
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A frequently reported unmet need is informati on about aft er care 3. In our study the perceived 
receipt of informati on about other services was low for all pati ents and we therefore could 
not identi fy diff erences between Type D and non-Type D pati ents on this scale. 
One of the strengths of our study is the high response rate among the diff erent populati on-
based tumour groups that facilitates generalizing the results to a larger populati on of cancer 
pati ents. In additi on, we evaluated a broad spectrum of possible confounding factors, 
including age at ti me survey, years since diagnosis, sex, marital status, educati onal level, 
primary treatment and comorbidity.
In conclusion, this study showed that pati ents with a Type D personality perceived to receive 
less informati on and reported less sati sfacti on with the amount of received informati on 
as compared to non-Type D pati ents. Future research could focus on the eff ecti veness of 
tailored communicati on possibly in combinati on with a behavioral interventi on to teach 
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background: Providing information, that is congruent with patients’ needs is an important 
determinant for patient satisfaction and might also affect health related quality of life 
(HRQoL), anxiety and depression levels of cancer survivors. 
design: The authors systematically reviewed the available literature on the relationship 
between information provision and health-related quality of life, anxiety and depression. A 
PubMed literature search for original articles published until February 2010 was performed. 
Twenty-six articles, all conducted between 1996 and 2009, which met the predefined 
inclusion criteria, were subjected to a quality checklist. 
results: Satisfied patients, patients with fulfilled information needs, and patients who 
experience less information barriers, in general have a better HRQoL and less anxiety and 
depression. Out of eight intervention studies that aimed to improve information provision, 
only one showed a positive association with better HRQoL.
Conclusion: Health care providers must pay more attention to patient-centered information 
provision. Additional research is needed to make definitive conclusions about information 
interventions, as most results did not reach statistical significance due to methodological 
constraints. The quick development of the relatively young research field of patient reported 
outcomes in cancer survivorship will make it possible to conduct better quality studies in the 
future.
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InTrOduCTIOn 
The provision of informati on to pati ents is one of the most important factors of supporti ve 
cancer care, across the whole cancer conti nuum. The goal of providing informati on is to 
prepare pati ents for their treatment, to increase adherence to therapy and to increase 
their abiliti es to cope with the illness and to promote recovery 1. However, the results 
of a systemati c review show that 6 to 93 percent of the cancer pati ents report adequate 
informati on provision as an unmet need throughout their cancer experience 2. Pati ents 
frequently report barriers to receive the informati on needed 3. Health care providers are 
oft en sti ll reluctant to give the full amount of informati on about cancer and its treatment, 
while the majority of cancer pati ents want as much informati on as possible about their 
disease, treatment and rehabilitati on 3. The informati on needs of cancer pati ents vary 
by gender, age, cultural background, educati onal level, cancer type, stage of disease and 
coping style 4, 5. Providing informati on, that is congruent with pati ents’ needs is an important 
determinant for pati ent sati sfacti on and might also aff ect health related quality of life 
(HRQoL) and anxiety and depression levels of cancer pati ents.
HRQoL is a multi dimensional construct that covers the pati ents’ percepti ons of his or her 
physical, emoti onal, social, and cogniti ve functi ons. HRQoL assessment is an important 
aspect of cancer care. HRQoL parameters providing prognosti c informati on can facilitate 
clinical decision making in terms of bett er treatment selecti on for cancer pati ents 6-8. 
Furthermore, cancer survivors oft en deal with adaptati on problems and assessment of 
their HRQoL could help to improve aft ercare 9. Cancer survivors experience high levels of 
psychological distress; a range of feelings and emoti ons that people experience in reacti on 
to cancer including depression and anxiety, with an important impact on HRQoL 10, 11. In 
the last decade, the role of informati on provision in cancer care has been acknowledged. 
Several studies have investi gated the relati onship between informati on provision and 
HRQoL, anxiety and depression, but results seem inconsistent 12. The evaluati on of a 
possible relati onship between HRQoL and informati on provision is diffi  cult because of the 
conceptualizati on of both constructs and methodological challenges in measuring these 
constructs. Throughout this review, informati on provision is defi ned as all cancer related 
informati on provided by the health care provider/nurse in oral, writt en or other form. 
From the perspecti ve of the pati ent, informati on provision is mostly measured in terms of 
‘sati sfacti on with received informati on’, ‘barriers to receive informati on’,’ informati on needs’ 
and ‘informati on quality’ and ‘informati on clarity’. Importantly, this review did not focus on 
informati on disclosure regarding the initi al cancer diagnosis or end of life issues. The goal of 
our review is to provide a complete overview of the literature on the impact of informati on 
on the HRQoL, anxiety and depression levels of cancer survivors. We used the defi niti on of 
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the US National Coalition for Cancer Survivorship that defines a person as a survivor from 
the moment of diagnosis through the balance of his or her life (http://www.canceradvocacy.
org/about/org/). We hypothesize that better information provision (fulfilled needs, less 
barriers, clear and high quality information) is related to higher satisfaction levels of cancer 
survivors regarding information which may impact HRQoL, especially mental health, anxiety 
and depression levels. 
meTHOds
search strategy
A computerized search of the literature through the search engines Pubmed and PsychINFO 
was performed on December 3, 2009. The search strategy combined the term ‘cancer’ with 
other key terms related to information provision and HRQoL. For ‘information provision’  we 
included the terms information, information provision, information disclosure, information 
needs, information satisfaction, information level, information barriers, written information, 
oral information, audiotape information, CDROM. For the constructs of HRQoL, anxiety and 
depression we included the terms quality of life, health related quality of life, health status, 
well-being, anxiety and depression. 
The reference lists of all identified publications were checked to retrieve other relevant 
publications, which were not identified by means of the computerized search. There were 
no restrictions with regard to the years of publication. The search yielded 5732 hits.
selection criteria
Studies that met the following criteria were included: (1) if they evaluated the relation 
between information provision and HRQoL, anxiety and depression in adult cancer survivors, 
and this evaluation was one of the key objectives of the study (2) if the publication was an 
original article (e.g. no poster abstract, letter to the editor etc.), (3) if the article was a full 
report published in English and (4) if it was published in a peer-reviewed journal. Studies 
were excluded for the following reasons: (1) if they were individual case reports or articles 
that reviewed the literature, (2) if the study was focused on end-stage cancer patients 
(terminal ill patients), because this patient group is dealing with specific end-of-life issues, 
(3) if the study focused on communication aspects (e.g. body language), (4) if the study 
focused on information provision to family members, (5) if the study focused on diagnosis 
or prognosis as primary information measure, or if (6) HRQoL was measured with one single 
item and was not a part of a validated questionnaire.
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Computerized search of databases and 
reference checking 
5695 articles excluded due to selection criteria 
and removal of duplicate articles* 
37 articles potential applicable 
Hard copies were obtained for more detailed 
evaluation of our selection criteria 
After applying our selection criteria to the hard 
copies, 25 articles were selected and were 
finally selected for this review 
Articles excluded because: 
- focused on diagnosis (9) 
- HRQoL was measured with one single 
item and was not a part of a validated 
 
figure 1: Flow diagram of papers accepted and rejected during selecti on procedure.
* The selecti on criteria are described in the methods secti on. 
The described inclusion and exclusion criteria were applied to our initi al 5732 hits. Based 
on their ti tles and abstracts, 37 arti cles met our criteria. The 37 hard copies were obtained 
and reviewed by three investi gators. Aft er careful review, 25 arti cles fulfi lled our selecti on 
criteria and were included in this review 12-36. The fl ow-chart of this selecti on procedure is 
shown in Figure 1.
Quality assessment
The methodological quality of each of the selected arti cles was independently assessed, by 
all three investi gators based on established criteria for systemati c reviews (Table 1) 37, 38. Each 
item of a selected study, that matched our criteria, was assigned one point. If an item did not 
meet our criteria or was described insuffi  ciently or not at all, zero points were assigned. The 
highest possible score was 13. Studies scoring 10 points or more were arbitrarily considered 
to be of ‘high quality’. Studies scoring between 6 and 10 points were rated as ‘adequate 
quality’. Studies scoring less than 6 points were considered to be of ‘low quality’.
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Table 1: List of criteria for assessing the methodological quality of studies on HRQoL, anxiety, 
depression and information provision among cancer survivors
Positive if with respect to
HRQoL
1.  A valid (health-related) quality of life, health status, anxiety or depression questionnaire is used. If items were 
deleted from the valid questionnaire, the new questionnaire must be validated. 
Information assessment
2.  A valid “information provision” questionnaire is used. If items were deleted from the valid questionnaire, the 
new questionnaire must be validated.
Study population
3. A description is included of at least two socio-demographic variables (e.g., age, employment   status, 
educational status).
4. A description is included of at least two clinical variables of the described patient population (e.g., tumour 
stage at diagnosis, treatment).
5. Inclusion and/or exclusion criteria are described.
6. Participation and response rates for patient groups have to be described and have to be more than 75%.
7. Information is given about the degree of selection of the patient sample (information is given about the ratio 
respondents versus non-respondents).
Study design
8. The study size is consisting of at least 50 patients (arbitrarily chosen).
9. The data is prospectively gathered.
10. The process of data collection is described (e.g., interview or self-report etc.).
Results
11. The results are compared between two groups or more (e.g., healthy population, groups with different 
treatment or age) and/or results are compared between at least two time points (e.g., pre- versus post-
treatment).
12. Mean, median, standard deviations or percentages are reported for the most important outcome measures.
13. Statistical proof for the findings is reported.
resulTs
study characteristics
In total, 25 studies were included, all published between April 1996 and December 2009. 
Different questionnaires with different outcome measures to assess HRQoL, anxiety and 
depression were used. All studies used different instruments to measure one or more 
aspects of information provision. Prospective, cross-sectional, observational as well as 
intervention studies were included. The main findings are summarized in Table 2. 
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methodological quality
The evaluati on of the methodological quality of the studies by the three reviewers yielded 
disagreement on some items, mostly due to diff erences in interpretati on. These were 
solved through discussion in a consensus meeti ng. The quality scores ranged from 7 to 13 
points (Table 2) and the mean quality score was 9.6. None of the studies had a low quality. 
Thirteen studies had a high quality 15, 17, 21, 22, 24, 26-28, 30, 31, 35, 36. The remaining twelve studies 
had an adequate quality 12-14, 16, 18-20, 25, 29, 32-34. General shortcomings of the included arti cles 
were the absence of a validated “informati on” questi onnaire, absence of informati on about 
the degree of selecti on of the pati ent sample, a cross-secti onal design, and the lack of 
comparison between two groups or ti me points. 
Health-related quality of life 
Fift een studies, 5 prospecti ve and 10 cross-secti onal, examined the relati on between 
informati on provision and HRQoL 12-14, 16-20, 26-29, 34-36. Three prospecti ve studies found a 
positi ve associati on between informati on sati sfacti on and HRQoL 12, 27, 35. A Swedish study of 
36 pati ents with a carcinoid tumour, showed a positi ve relati on between sati sfacti on with 
doctors’ provision of informati on and emoti onal functi on and global quality of life (QoL) 
at three of the four ti me points 12. In a study among 82 head and neck cancer pati ents, 
sati sfacti on with informati on before treatment was predicti ve of bett er Mental Component 
Summary scores 6-8 months aft er the end of treatment, but not to the Physical Component 
Summary scores 27. The third study among 211 Chinese nasopharyngeal carcinoma pati ents 
found that more sati sfacti on with the medical informati on provided one month aft er the 
end of radiotherapy, was related to a bett er QoL four months later 35. 
Two other prospecti ve studies focused on the clarity and quality of the informati on provided, 
and the need for informati on. Breast cancer pati ents reporti ng unclear informati on provision 
scored signifi cantly worse, up to 4 years aft er diagnosis, on 17 of the 27 QoL variables, 
including emoti onal functi oning, social functi oning and global QoL 26. Breast cancer pati ents 
who rated their level of informati on at baseline as high, experienced higher quality of life 
aft er three (p < .001) and six months (p = .049) 36. Overall, prospecti ve studies showed that 
sati sfi ed pati ents, pati ents who reported to receive clear and high levels of informati on, 
reported bett er mental HRQoL and global HRQoL. Positi ve associati ons between informati on 
provision and physical HRQoL have not been found.
Five out of six cross-secti onal studies found a positi ve relati on between informati on 
sati sfacti on and HRQoL 13, 17-20, 28.  Two studies among breast cancer survivors found a strong 
positi ve associati on between sati sfacti on with treatment and survivorship informati on and 
mental health and vitality 20, 28. A Briti sh study among 102 breast cancer and 112 prostate 
cancer pati ents concluded that aft er controlling for demographic and disease characteristi cs, 
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information satisfaction explained 21% of the variance in global QoL, 12% in physical well-
being, 13% in social well-being, 8% in emotional well-being, and 10% in functional well-
being (all p < 0.001) 18. This study, and an Italian study among a varied sample of 175 cancer 
patients, also found a positive association between satisfaction with information received 
and QoL 13, 18. Besides, the Italian study found no differences  in QoL of adequately versus 
inadequately informed patients 13. A French study of cancer patients with different diagnoses 
showed that higher global scores for QoL were related to higher satisfaction with all aspects 
of care, including the information provision 17. Contradictory, lower physical and emotional 
functioning also predicted higher satisfaction with the doctors’ information provision in this 
study. One cross-sectional study among 30 cancer patients undergoing chemotherapy found 
no differences in QoL between satisfied and dissatisfied patients 19. 
Four other cross-sectional studies focused on the clarity and quality of the information 
provided, and the need for information 14, 16, 29, 34. Worse physical and emotional functioning 
were significantly associated with worse ratings of information quality, more barriers 
to obtain information and a greater need for information in two large American studies 
among a sample of diverse cancer survivors 16, 29. Breast cancer patients who reported 
greater difficulty in accessing needed information or had greater unmet information needs 
experienced lower emotional, functional, and social well-being and worse physical, cognitive 
and role functioning as well as lower perceptions of health competence (p<0.01) 14, 34. In 
the cross-sectional studies better mental, physical and global HRQoL were associated with 
fulfilled informational needs, satisfaction with the received information, the receipt of good 
quality and clear information and less information barriers. However, one study found no 
difference in HRQoL 19 and one study reported conflicting results 17.
anxiety and depression
Five studies, three prospective and two cross-sectional, focused on anxiety and depression 
in relation to information provision 12, 25, 27, 33, 36. A study of 82 head- and neck cancer patients 
found satisfaction with information before treatment, to be predictive of depression but 
not anxiety, 6-8 months after the end of treatment 27. However, a study of 36 carcinoid 
tumour patients found a negative relation between satisfaction with doctors’ provision of 
information and anxiety and depression at the first three of four time points (T1-T3) 12. 
Breast cancer patients who rated their level of information at baseline as high were less 
depressed after three (p = .010) and six months (p < .001) 36.  The studies with a prospective 
design showed that, satisfaction with the received information and less information needs 
were independently related to less anxiety and depression.
The receipt of information was positively associated with the cancer patients’ physical 
condition and negatively with mood and depression in a Finnish cross-sectional study 33. A 
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study among breast, prostate, cervical and laryngeal cancer pati ents showed that pati ents 
who were dissati sfi ed with the received informati on were much more likely to be depressed 
and were marginally more likely to be anxious 25. The results of the cross-secti onal studies 
support the results of the prospecti ve studies.
Interventi ons
Some studies examined the eff ect of diff erent informati on interventi ons on the HRQoL or 
depression and anxiety levels of cancer pati ents 15, 21-24, 30-32. In a Swedish study, 210 consecuti ve 
cancer pati ents were randomized to one of three informati on conditi ons before the start 
of curati ve radiati on treatment 23. Compared to pati ents receiving standard informati on or 
standard informati on plus an extra brochure, pati ents who received standard informati on 
plus group and repeated individual informati on were signifi cantly more sati sfi ed with 
the informati on. However, there were no diff erences with respect to anxiety, depression, 
subjecti ve distress and QoL. A Dutch study investi gated the eff ects of the Interacti ve Breast 
Cancer CDROM, compared to the standard oral informati on, as a decision aid for 180 breast 
cancer pati ents with a choice between breast conserving therapy and mastectomy 30.  An 
overall positi ve eff ect of the CDROM was found on sati sfacti on with the general and breast 
cancer-specifi c informati on received. Further, an overall positi ve eff ect of the CDROM 
conditi on was found on generic QoL as well as on breast-specifi c QoL. Subsequent analyses 
revealed that at 3 and 9 months follow-up pati ents in the CDROM conditi on reported bett er 
general health than control pati ents. Additi onally, at 9 months follow-up, the CDROM 
conditi on reported bett er physical functi oning, and less pain and arm symptoms.
Three studies tested the effi  cacy of an audio-taped consultati on on the QoL of cancer 
pati ents showing no main eff ect of the interventi on on QoL or mood state 21, 22, 31. The fi rst 
study showed that the provision of a taped initi al consultati on resulted in more sati sfi ed 
pati ents than pati ents allocated to the control group 31. The other two studies among 
breast and prostate cancer pati ents showed that the provision of an audiotape of their 
primary treatment consultati on was not signifi cantly related to pati ent sati sfacti on with 
communicati on and was not signifi cantly aff ected by choice of receiving the audiotape 21. 
Furthermore, the compliance was low with 40% of the pati ents who did not listen to the 
audiotapes, mainly because they felt emoti onally not prepared to listen 21. However, pati ents 
rated the audiotape interventi on positi vely. Pati ents receiving the consultati on audiotape 
reported having been provided with signifi cantly more disease and treatment informati on 
in general and more informati on about treatment alternati ves and treatment side eff ects in 
parti cular, than pati ents who did not receive the audiotape 22. 
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A Greek study of 145 cancer patients who were randomized to receive a booklet about 
chemotherapy or not, showed that patients provided with the information booklet reported 
significantly higher rates of satisfaction with information than the control group, felt better 
and more informed, and perceived the information received as being clearer and more 
detailed 24. However, no significant benefits in anxiety, depression and QoL occurred. 
Another study randomized patients to receive oral information only or oral plus written 
information describing the disease and its associated surgery and outcomes 15. There was no 
significant difference in QoL at baseline, during the postoperative period or at 3 months post 
surgery. In addition, the QoL scores for each dimension (anxiety, depressed mood, positive 
well-being, self-control, general health, and vitality) were not statistically different between 
both groups at each time of analysis.
In a cluster randomized trial, no statistically significant effects of a Point of Information and 
Support (PIS) on anxiety or dissatisfaction levels was observed 32. However, 52% of centers 
in the experimental group did not implement the PIS in accordance with the protocol. The 
same study highlighted that a greater likelihood of dissatisfaction was associated with the 
presence of anxiety and/or depression 32. 
dIsCussIOn 
The aim of this systematic review was to summarize and evaluate the results of all studies 
focussing on the relationship between information provision and HRQoL and psychological 
distress. All five prospective observational studies found a positive relation between 
appropriate information provision (satisfaction with the received information, fulfilled 
informational needs, high quality and clear information) and mental and global HRQoL 
and a negative relation between appropriate information provision and depression and 
anxiety. The results of all 12 cross-sectional observational studies are in accordance with the 
findings of the prospective studies, however they also found a positive association between 
appropriate information provision and physical HRQoL. Only one out of eight intervention 
studies found a positive effect of information on HRQoL.
The prospective observational studies found a strong positive relation between adequate 
information provision and mental health but not physical health. A better understanding 
of a patients’ situation after the information provision or the receipt of information aimed 
at learning to cope with cancer or reducing distress might be responsible for better mental 
health and lower levels of anxiety and depression 35. Patients who had difficulties in obtaining 
the information they desire were found to have less confidence in their ability to deal with 
health-related issues 14.
4



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appropriate information provision lead to an improved health competence, a better sense 
of control over cancer, and better symptom management 14, 20. From the cross-sectional 
observational studies the direction of the relationship is not clear. A lack of information, 
or information of low quality, can lead to anxiety, depression or a decreased mental and/
or global HRQoL as suggested by the prospective studies. However some information 
can elevate patients’ distress levels 39. On the other hand anxiety can inhibit information 
processing, patients with a poorer mental health may have more difficulty to understand 
the information even when the information is of high quality, while patients with better 
global health are more satisfied beforehand because of their better emotional state 20, 40. 
The results of the observational studies were not confirmed by the intervention studies. This 
can be explained by the nature of the intervention studies. The objective of these studies 
was to test the efficiency of an information intervention in terms of information satisfaction, 
HRQoL, anxiety or depression, while the observational studies searched for a possible 
relation of information provision and HRQoL, anxiety or depression. Although patients in 
the experimental conditions overall rated the additional information positive, felt that they 
received more information, and were satisfied with the overall received information, only 
one intervention study observed positive relations with HRQoL, anxiety or depression. 
Most patients tend to adjust well to their disease and it is therefore possible that additional 
gains in HRQoL are not easily achieved 30.  A further explanation for these results might 
be the limited surplus value of the additional information given in the experimental 
conditions. Written information can be useful but is often non-specific and not tailored to 
patients’ information needs, this can lead to confusion or even elevation of anxiety and 
depression levels 31, 41. Audiotapes seem to facilitate patients’ requests to clarify earlier 
provided information and might enhance the recall of information. Interventions that 
aim to empower patients might be more useful and effective to decrease anxiety and 
depression and enhance HRQoL 23. Mostly, information is given in a neutral mode, with no 
direct attempt to promote active participation of the patient in the conversation and no 
attempts to influence patients’ inferences. The information provided has an impact on the 
cognitive level, with no emphasis on affect or the emotions related to the receipt of medical 
information. The intervention study with a CDROM as decision aid operates both at the 
cognitive and affective level. Patients who exit their consultation with the belief that they 
played an active role had better HRQoL scores 21. An intervention might therefore be more 
powerful with elements of counselling or psychotherapy 24. 
Another explanation for the lack of intervention effects on HRQoL, anxiety and depression 
levels may be the short duration of some of the interventions. The information booklet 
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about chemotherapy was presented for only 30 minutes 24. A recent meta analysis showed 
that psychosocial interventi ons should last 12 weeks or more to improve HRQoL 42. When the 
informati on is off ered for a short ti me it seems reasonable that pati ents forget a substanti ve 
amount of that provided informati on.  Further in six out of eight interventi on studies, cancer 
pati ents were randomized on individual level, which might result in contaminati on bias 
when the health care practi ti oner gives more than the usual standard informati on to the 
control group pati ents. When this happens, the eff ects of the experimental conditi ons might 
be underesti mated. The CDROM study used a quasi-experimental pre-test/post-test design 
and the PIS study used cluster randomizati on to overcome the problem of contaminati on 
bias and maximize internal validity 30, 32, 43.
In additi on, in some of the interventi on studies the compliance was low, parti cipants did 
not use the additi onal informati on. For example just below 40% of the pati ents in the 
experimental group did not listen to the audiotapes 21, and the Italian PIS-study showed 
that eventually only 48% of the centers indeed started a PIS 32. Results favouring these 
interventi ons are therefore diffi  cult to fi nd. When the centers who did not comply with 
the PIS protocol were removed from the analyses, the interventi on did improve pati ent-
centered outcomes 32. The interventi on studies show that it is not the quanti ty but the 
quality of informati on that is important for adequate informati on provision. The additi on 
of general informati on, with limited surplus value, to the standard informati on provided did 
not have an infl uence on HRQoL or anxiety and depression levels. Instead of adding general 
informati on to the standard informati on provided, the interventi ons must be directed to 
give each pati ent the specifi c, high quality informati on they need.
Another important issue is the role of cross-cultural diff erences in informati on provision. 
Truth telling and honest disclosure of cancer informati on appears to remain controversial in 
southern and eastern (European) countries 44. Awareness of a cancer diagnosis or prognosis 
is associated with more anxiety and depression, poorer physical, social and emoti onal QoL 
in those countries 45-47. However, among the included papers, the associati on between 
informati on provision and HRQoL, anxiety and depression was not diff erent between the 
diff erent countries. 
There are several methodological issues that impede drawing strong conclusions on the 
relati on between informati on provision and HRQoL. The included studies in this review all 
used diff erent measures and questi onnaires of informati on provision. There was only one 
validated informati on provision questi onnaire, the sati sfacti on with informati on profi le 27. 
All other studies used subscales of (validated) questi onnaires, self-developed and not yet 
validated questi onnaires or single questi ons. This makes it diffi  cult to compare the results of 
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the different studies. Only recently the European Organization for Research and Treatment 
of Cancer (EORTC) developed a questionnaire that evaluates the information received by 
cancer patients 48. It might be helpful to use this validated questionnaire in future studies 
because it is available in many languages which makes international comparison possible. 
Also, many different questionnaires are used to assess HRQoL. All these questionnaires 
claim to assess HRQoL or the individual’s perception about their position in life, however 
many questionnaires measure different constructs and therefore comparison between the 
studies is difficult. Taken into account these methodological limitations, the overall picture 
suggests a positive association between information provision and HRQoL.
We can conclude that doctors should provide patients with the information patients desire 
in order to optimize patient satisfaction. Satisfied patients, patients with fulfilled information 
needs, and patients who experience less information barriers, in general have a better HRQoL 
and lower levels of depression and anxiety. The consistency of these associations indicates 
that further attention must be paid to more patient-centered information provision taking 
into account the differences in information needs by gender, age, cultural background, 
educational level, stage of disease and coping style. Additional research is needed to 
make definitive conclusions about information interventions, as most results did not reach 
statistical significance due to methodological constraints. The recent emergence of cancer 
survivorship research and the increasing recognition of its importance will hopefully lead 
to more research focussing on good information provision interventions that are able to 
improve HRQoL and decrease psychological distress.
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Illness percepti ons in cancer survivors: 
What is the role of informati on provision?
O. Husson, M.S.Y. Thong, F. Mols, S. Oerlemans, A.A. Kaptein, L.V. van de Poll-Franse




Objective: The aim of this study was to provide insight into the relationship between 
information provision and illness perceptions among cancer survivors.
methods: All individuals diagnosed with lymphoma, multiple myeloma, endometrial cancer 
or colorectal cancer between 1998-2008 as registered in the Eindhoven Cancer Registry were 
eligible for participation. In total, 4446 survivors received a questionnaire including EORTC-
QLQ-INFO25 and the Brief Illness Perception Questionnaire; 69% responded (n=3080).
results: Lymphoma and multiple myeloma patients were most satisfied with the information 
they received and they perceived to having received more information about their treatment 
and other services (after care) compared to colorectal and endometrial cancer survivors 
(p<0.05). Multiple myeloma patients reported the highest scores (conceptualized their 
illness as very serious) on the illness perception scales. 
The perceived receipt of more disease-specific information was associated with more personal 
and treatment control and a better understanding of the illness, while the perceived receipt 
of more information about other services was associated with more negative consequences 
of the illness on the patients’ life, longer perceived duration of illness, less treatment control, 
more symptoms attributable to the illness, less understanding of, and stronger emotional 
reaction to the illness (p<0.05). Satisfaction with the received information was associated 
with better illness perception on all subscales, except for personal control (p<0.05). 
Conclusion: Improving the patients’ illness perceptions by tailoring the information provision 
to the needs of patients may help patients to get a more coherent understanding of their 
illness and will possibly lead to a better health-related quality of life.
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InTrOduCTIOn
Health-related quality of life (HRQoL) of cancer pati ents has been identi fi ed as an important 
endpoint in research and clinical practi ce. A major determinant of HRQoL, next to the illness 
itself, is the way pati ents’ perceive and respond to their illness 1. Research on these illness 
percepti ons is guided by the self-regulati on model  2. This model is based on the assumpti on 
that pati ents respond to symptoms and signs of illness by forming cogniti ve and emoti onal 
representati ons of the illness, that lead to coping responses 3. These representati ons can be 
divided into eight dimensions: 1. consequences, anti cipated and experienced consequences 
of the illness on the pati ent’s life; 2. ti meline, the perceived progress and durati on of the 
illness; 3. personal control, the percepti on of having self-control and whether the illness is 
easy to cure; 4. treatment control, how much treatment can help to control the illness; 5. 
identi ty, complaints or symptoms a pati ent att ributes to his/her illness; 6. illness concern, 
worries about illness; 7. coherence, how well the pati ent feels (s)he understands the illness; 
8. emoti onal representati on, how much pati ents are emoti onally aff ected by the illness 3.
Results of studies among diff erent groups of cancer pati ents show that negati ve illness 
percepti ons predicted worse HRQoL and depression aft er treatment 4-9 .
  
Another important factor associated with HRQoL in cancer pati ents is adequate informati on 
provision 10. The provision of informati on to pati ents is one of the most important factors 
of supporti ve cancer care across the whole cancer conti nuum. Appropriate informati on 
provision can result in informed decision making, bett er treatment adherence, lower levels 
of distress (anxiety and depression) and higher levels of HRQoL, improved sati sfacti on with 
care and sense of control 11-16. However, one of the most frequently reported unmet needs 
by cancer pati ents in all phases of the disease is informati on disclosure (6-93%) 17, especially 
the informati on needs of cancer survivors (post-treatment) are unrecognized 18. There is a 
discrepancy between the actual informati on needs of cancer pati ents and the percepti on 
of health care providers about the needs of these pati ents 16, 19. A recent study showed 
that informati on needs of cancer pati ents vary as a functi on of adjustment to cancer 20. 
The self-regulati on model proposes that pati ents form beliefs about their illness based on 
abstract and concrete sources of informati on available to them 7. Informati on provision 
seems to play an important role in illness percepti on and HRQoL 10 . However, research into 
the relati onship between informati on provision and illness percepti on is lacking. Therefore, 
the aim of this study was to examine the associati on between illness percepti ons and 
informati on provision. We hypothesized that pati ents who were sati sfi ed with the received 





In this study, data from five large population-based cross-sectional surveys on survivors 
of Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma, endometrial and colorectal 
cancer was used 21. These surveys were set up between 2008 and 2009 using data from the 
Eindhoven Cancer Registry (ECR), and were designed to evaluate different patient reported 
outcomes (e.g., late effects, physical and mental health status) among cancer survivors. The 
data collection procedure across those five surveys was comparable and is described below.
The ECR compiles data of all individuals newly diagnosed with cancer in the southern part of 
the Netherlands, an area with 10 hospitals serving 2.3 million inhabitants 22. All individuals 
diagnosed with Hodgkin lymphoma, non-Hodgkin lymphoma or multiple myeloma between 
1999 and 2008, or with endometrial cancer or colorectal cancer between 1998 and 2007 as 
registered in the ECR were eligible for participation. Due to the large number of colorectal 
cancer survivors (n=5399) a weighted random selection of 2219 patients based on tumour 
(colon/rectal), sex, and year of diagnosis was made 23, 24. The weights on tumour and sex 
were derived from the total distribution of colorectal cancer survivors in the ECR region. 
Patients with shorter years since diagnosis were oversampled for inclusion in future follow-
up assessments. 
After excluding those patients who had cognitive impairment (medical records and advice 
attending specialist), had unverifiable addresses, or had died prior to study initiation 
(according to the ECR, hospital records, and the Central Bureau for Genealogy which collects 
information on all deceased Dutch citizens via the civil municipal registries), data collection 
started between 2008 and 2009. All surveys were approved by a local certified Medical 
Ethics Committee. 
data collection
Survivors were informed of the surveys via a letter from their (ex)-attending specialist. 
The letter explained that by completing and returning the enclosed questionnaire, 
patients consented to participate and agreed to the linkage of the questionnaire data with 
their disease history in the ECR. Patients were reassured that non-participation had no 
consequences on their follow-up care or treatment. Non-respondents were sent a reminder 
letter and the questionnaire within 2 months.
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measures
Sociodemographic and clinical characteristi cs
Data on tumour and pati ent background characteristi cs were obtained from the ECR 25. 
The questi onnaire contained questi ons on sociodemographic data, including marital 
status, current occupati on, educati onal level, and comorbidity. Socioeconomic status was 
determined by an indicator developed by Stati sti cs Netherlands based on individual fi scal 
data from the year 2000 on the economic value of the home and household income, and 
provided as aggregate level for each postal code (average 17 households), which were then 
categorized into terti les 26. Disease progression (e.g. recurrence, metastasis, or new primary 
tumour) was determined through check of medical fi les. 
Informati on provision 
To evaluate the informati on received by cancer survivors, the EORTC QLQ-INFO25 
questi onnaire was used 27. The EORTC QLQ-INFO25 consists of 25 items, grouped into four 
informati on provision subscales: perceived receipt of informati on about the disease (four 
items regarding diagnosis, spread of disease, cause(s) of disease and whether the disease 
is under control), medical tests (three items regarding purpose, procedures and results 
of tests), treatment (six items regarding medical treatment, benefi ts, side-eff ects, eff ects 
on disease symptoms, social life and sexual acti vity) and other care services (four items 
regarding additi onal help, rehabilitati on opti ons, managing illness at home, psychological 
support). The questi on format was as follows: “During your current disease or treatment, 
how much informati on have you received on”. In additi on, it contains eight single items on 
receiving writt en informati on or informati on on CDs or tape/video, receiving more or less 
informati on, and items on the sati sfacti on with, amount of, and helpfulness of informati on. 
All responses were ranged according to a four-point Likert scale, except for the fi rst four single 
items which had a binary yes/no scale. All scales were linearly converted to a 0-100 scale, 
with higher scores indicati ng bett er perceived informati on provision. Internal consistency 
for all scales is good (α > 0.70), as is test–retest reliability (intraclass correlati ons > 0.70) 27.
Illness percepti ons 
Illness percepti ons were assessed using the Brief Illness Percepti on Questi onnaire (B-IPQ), 
a nine-item instrument used to assess cogniti ve and emoti onal representati ons of the 
illness 28. The English version of the B-IPQ was translated into Dutch by forward-backward 
translati on procedures and adapted for use among cancer pati ents. The B-IPQ uses a single-
item scale approach to assess percepti ons on a conti nuous linear 0-10 point scale. Five of the 
items assess cogniti ve illness representati ons: 1. How much does your illness aff ect your life 
(consequences); 2. How long do you think your illness will conti nue (ti meline); 3. How much 
control do you feel you have over your illness (personal control); 4. How much do you think 
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your treatment can help your illness (treatment control); 5. How much do you experience 
symptoms from your illness (identity). Two items assess emotional representations: 6. How 
concerned are you about your illness (concern) and 7. How much does your illness affect 
you emotionally (emotional representation). One item assesses illness comprehensibility: 
8. How well do you understand your illness (coherence). Answer scales of three items 
(personal control, treatment control and coherence) were reversed for statistical analyses 
to get the same response direction as the other five items. A higher score means worse 
illness perception.
Statistical analyses
Routinely collected data from the ECR on patient and tumour characteristics enabled us 
to compare the group of respondents, non-respondents and patients with unverifiable 
addresses, using t-tests for continuous variables and chi-square analyses for categorical 
variables.
Mean scores on the B-IPQ and EORTC-QLQ-INFO25 for different subgroups were compared 
using Analyses of Variance (ANOVA) or chi-square analyses for dichotomous items of EORTC-
QLQ-INFO25. Multivariate linear regression analyses were carried out in order to investigate 
the association between the four information provision subscales of the EORTC-QLQ-INFO25 
with the B-IPQ items, controlled for demographics and tumour characteristics. Eight linear 
regression models, respective of the eight single items of the B-IPQ, were estimated with 
outcomes. Multicollinearity was checked for every analysis. We reran these linear regression 
analyses stratified by tumour group (endometrial, colorectal, Hodgkin lymphoma, non-
Hodgkin lymphoma and multiple myeloma), age group (younger 65, older 65), gender, 
treatment modality (surgery, radiotherapy, chemotherapy), time since diagnosis (<2 years, 
>2 years), and comorbidity (none, 1 or >1), based on a priori assumptions that information 
provision or disease perception may be different among these strata. We tested for effect 
modification by including cross-product terms in the regression models for variables where 
stratified analyses showed different results as the main regression models. All statistical 
tests were two-sided and considered significant if p<0.05. All analyses were conducted using 
SPSS version 17.0 (Statistical Package for Social Sciences, Chicago, IL, USA).
resulTs
Patient characteristics
Three thousand and eighty (69.3%) patients returned a completed questionnaire. A 
comparison of respondents, non-respondents and patients with unverifiable addresses 
indicated that patients with unverifiable addresses were younger, with more years since 
diagnosis, and they were less often treated with surgery, and less often diagnosed with 
colorectal cancer. Non-respondents were more often female, and were less often treated 
with radiotherapy or chemotherapy21.
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Sociodemographic and clinical characteristi cs of cancer survivors, according to type of 
tumour, are presented in Table 1. Hodgkin lymphoma pati ents were signifi cantly younger, 
were more likely to have a job and reported less comorbid conditi ons than the other four 
pati ent groups. Multi ple myeloma pati ents where more recently diagnosed compared to 
the other four tumour groups. Lymphoma and multi ple myeloma pati ents did not receive 
surgery as a primary treatment, but signifi cantly more oft en received chemotherapy and 
radiotherapy compared to colorectal and endometrial cancer pati ents.

















age at diagnosis 61.8 ± 8.3 65.0 ± 9.7 41.2 ± 15.4 58.9 ± 12.4 63.0 ± 9.9 <0.01
age at ti me of survey 66.7 ± 8.5 69.4 ± 9.6 46.6 ± 15.3 63.7 ± 12.3 66.5 ± 9.4 <0.01





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Information provision and satisfaction
Satisfied cancer patients perceived to have received more information (disease, medical 
tests, treatment and other services) than dissatisfied patients (p<0.01; Table 2). Hodgkin 
lymphoma cancer patients perceived to have received more information and were more 
satisfied compared to the other four tumour groups. Non-Hodgkin and multiple myeloma 
cancer patients perceived to have received more information about treatments than 
colorectal and endometrial cancer patients (p<0.01). Endometrial cancer patients perceived 
to have received less information about other services (like options for after care) than the 
other four tumour groups (p<0.01).
Patients with a advanced stage of the disease at diagnosis (III or IV) were more satisfied 
with- and perceived to have received more information about treatment and other services 
(p<0.01) than patients with earlier stage of disease (I and II). Patients who underwent 
radiotherapy perceived to have received more information about medical tests, treatment 
and other services, while patients who underwent chemotherapy also perceived to 
have received more information about the disease and were more satisfied than their 
counterparts (p<0.01). Patients without comorbidities received more information about the 
disease, medical tests and treatment and were more satisfied than patients with one or 
more comorbidities (p<0.01). 
Men were more satisfied and wanted to receive more information than women (p<0.01), 
while women more frequently reported to want less information (p<0.05). Employed 
patients, patients under 65 years of age, patients with a partner and patients less than two 
years after diagnosis were more satisfied and scored better on most information provision 
subscales than their counterparts (p<0.01). Higher educated patients perceived to have 
received more information about the disease and medical tests than lower educated 
patients (p<0.05).
Illness perceptions
Endometrial cancer patients experienced less serious consequences and symptoms of their 
cancer, had shorter timeline beliefs, were less concerned and emotionally affected by their 
illness compared to the other four tumour groups (all p<0.05; Table 3). Endometrial and 
Hodgkin lymphoma cancer patients felt to have more personal control over their illness 
compared to the other three tumour groups, while Hodgkin lymphoma patients also felt 
their treatment could control their illness more compared to the other groups. Multiple 
myeloma patients scores highest on all illness perception dimensions, indicating worse 
illness perceptions. No differences between the cancer types were seen on coherence 
(understanding) of their illness.
Patients who were not satisfied with the received information, were less than two years 
after diagnosis, had a higher stage disease, had one or more comorbidities and who received 
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multi variate analyses
Receiving more disease specifi c informati on was associated with more personal control 
and treatment control over the illness, and bett er understanding of the illness (Table 4). 
More receipt of informati on about other services was associated with worse consequences 
and symptoms of the illness, less treatment control, more concerns and higher emoti onal 
impact. Sati sfacti on with received informati on was associated with bett er scores on all 
illness percepti on items, except for personal control. 
The associati ons between informati on about the disease, treatment, other services and 
illness percepti ons were not found in subanalyses among pati ents less than two years aft er 
diagnosis (data not shown). The relati on between treatment informati on and emoti onal 
representati on was not found for pati ents who underwent adjuvant chemotherapy and/
or radiotherapy (data not shown). The formal tests for interacti ons between treatment and 
years since diagnosis with the informati on subscales only confi rmed eff ect modifi cati on for 
years since diagnosis (data not shown).
Table 4: Standardized betas of multi variate linear regression analyses evaluati ng the associati on of 






















Informati on about 
disease
0.02 -0.04 -0.11** -0.10** 0.05 -0.05 -0.12** 0.03
Informati on about 
medical tests
0.01 0.03 -0.01 -0.05 -0.02 0.04 -0.03 -0.04
Informati on about 
treatment
0.02 -0.01 -0.01 -0.03 -0.04 0.04 -0.04 0.06
Informati on about 
other services
0.13** 0.04 -0.04 0.06* 0.13** 0.08** 0.05 0.10**
Sati sfacti on with 
informati on
-0.23** -0.1** -0.05 -0.11** -0.16** -0.19** -0.10** -0.24**
*< 0.05; ** < 0.01; Corrected for gender, age, ti me since diagnosis, tumour type, treatment, comorbidity, 
educati onal level, marital status and current occupati on
dIsCussIOn
In general, lymphoma and multi ple myeloma pati ents were most sati sfi ed with the received 
informati on and perceived to have received more informati on about their treatment and 
other services compared to colorectal and endometrial cancer survivors. Multi ple myeloma 
pati ents reported the worst scores on the illness percepti on scales, which is in accordance 
with their disease severity. The perceived receipt of more disease specifi c informati on 
was associated with more control and understanding, while the perceived receipt of more 
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information about other services was associated with worse illness perceptions. This last 
finding can be explained by the fact that patients who received more information about 
other services were the more severely affected patients and therefore had worse illness 
perceptions. Satisfaction with the received information was the strongest predictor of good 
illness perceptions. 
Our findings are in agreement with the results of a study among head and neck cancer 
patients 7. This study found that higher levels of satisfaction with information were related to 
stronger beliefs in the usefulness of treatment and the controllability of the illness, a better 
understanding of the illness, and a weaker illness identity, before treatment. However this 
study only reported correlation coefficients and did not look deeper into the relationship. 
Another study among six illness groups (without cancer) showed that personal and treatment 
control and coherence were best in hospitalized myocardial infarction patients, who just 
received a lot of disease related information, while patients who did not receive a diagnosis 
reported the worst identity scores, lowest understanding, shortest timeline perceptions, 
lowest treatment control beliefs and highest emotional response 28. Both studies were not 
specifically focused on the relation between information provision and illness perceptions. In 
our study we found that time after diagnosis was an effect modifier of the relation between 
information provision and illness perceptions. Patients diagnosed less than two years ago 
received more information and had worse illness perceptions; this might indicate that illness 
perceptions change over time. This finding could also be ascribed to information bias, as 
the majority of cancer patients receive most information immediately after diagnosis and 
patients who are more recently diagnosed could therefore better remember the amount of 
information they received.
Negative illness perceptions were associated with a worse HRQoL, poor adjustment to 
cancer, depression, treatment adherence and even the perceived benefit from surgery 6-8, 29, 
30. Besides the association of illness perceptions with HRQoL, adequate information provision 
and satisfaction with information also have a positive influence on HRQoL, anxiety and 
depression levels of cancer survivors  10. Our study showed that the illness perceptions were 
better for patients who were satisfied with the information they received. It is important 
to gain insight into patients’ perceptions of their illness in relation to their satisfaction with 
information prior to and during treatment 7 as patients compare the received information 
with their own ideas and theories of their illness (comparing own current health status with 
that of past and also health of others) and interpret their disease within this framework 31, 32. 
Inaccurate information provision, misunderstanding, or negative conceptualizations of the 
illness can all lead to maladaptive responses to the illness. Restructuring illness perceptions 
by providing appropriate information according to patients’ needs, may help patients to 
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get a more coherent understanding of their illness and will help in a bett er (long-term) 
adjustment to cancer 1, 8.
Pati ents diff er in the kind and amount of informati on they require and sati sfacti on is more 
related to the extent informati on needs are met, than to having received all possible 
informati on available.  The informati on needs of cancer pati ents vary by gender, age, 
cultural background, educati onal level, cancer type, stage of disease and coping style 33, 
34. For example, some pati ents (monitoring style) search for all kinds of informati on about 
their disease, while others (blunti ng style) distract themselves from informati on. Pati ents 
feel bett er when the informati on they receive is tailored to their own coping style 33. Health 
care practi ti oners need to move from a “one size fi ts all” method of informati on provision 
to a more pati ent centered approach that considers the unique needs, skills, values, illness 
percepti ons, and emoti ons of pati ents 35. Research shows that informati on needs of cancer 
pati ents are broader than disease and treatment related informati on, also encompassing 
issues of psychosocial well-being which are oft en not discussed 35, 36. The inclusion of 
a psychologist into the multi disciplinary oncology team could be helpful to identi fy 
maladapti ve illness percepti ons. Discussing psychosocial items more extensively could help 
pati ents interpret the informati on in the right way 1. Maladapti ve illness percepti ons could 
be changed by giving informati on meeti ng pati ents’ needs, when necessary in combinati on 
with an individualized behavioral interventi on. Empowerment of pati ents by teaching them 
adequate coping skills and self management training will translate into illness percepti ons 
refl ecti ng greater sense of control 37. More research into this area is needed. 
The present study has limitati ons that should be menti oned. Although the response rate was 
high and informati on was present concerning demographic and clinical characteristi cs of the 
non-respondents and pati ents of with unverifi able addresses, whether non-respondents 
declined to parti cipate in the study because of poor health remains unknown. Second, the 
cross-secti onal design of the study limits the determinati on of causal associati on between 
informati on provision and illness percepti on, and the change in illness percepti ons over ti me. 
Diff erent studies found that illness percepti ons predicted HRQoL, however a randomized 
controlled trial showed that pati ents’ illness percepti ons before consultati on (uncertainty 
and negati vely emoti onally involved) predicted pati ent sati sfacti on with the consultati on 38. 
Therefore more research is needed to the directi on of this relati onship. 
In conclusion, we have demonstrated that sati sfacti on with the received informati on was 
the most important factor associated with bett er illness percepti on. Improving the pati ents’ 
illness percepti ons by tailoring the informati on provision to the needs of pati ents can 
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CHaPTer 6
Informati on provision and pati ent reported 
outcomes in pati ents with metastasized colorectal 
cancer: results from the PrOfIles registry
O. Husson, M.S.Y. Thong, F. Mols, T. Smilde, G.J. Creemers, L.V. van de Poll-Franse




background: Patients with metastasized colorectal cancer (mCRC) have different information 
needs compared to patients with non-metastatic colorectal cancer (CRC). Appropriate 
information provision leads to better patient reported outcomes for patients with non-
metastatic disease.
Objective: To measure the perceived level of, and satisfaction with, information received 
by patients with mCRC as compared to those with non-metastatic (stage I,II,III) CRC. Also, 
associations of information provision with health status, anxiety, depression, and illness 
perceptions were investigated.
design: A cross-sectional population-based survey was conducted. 
subjects: All CRC patients diagnosed between 2002 and 2007 according to the Eindhoven 
Cancer Registry were selected. Response was 75% (n=1159; of which 139 had mCRC). 
measurements: Participants completed questionnaires on information provision (EORTC-
QLQ-INFO25), health status (SF-36), anxiety and depression (HADS), and illness perceptions 
(B-IPQ). 
results: The perceived receipt of information was quite comparable between CRC patients 
with and without mCRC. Only perceived receipt of treatment information was higher 
for patients with mCRC (45 v. 37; p<0.01). Sixty percent of the patients with mCRC was 
satisfied with the amount of received information and almost 30% wanted to receive more 
information. The perceived receipt of more disease information and information about other 
services was associated with worse health outcomes, while satisfaction with the received 
information was not associated with health outcomes
Conclusion: The findings of this study indicate that some improvements can be made in 
the provision of information to patients with mCRC. Adequate assessment of information 
needs of mCRC patients, as well as appropriate responses to these needs by providing 
the information in an appropriate way could possibly lead to improvements in patient 
satisfaction.
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InTrOduCTIOn
The provision of informati on to pati ents is one of the most important factors of supporti ve 
cancer care. Appropriate informati on provision can result in informed decision making, 
bett er treatment adherence, bett er health status, lower levels of distress, improved 
sati sfacti on with care and a sense of control 1-5. However, adequate informati on provision is a 
frequently reported unmet need among cancer pati ents across the whole cancer conti nuum 
6. There is a discrepancy between the actual informati on needs of cancer pati ents and the 
percepti on of health care providers (HCPs) about the needs of cancer pati ents 7, 8. Most 
cancer pati ents want as much informati on as possible, however this varies by gender, age, 
cultural background, educati onal level, coping style and stage of disease 5, 9, 10.
About one fi ft h of colorectal cancer (CRC) pati ents will present with metastati c disease, 
and 20-30% of pati ents will develop metastati c CRC (mCRC) aft er successful curati ve 
treatment of the primary tumour 11. Pati ents with mCRC are living longer due to earlier 
detecti on and eff ecti veness of treatments 12. It is important to ensure pati ents’ well-being 
during this phase of fi ghti ng against a potenti ally life threatening disease.  Pati ents with 
mCRC  experience decline in health status 13, report high levels of anxiety and depression 14 
and have problems with illness percepti on 15. Furthermore, they  are dealing with specifi c 
questi ons and uncertainti es concerning end-of-life issues, symptom relief and patt erns of 
decline 16.  For pati ents with advanced disease, informati on about the course of the disease, 
prognosis, available (palliati ve) treatment opti ons, how to manage disease symptoms and 
how cancer will aff ect daily life are the most important informati onal needs 17. Pati ents need 
to be aware of the nature of and the course of their disease to make informed medical 
decisions and to handle and plan this phase of their lives 7, 8, 16, 18, 19. However, a recent study 
showed that oncologists are oft en unwilling, unable or uncomfortable to honestly disclose 
and discuss informati on regarding diagnosis and prognosis with pati ents with advanced 
disease 20. In additi on, many HCPs avoid discussing the topic or withhold informati on 21. 
Furthermore HCPs tend to underesti mate pati ents’ need for informati on and overesti mate 
pati ents’ understanding of their prognosis 7.
Since a positi ve associati on was found between sati sfacti on with received informati on and 
health outcomes among cancer pati ents with less advanced disease 1, 22, it is important to 
study these relati ons among pati ents with metastati c disease. Therefore, the objecti ve of 
this study was to measure the perceived level of, and sati sfacti on with, informati on received 
by pati ents with mCRC (stage IV) as compared to those with non-metastati c (stage I,II,III) 
CRC. Second, our objecti ve was to investi gate the associati on of informati on provision with 





This study is part of a long-term follow-up assessment of CRC patients registered with the 
Eindhoven Cancer Registry (ECR). The ECR compiles data of all individuals newly diagnosed 
with cancer in southern Netherlands, an area with 10 hospitals serving 2.3 million inhabitants 
23. For this study, all patients identified from the ECR and diagnosed with CRC between 
2002 and 2007 were eligible for participation. A local certified Medical Ethics Committee 
approved this study.
data collection
Data collection started in January 2009 within PROFILES (Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation of Survivorship). PROFILES is a registry 
for the study of the physical and psychosocial impact of cancer and its treatment from a 
dynamic, growing population-based cohort of both short and long-term cancer survivors. 
PROFILES contains a large web-based component and is linked directly to clinical data from 
the Eindhoven Cancer Registry (ECR). CRC patients (N=1542) were informed of the study 
with a letter from their (ex-) attending surgeon. The letter explained that by completing and 
returning the enclosed questionnaire, patients consented to participate in the study and 
agreed to the linkage of the questionnaire data with their disease history in the ECR. Details 
of the data collection method have been previously described 24. 
measures
Sociodemographic and clinical characteristics
Patients’ sociodemographic and clinical information were available from the ECR. The ECR 
routinely collects data on tumour characteristics, including date of diagnosis, tumour grade 
25, clinical stage 25, treatment, and patient background characteristics. Since the ECR only 
collects clinical disease stage at primary diagnosis, we conducted a chart review to identify 
the respondents who have developed metachronous metastasis between initial diagnosis 
and the start of our study. Questions on marital status, educational level, current occupation 
and comorbidity at time of questionnaire were added to the questionnaire. 
Information provision
To evaluate the information received by cancer patients, the internationally validated 
EORTC QLQ-INFO25 questionnaire was used 26. The EORTC QLQ-INFO25 consists of 25 
items, grouped into four information provision subscales: perceived receipt of information 
about the disease (four items regarding diagnosis, spread of disease, cause(s) of disease 
and whether the disease is under control), medical tests (three items regarding purpose, 
procedures and results of tests), treatment (six items regarding medical treatment, benefits, 
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side-eff ects, eff ects on disease symptoms, social life and sexual acti vity) and other care 
services (four items regarding additi onal help, rehabilitati on opti ons, managing illness at 
home, and psychological support). Additi onally, it contains eight single items on for instance 
wanti ng to receive more or less informati on, and on the sati sfacti on with and helpfulness of 
the received informati on. Answer categories range from one (not at all) to four (very much), 
except for four items with a two point scale (yes/no). Aft er linear transformati on, all scales 
and the items range in scores from 0 to 100, with higher scores indicati ng bett er perceived 
informati on provision.
Health status
Health status was assessed with the validated Dutch version of the SF-36 questi onnaire 
which incorporates eight domains: physical functi on, role limitati ons due to physical health, 
bodily pain, general health percepti ons, vitality, social functi on, role limitati ons due to 
emoti onal health and general mental health 27. According to standard scoring procedures, 
the subscales were linearly converted to a 0–100 scale, with higher scores indicati ng bett er 
functi oning.
Anxiety and depression
Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression 
Scale (HADS). The HADS is a self-report questi onnaire comprising 14 items on a four-point 
Likert-scale; seven for depression and seven for anxiety 28. We used a score of eight as a cut-
off  value for both depression and anxiety 28, 29.
Illness percepti ons
Illness percepti ons were assessed using the Brief Illness Percepti on Questi onnaire (B-IPQ), a 
nine-item instrument used to assess cogniti ve and emoti onal representati ons of the illness 
30. The B-IPQ uses a single-item scale approach to assess percepti ons on a conti nuous linear 
0-10 point scale. Five of the items assess cogniti ve illness representati ons (consequences, 
ti meline, personal control, treatment control and identi ty), two items assess emoti onal 
representati ons (concern and emoti on) and one item assesses illness comprehensibility 
(coherence). 
stati sti cal analyses
Routi nely collected data from the ECR on pati ent and tumour characteristi cs enabled us 
to compare the group of respondents, non-respondents and pati ents with unverifi able 
addresses, using ANOVA for conti nuous variables and chi-square analyses for categorical 
variables. Furthermore, diff erences between pati ents with mCRC and non-metastati c CRC in 
sociodemographic and clinical characteristi cs and on the subscales of the EORTC-INFO25, SF-
36, HADS and B-IPQ were also analyzed using ANOVA or Wilcoxon tests (when normality and 
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homogeneity assumptions are violated) for continuous variables and chi-square analyses for 
categorical variables. 
Multivariate linear regression analyses were carried out to investigate the associations 
of the different information subscales (perceived receipt of disease information, medical 
test information, treatment information, information about other services and satisfaction 
with received information) with the subscales of the SF-36, HADS and B-IPQ for patients 
with mCRC only. We controlled for sociodemographic variables (age, gender) and clinical 
variables (primary treatment, years since diagnosis and comorbidity).
All statistical tests were two-sided and considered significant if p < 0.05. All analyses were 
conducted using SPSS version 17.0 (Statistical Package for Social Sciences, Chicago, IL, USA).
resulTs
Patient characteristics
Of the 1542 eligible CRC patients, 1159 (75%) returned a completed questionnaire. A 
comparison of respondents, non-respondents and patients with unverifiable addresses 
indicated that respondents and patients with unverifiable addresses were younger and 
more often male compared to non-respondents (Table 1). No differences were found in 
mean years after diagnosis, stage of disease and treatment.




Patients with unverifiable 
addresses  (N=118)
P-value
mean age at time of 
survey (SD)
69.2 (9.7) 71.1 (10.2) 68.3 (11.4) 0.008
mean years since 
diagnosis (SD)



















































*Disease stage at primary diagnosis
SU = surgery; RT = radiotherapy; CT = chemotherapy
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Pati ents with mCRC were signifi cantly younger, were more recently diagnosed, were more 
oft en men, had a higher socioeconomic status and more oft en received chemotherapy (in 
additi on to surgery) as primary treatment compared to pati ents without metastasis (Table 
2). No diff erences were found in the number of comorbiditi es, marital status, educati onal 
level and employment between these two groups.
Table 2: Demographic and clinical characteristi cs of respondents strati fi ed by stage of the disease
Pati ents with metastasis  
at ti me of  study
(N=139)
Pati ents without  
metastasis at ti me of study 
(N=1020)
P-value
mean age at ti me of diagnosis (SD) 62.7 (9.2) 66.1 (9.7) <0.001
mean age at ti me of survey (SD) 65.9 (9.2) 69.7  (9.7) <0.001
mean years since initi al diagnosis (SD) 3.2 (1.3) 3.6 (1.5) 0.01











































































SU = surgery; RT = radiotherapy; CT = chemotherapy
Educati on levels included  low: no/primary school, medium: lower general secondary educati on/vocati onal 
training, or high: pre-university educati on/high vocati onal training/university.
CHAPTER 6
92
Table 3: Information provision, health status, anxiety and depression and illness perceptions stratified 
by stage of the disease (mean (SD))
Patients with metastasis 
at time of  study
(N=139)
Patients without  metastasis  




Information about the disease 49.7 (21.2) 48.2 (20.4) 0.44
Information about medical tests 64.6 (21.9) 61.4 (23.3) 0.14
Information about treatments 45.2 (19.8) 36.6 (23.4) <0.01
Information about other services 19.9 (21.9) 19.0 (21.1) 0.65
Satisfaction with information 55.2 (26.3) 53.9 (25.7) 0.60
Usefulness of information 62.0 (26.0) 58.7 (26.1) 0.18
Want more information N(%) 38 (28.6%) 220 (23.5%) 0.20
Want less information N(%) 2 (1.5%) 27 (3.0%) 0.57
Health status (sf36)++
General Health 44.4 (24.3) 63.6 (21.0) <0.01
Physical Functioning 60.7 (30.8) 70.1 (27.2) <0.01
Role Limitations Physical Health 44.3 (43.9) 66.4 (41.9) <0.01
Bodily Pain 70.6 (28.6) 76.9 (24.2) <0.01
Vitality 58.4 (23.1) 65.9 (20.4) <0.01
Social Functioning 71.8 (27.4) 82.2 (21.0) <0.01
Role Limitations Emotional Problems 70.9 (41.3) 81.9 (34.7) <0.01
Mental Health 75.0 (18.0) 77.7 (17.3) 0.09
anxiety +++ 5.5 (4.2) 4.7 (3.7) 0.02
anxiety dichotomized# 0.09
 0-7 N(%) 95 (72.5%) 759 (79.3%)
8-21 N(%) 36 (27.5%) 198 (20.7%)
depression +++ 5.6 (3.5) 5.2 (3.5) 0.24
depression dichotomized# 0.27
 0-7 N(%) 91 (71.7%) 722 (76.4%)
8-21 N(%) 36 (28.3%) 223 (23.6%)
Illness perceptions++++
1 Consequences 6.1 (2.8) 4.0 (2.5) <0.01
2 Timeline 7.6 (2.8) 4.2 (3.3) <0.01
3 Personal control 6.8 (2.9) 6.0 (3.1) <0.01
4 Treatment control 5.1 (2.8) 3.5 (2.6) <0.01
5 Identity 5.0 (2.6) 3.5 (2.6) <0.01
6 Concern 6.5 (2.7) 4.0 (2.5) <0.01
7 Coherence 3.7 (2.9) 4.4 (3.0) 0.01
8 Emotional representation 5.0 (2.7) 3.6 (2.5) <0.01
+ Higher score indicates more perceived receipt of information
++ Higher score indicates better functioning; 
+++ Higher score indicates higher levels of anxiety/depression; 
++++Higher score indicates worse illness perceptions
# Based on their sum score, participants can be divided over two categories (<8 no anxiety/depression; ≥8 anxiety/
depression)28, 29 
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Informati on provision and sati sfacti on: diff erences between pati ents with non-metastati c 
and mCrC
On the subscales of the EORTC-QLQ-INFO25, pati ents with mCRC indicated to having 
received more informati on compared to pati ents with non-mCRC. However this was only 
signifi cant for the subscale informati on about treatments (Table 3). 
In-depth analyses of single items of the EORTC-QLQ-INFO25 showed comparable results 
between both groups, where 72% of the cancer pati ents with mCRC received (quite) 
a lot informati on about their diagnosis (versus 66% of the pati ents without metastasis). 
Seventeen percent (vs. 15%) received (quite) a lot informati on about the causes of their 
disease. The perceived receipt of medical test informati on was high: 73% (vs. 64%) received 
(quite) a lot informati on about the goals of the tests, 74% (vs. 68%) about the course of 
the tests and 79% (vs. 74%) received informati on on the results of the tests. Most pati ents 
with mCRC received (quite) a lot treatment informati on (80% vs. 64%), about the results 
of the treatment (51% vs. 47%) and about the side eff ects of treatments (65% vs. 35%). In 
contrast, a lot less informati on was received on other services, for example rehabilitati on 
opti ons (14% vs. 13%), dealing with cancer at home (21% vs 20%) and psychological help 
(12% vs. 7%).
There were no signifi cant diff erences between the two groups on sati sfacti on with and 
usefulness of the received informati on (Table 3). More than half (60% vs. 55%) of the 
pati ents with metastasis was (quite) sati sfi ed with the received informati on and 68% (vs. 
63%) perceived the received informati on as (quite) useful. Pati ents with mCRC wanted 
to receive more informati on (29% vs. 24%), especially about the course of the disease 
(prognosis, future), side eff ects of treatment(s) and supporti ve care (open fi eld questi on).
Health status, anxiety and depression, illness percepti on: diff erences between pati ents 
with metastati c and non-metastati c CrC
Pati ents with mCRC reported worse health status except for mental health (all p<0.01), higher 
levels of anxiety (p=0.02) and quite similar levels of depression (p=0.24) (Table 3). Pati ents 
with mCRC perceived their illness as worse (belief that their life is more aff ected,  their 
disease is of longer durati on, have less treatment and personal control, more symptoms, and 
were more concerned and emoti onally aff ected) compared to pati ents without metastasis, 
which is in accordance with their disease severity (all p<0.01). Pati ents with mCRC had 
a bett er understanding of their illness compared to pati ents without mCRC (p=0.01). No 
diff erences in health outcomes were found between pati ents with synchronous (n=69) and 
metachronous metastasti s (n=70; data not shown).
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association of information provision and information satisfaction with health status, 
anxiety and depression, and illness perceptions among CrC patients with mCrC
Among patients with mCRC more information about the disease was associated with 
worse general health, social functioning and bodily pain, while more information about 
the treatment was associated with less role limitations due to emotional problems when 
corrected for covariates (Table 4). More information about other services was associated 
with worse functioning on all domains (except social functioning and general health), higher 
levels of depression and more symptoms attributed to their illness.
Among patients without metastatic disease, higher satisfaction with the received information 
was associated with better health status, lower levels of anxiety and depression and better 
illness perceptions, whereas more perceived receipt of information about other services 
was negatively associated with these outcomes (data not shown).
dIsCussIOn
The present study showed that the perceived receipt of information was quite comparable 
between patients with and without mCRC. Patients with mCRC perceived receiving more 
treatment-related information compared to patients with non-mCRC. However, both groups 
perceived having received little information about other services and indicated to want more 
information. Issues related to disease course and supportive care were mentioned most 
frequently as topics that patients with mCRC wanted to receive more information about. 
Only 60% of the patients with mCRC was (quite) satisfied with the received information. 
Despite the severity of their disease, the majority of cancer patients with metastasis want to 
be fully informed 31. However, 40% of the patients with mCRC in our study was not satisfied 
with the received information and almost 30% wanted to receive more information. This 
possibly indicates that not all informational needs were met. This is confirmed by our finding 
that patients with mCRC reported receiving only a little information about other services, 
and wanted more information about these topics. Other studies showed that the perceived 
need for additional help was very high among advanced cancer patients, but HCPs are often 
unaware of this need 32. HCPs are inclined to give routine medical/technical information 
(diagnosis, type of treatment) and avoid emotional and quality of life issues 33. Furthermore, 
patients with mCRC possibly want (and expect) more direct emotional support from their 
HCP instead of only a referral to more formal organized support 32.
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Table 4: Standardized betas of multi variate linear regression analyses evaluati ng the associati on of 
informati on provision subscales with health status, anxiety and depression, and illness percepti ons 

















General Health -0.24* ns ns ns ns
Physical Functi oning ns ns ns -0.36** ns
Role Limitati ons Physical Health ns ns 0.32* -0.32** ns
Bodily Pain -0.24* ns ns -0.26* ns
Vitality ns ns ns -0.37* ns
Social Functi oning -0.26* ns ns ns ns
Role Limitati ons Emoti onal ns ns ns -0.25* ns
Mental Health ns ns ns -0.32** ns
anxiety and depression#
Anxiety ns ns ns ns ns
Depression ns ns ns 0.29** ns
Illness percepti ons^
1 Consequences ns ns ns ns ns
2 Timeline ns ns ns ns ns
3 Personal control ns ns ns ns ns
4 Treatment control ns ns ns ns ns
5 Identi ty ns ns ns 0.27* ns
6 Concern ns ns ns ns ns
7 Coherence ns ns ns ns ns
8 Emoti onal representati on ns ns ns ns ns
** < 0.01; *< 0.05; ns = not signifi cant
Corrected for gender, age, ti me since diagnosis, chemotherapy and comorbidity
+ Higher score indicates bett er functi oning; # Higher score indicates higher levels of anxiety/depression; ^Higher 
score indicates worse illness percepti ons
Our results do not show diff erences in the perceived level of received informati on between 
pati ents with or without mCRC. This could indicate that the informati on HCPs provide is very 
general and routi nely given, and not tailored to the individual pati ent. Further complicati ng 
the interpretati on of our results is that cancer pati ents tend to forget a substanti al amount 
of informati on that has been given to them, because they may be emoti onally overwhelmed 
34, impaired in their cogniti ve capability, may not understand the medical terminology used, 
or in the case of metastasized disease deny the “terminal” nature of their illness  as a coping 
strategy to retain hope 16, 35. HCPs may have provided the required informati on but pati ents 
do not recall having received this informati on. Since sati sfacti on with informati on provision 
is for a part determined by the amount of informati on received, it is important that HCPs 
constantly check what the pati ent has understood and whether the informati on was helpful  36. 
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When necessary, the HCP must repeat the information several times, both between and 
within consultations 7.
The perceived receipt of more disease information and information about other services 
was associated with worse health outcomes among patients with mCRC. Part of this result 
could be influenced by confounding. Information provision about metastasis and other 
services may cause negative feelings on its own, since it is often emotionally loaded, while 
information about treatment options possibly gives the patient new hope. Hope is an 
important factor for a person’s well-being and quality of life 37. Also, treatment information 
could empower the patient to anticipate and react to expected toxicities with a clear action 
plan. Furthermore, information provision about other services was too limited for most 
patients, possibly leading to more uncertainty or confusion.
While satisfaction with the received information was associated with better health outcomes 
among patients with curable cancer 1, we did not find this association in our study among 
patients with mCRC. A possible explanation for the absence of this association is that next 
to the amount of information, the content of information and the way the information is 
provided are at least equally important for the satisfaction levels of patients with mCRC 
38. Furthermore, patient satisfaction is associated with supportive HCP behaviors 33, the 
way information is provided (although not assessed in this study) could influence the way 
information will be perceived 16. Advanced cancer patients want the HCP to be honest, 
to convey hope, to speak plain language instead of difficult medical terminology, to be 
empathic, to give enough time during discussion and to pace the amount of information to 
what they can assimilate 16. Another study reported that 100% of the respondents wanted 
HCPs to be honest, while 91% also wanted HCPs to be optimistic. However, it is difficult for 
HCPs to remain optimistic while being honest about a poor prognosis 39. 
Further, our results showed that patients with mCRC had worse illness perceptions compared 
to CRC patients without metastasis. Patients with mCRC were aware of the severity of their 
disease and also reported a better understanding of their illness compared to patients 
without mCRC. This indicates that HCPs did a good job in informing patients about their 
disease severity. However, we did not find an association between information provision 
and illness perceptions for patients with mCRC. In comparison, a recent study showed that 
patient awareness of incurable disease was associated with improvements in health status 
40, since they were better able to understand and manage their symptoms. 
 
Our results indicate that the delivery of information to patients with mCRC can be improved. 
Adequate assessment of patients’ individual information needs as well as appropriate 
responses to these needs might lead to higher levels of satisfaction. HCPs can start a 
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conversati on by giving general informati on per topic and then ask whether or not a pati ent 
want to discuss this topic in more detail 41. In parti cular, providing informati on about other 
services can be bett ered as both metastati c and non-mCRC survivors perceived receiving 
litt le informati on on this topic. HCPs need to become aware of the supporti ve care needs 
and provide the pati ent with more emoti onal and quality of life informati on when necessary. 
However, HCPs might not feel competent to provide pati ents with informati on about 
advanced disease 42. Since sati sfacti on levels of mCRC pati ents might not only be related 
to the amount of informati on received, but also to the way the informati on is provided it 
seems important to pay att enti on to the communicati on skills of HCPs by developing and 
implementi ng educati on and training programs 43.
The study has limitati ons. First, pati ents with mCRC included in our study were long-term 
survivors which could have biased our results. Relati ve survival for stage IV colon and rectal 
cancer was respecti vely 7% and 6% in the period 2004-2006 44. Multi -agent chemotherapy 
has enabled previously unresectable mCRCs to be resected 11 and fi ve-year relati ve survival 
for pati ents undergoing hepati c resecti on has increased to 45% 45. It is therefore possible that 
part of the pati ents with mCRC were cured at ti me of our study. Since we aimed to compare 
the levels of received informati on between pati ents who are curable (non-mCRC) and those 
who are incurable (mCRC), the potenti al curability of mCRC could have confounded our 
results. Unfortunately, we did not have data about the exact rates of cure in our study sample. 
Future research is needed to determine diff erences over ti me in health outcomes between 
pati ents with mCRC who are actually cured and those with incurable mCRC. Second, the 
cross-secti onal design of the study limits the determinati on of causal associati ons between 
informati on provision and health outcomes. Third, since all parti cipants were CRC pati ents, 
we can only generalize our results to this group of cancer pati ents. Finally, the EORTC QLQ-
INFO25 does not measure who provided the informati on and when the informati on was 
provided exactly. It would be interesti ng to assess which aspects of informati on pati ents 
receive from diff erent HCPs or other sources and at what point in their disease trajectory 
they receive the informati on. Prospecti ve research is needed to overcome part of the recall 
bias. 
In conclusion, the fi ndings of this study indicate that some improvements can be made 
in the provision of informati on to pati ents with mCRC. Pati ents especially wanted more 
informati on about supporti ve care. Our results with regard to the associati ons between 
perceived receipt of more disease informati on and informati on about other services with 
worse health outcomes should be interpreted with care, since the way and the content 
of the informati on provided are probably more important for pati ent sati sfacti on than the 
amount of received informati on. This can possibly also explain the lack of a relati on between 
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sati sfacti on with informati on is associated with 
baseline and follow-up quality of life among 
lymphoma and multi ple myeloma survivors: 
results from the PrOfIles registry





background: Providing information that is congruent with patients’ needs is an important 
determinant for patient satisfaction and might also affect health-related quality of life 
(HRQoL), anxiety and depression levels of cancer survivors.
aim: To obtain insight into the relationship between information provision and HRQoL, 
anxiety and depression levels among lymphoma and Multiple Myeloma (MM) survivors.
methods: All patients diagnosed with lymphoma or MM between 1999 and 2009, registered 
in the Eindhoven Cancer Registry, received a questionnaire including the EORTC QLQ-INFO25, 
EORTC QLQ-C30 and HADS. Subsequently, 407 of the 1369 participants completed these 
questionnaires again two years later. Paired sample t-tests were used to assess changes 
over time and multivariate linear regression analyses were used to determine independent 
associations of information provision with HRQoL, levels of anxiety and depression.
results: The perceived receipt of information about medical tests (65 vs. 62, p<0.01), 
treatment (48 vs. 45, p=0.01) and the helpfulness of the received information (66 vs. 63, 
p=0.04) were significantly higher at baseline compared to 2-year follow-up. The perceived 
level of information about the disease and other services and the HRQoL and levels of 
anxiety and depression did not change over time.
Higher satisfaction with the received information at T1 was associated with better physical, 
role, emotional and social functioning and global quality of life at T2 (ß ranging from 0.15 – 
0.25; all p<0.05). After correction for baseline functioning levels, this relationships remained 
only significant for role functioning (ß=0.17, p<0.05) and global quality of life (ß=0.14, 
p<0.05). Survivors who were satisfied at both time points (56%) reported highest levels of 
mental HRQoL. 
discussion: Satisfaction with the received information is associated with better HRQoL and 
lower levels of anxiety and depression. Survivors, who are stable satisfied with information, 
report better mental HRQoL. Future studies should explore strategies to optimize patient 
satisfaction with received information.
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InTrOduCTIOn
The provision of informati on to pati ents is one of the most important factors of cancer 
care across the cancer conti nuum. The goal of providing informati on is to prepare pati ents 
for their treatment, to increase treatment adherence and abiliti es to cope with the illness 
as well as to promote recovery 1. Adequate informati on provision is a diffi  cult task since 
informati on is oft en complex, meant to make serious decisions, and potenti ally upsetti  ng 2. 
The majority of cancer pati ents (>80%) want as much informati on as possible about their 
disease, treatment and rehabilitati on 3-5. Informati on preferences vary by sex, age, cultural 
background, ti me since diagnosis, educati onal level, stage of the disease and coping style 
6-8. Results of a systemati c review show that  6-93% of the cancer pati ents report adequate 
informati on provision as an unmet need 9, indicati ng the existence of misconcepti ons among 
health care providers (HCP) regarding pati ents’ needs for informati on 10. 
A study among lymphoma and multi ple myeloma (MM) survivors showed that informati on 
provision and sati sfacti on with the received informati on were relati vely good, however one 
third of pati ents sti ll expressed unmet informati on needs 11. A recent review from our group 
showed that sati sfi ed pati ents and pati ents with fulfi lled informati on needs in general have 
a bett er health-related quality of life (HRQoL) and lower levels of  anxiety and depression 12. 
However, most studies included in this review were inconclusive because of methodological 
fl aws. Almost all included studies used non-validated questi onnaires to measure informati on 
provision, sample sizes were small, and most studies had a cross-secti onal design which 
limits the determinati on of causal associati ons. Therefore, the aim of the current study was 
to examine the relati onship between informati on provision at baseline and HRQoL, anxiety 
and depression among lymphoma and MM survivors 2 years later. 
meTHOds
setti  ng and populati on
This study is part of a dynamic longitudinal populati on-based survey among lymphoma and 
MM survivors registered within the Eindhoven Cancer Registry (ECR) of the Comprehensive 
Cancer Centre South. The ECR records data on all pati ents who are newly diagnosed with 
cancer in the southern part of the Netherlands, an area with 2.3 million inhabitants, 18 
hospital locati ons and 2 large radiotherapy insti tutes. The ECR was used to select all pati ents 
who were diagnosed with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and MM 
between 1/1/1999 and 1/1/2009. We included indolent (including Chronic Lymphocyti c 
Leukemia) and aggressive B-cell NHL, HL, and MM as defi ned by the Internati onal 
Classifi cati on of Diseases for Oncology-3 codes (ICD-O-3)13. Ethical approval for the study 




Data collection was done within PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship). PROFILES is a registry for the study of 
the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors. PROFILES contains 
a large web-based component and is linked directly to clinical data from the ECR. Details 
of the data collection method were previously described 14. From May until November 
2009, patients between 6 months and 10 years after diagnoses were included in the study 
and received the first questionnaire at baseline (T1). From May until November 2011, the 
patients who agreed to participate in the follow-up received the second questionnaire 
containing the same study measures (T2).
study measures
Socio-demographic and clinical characteristics
Clinical information was available from the ECR that routinely collects data on tumour 
characteristics, including date of diagnosis, tumour grade, histology,  stage 15, primary 
treatment, and patients background characteristics, including sex and date of birth. 
Comorbidity at the time of survey was categorized according to the adapted Self-
administered Comorbidity Questionnaire (SCQ) 16. Questions on marital status, educational 
level, and current occupation were added to the questionnaire.
EORTC QLQ-INFO25 
The Dutch version of the internationally validated European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Information (EORTC QLQ-INFO25)  was 
used to evaluate the information received by lymphoma and MM patients 17 18. This 25-
item questionnaire incorporates four information provision subscales: perceived receipt of 
information about the disease (four items regarding diagnosis, spread of disease, cause(s) 
of disease and whether the disease is under control), medical tests (three items regarding 
purpose, procedures and results of tests), treatment (six items regarding medical treatment, 
benefits, side-effects, effects on disease symptoms, social life and sexual activity) and other 
care services (four items regarding additional help, rehabilitation options, managing illness 
at home, psychological support). Additionally, it contains eight single items on for instance 
wanting to receive more or less information, and on the satisfaction with and helpfulness of 
the received information. Answer categories range from one (not at all) to four (very much), 
except for four items with a two point scale (yes/no). After linear transformation, all scales 
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EORTC QLQ-C30
HRQoL was measured by the Dutch version of the validated EORTC QLQ-C30 19. This 30-item 
HRQoL questi onnaire consists of fi ve functi onal scales (physical, role, cogniti ve, emoti onal 
and social), a global health status quality of life scale and three symptom scales and single 
symptom items. Answer categories range from one (not at all) to four (very much). Aft er 
linear transformati on, all scales and single item measures range in score from 0 to 100 20. A 
higher score on functi on scales and global quality of life implies bett er HRQoL.
Anxiety and depression
Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression 
Scale (HADS). The HADS is a self-report questi onnaire comprising 14 items on a four-point 
Likert-scale; seven for depression and seven for anxiety 21. The depression subscale mainly 
covers loss of interest and pleasure (anhedonia), which are core depressive symptoms, 
while the anxiety subscale covers the core anxiety features of worry and tenseness. The 
scores range from 0-21, with higher scores indicati ng higher levels of anxiety or depression. 
A cut-off  score of 8 was used to determine symptoms of depression or anxiety 21, 22.
stati sti cal analyses
Diff erences in socio-demographic and clinical characteristi cs between respondents and non-
respondents or pati ents with unverifi able addresses and pati ents who completed one or 
two questi onnaires were compared with a chi-square or t-test, where appropriate.
Paired sample t-tests were performed to compare the mean EORTC QLQ-INFO25, EORTC 
QLQ-C30 and HADS scores on T1 and T2. The same analyses were performed for the 
subgroup of short-term survivors (<2 years since diagnosis at baseline) only.
The mean scores on the EORTC QLQ-C30 functi oning and HADS scales on T1 and T2, strati fi ed 
by the score on the sati sfacti on with received informati on questi on of the EORTC QLQ-
INFO25 1) unsati sfi ed, 2) a litt le sati sfi ed, 3) quite sati sfi ed, 4) very sati sfi ed, were compared 
by ANOVA.
Multi variate linear regression analyses were carried out in order to investi gate the 
associati on on T1 between HRQoL, anxiety and depression (dependent variables) with 
the four  informati on provision subscales and sati sfacti on with received informati on 
(independent variables), controlled for covariates age, sex educati onal level, marital status, 
ti me since diagnosis, tumour type, disease stage and number of comorbiditi es, that were 
determined a priori 23. 
Furthermore, the predicti ve value of the four informati on provision subscales and sati sfacti on 
with received informati on (T1) on HRQoL, anxiety and depression (T2) was investi gated by 
multi variate linear regression analyses corrected for baseline HRQoL, anxiety and depression 
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(T1) and the same covariates as described above. These analyses were also performed for 
the subgroup of short-term (<2 years since diagnosis at baseline) only.
Additionally, mean EORTC QLQ-C30 subscale scores, stratified by survivors who were 1) 
satisfied at T1 and T2 (stable satisfied), 2) unsatisfied at T1 and satisfied at T2 (became 
satisfied), 3) satisfied at T1 and unsatisfied at T2 (became unsatisfied) 4) unsatisfied at 
T1 and T2 (stable unsatisfied), were compared by ANOVA. Multivariate linear regression 
analyses were carried out, to investigate the association between the stability of satisfaction 
with received information (independent) with HRQoL, anxiety and depression (dependent), 
corrected for baseline HRQoL, anxiety and depression and the same covariates as described 
above. 
All statistical tests were two-sided and considered significant if p<0.05. All analyses were 
conducted using SPSS version 17.0 (Statistical Package for Social Sciences, Chicago, IL, USA). 
resulTs
Patient characteristics
Of the 2.033 lymphoma and MM survivors who were sent a questionnaire, 1.369 (67%) 
completed this. Subsequently, 407 (30%) completed this questionnaire again two years later. 
Patients with unverifiable addresses were younger and diagnosed longer ago compared to 
respondents and non-respondents (Table 1). Non-respondents were more often diagnosed 
with MM, less often with aggressive NHL, disease stage was more often unknown, and 
they received chemotherapy less often but active surveillance more often compared to 
respondents. 
The mean age at baseline survey completion was 61.6 years with a mean time since 
diagnosis of 3.8 years (Table 1). Chemotherapy was the most common primary treatment 
(66%). Two third of the survivors reported one or more comorbid conditions; most common 
were arthritis, back pain and hypertension. 
A baseline comparison between survivors who completed one or two questionnaires 
indicated that the latter had a significant longer mean time since diagnosis, more often 
received stem cell transplantation, were employed and had a partner more often (Table 
1). Furthermore, survivors who completed both questionnaires scored somewhat better on 
physical and emotional functioning, global quality of life and had lower levels of anxiety and 
depression compared to survivors who only completed the baseline questionnaire (Table 2), 
although differences were not clinically relevant 24.
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Changes over ti me in informati on provision, HrQol, anxiety and depression
The perceived receipt of informati on about medical tests (65 vs. 62, p<0.01) and treatment 
(48 vs. 45, p=0.01) and the usefulness of the received informati on (66 vs. 63, p=0.04) were 
signifi cantly higher at T1 compared to T2 for the total group of survivors (Table 2). Survivors 
<2 years since diagnosis showed a signifi cant decrease in medical test informati on and 
sati sfacti on with and helpfulness of the received informati on (Figure 1).
In total, 28% of the survivors would have liked to receive more informati on at T1 and 23% at 
T2. Most frequently menti oned topics to receive more informati on about were the possible 
causes of cancer, possible side-eff ects of their treatment, long-term eff ects of cancer on 
diff erent aspects of life, aft ercare, and overall informati on on cancer.  Overall, 22% of the 
survivors wanted to receive more informati on at one of the assessment periods, 63% 
wanted no additi onal informati on and 15% did want to receive more informati on at both 
assessment periods. Of this latt er group, 47% wanted to receive informati on about the same 
topics and 53% wanted to receive diff erent informati on at T2 compared to T1 (from more 
general disease specifi c informati on to informati on about the course of the disease and 
aft ercare).
figure 1: Diff erences in perceived level of informati on received and sati sfacti on with and usefulness of 
informati on over ti me for survivors <2 years since diagnosis.
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Table 2: Comparison of mean EORTC QLQ-INFO25, EORTC QLQ-C30 and HADS subscale scores between 














mean (sd) mean (sd) mean (sd)
survivors who 
completed 





Information about disease 52 (21) 53 (20) 53 (20) 0.95 0.98
Information about medical tests 65 (22) 65 (22) 62 (23) 0.55 <0.01
Information about treatment 47 (23) 48 (22) 45 (23) 0.49 0.01
Information about other services 21 (22) 22 (23) 23 (23) 0.78 0.18
Satisfaction with information 62 (27) 62 (27) 61 (25) 0.99 0.41
Usefulness of information 65 (24) 66 (24) 63 (22) 0.95 0.04
eOrTC QlQ-C30++
Physical functioning 79 (21) 81 (20) 79 (21) 0.02 <0.01
Role functioning 76 (29) 78 (27) 77 (26) 0.12 0.31
Emotional functioning 83 (21) 85 (20) 85 (20) 0.03 0.67
Cognitive functioning 82 (23) 84 (21) 83 (19) 0.07 0.81
Social functioning 84 (24) 86 (23) 87 (21) 0.07 0.16
Quality of life 73 (20) 76 (20) 75 (19) <0.01 0.71
Hads+++
Anxiety 4.6 (3.9) 4.0  (3.5) 4.2 (3.7) <0.01 0.22
Depression 4.3 (3.9) 3.8 (3.5) 3.9 (3.6) <0.01 0.37
¥ Based on paired t-test
+ Higher score (0-100) indicates more perceived receipt of information;
++ Higher score (0-100) indicates better functioning; 
+++ Higher score (0-21) indicates higher levels of anxiety/depression 
Survivors’ HRQoL scores and anxiety and depression levels did not change across the two 
time points, except for physical functioning which slightly but significantly decreased (81 vs. 
79, p<0.01; Table 2). This decrease was not clinically meaningful 24. Survivors <2 years since 
diagnosis showed no differences in functioning, anxiety and depression levels over time. 
associations of information provision with HrQol, anxiety and depression at baseline (T1)
Survivors who were satisfied with the received information reported better HRQoL (Figure 
2) and lower levels of anxiety and depression compared to unsatisfied survivors.
Multivariate linear regression analyses showed that, at baseline, receiving more disease-
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related informati on was associated with lower levels of anxiety (ß=-0.10) and depression 
(ß=-0.10; p<0.05), while receiving more informati on about the treatment was associated 
with worse emoti onal (ß=-0.10) and cogniti ve functi oning (ß=-0.11) and higher levels of 
anxiety (ß=0.12) and depression (ß=0.09; all p<0.05). The perceived receipt of more 
informati on about other services was related to worse functi oning on all scales (ß ranging 
from -0.09 to -0.14), except for emoti onal functi oning, and higher levels of anxiety (ß=0.10) 
and depression (ß=0.07). Higher sati sfacti on with the received informati on was associated 
with bett er HRQoL (ß ranging from 0.13 to 0.22) and lower levels of anxiety (ß=-0.23) and 
depression (ß=-0.21; all p<0.01).
figure 2: HRQoL according to the level of sati sfacti on with the received informati on at T1.
Functioning scales of EORTC QLQ-C30 stratified to 
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associati ons of informati on provision on T1 with HrQol, anxiety and depression on T2
Multi variate linear regression analyses including the covariates age, sex, ti me since 
diagnosis, tumour type, disease stage, number of comorbiditi es, educati onal level and 
marital status showed that receiving more informati on about the treatment at baseline 
(T1) was associated with worse emoti onal functi oning (ß=-0.18, p<0.05) at T2, and more 
informati on about other services at T1 was associated with worse social functi oning (ß=-
0.15, p<0.05) at T2.  Higher sati sfacti on with the received informati on at T1 was associated 
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with better HRQoL (ß ranging from 0.15 – 0.25; all p<0.05) on all scales at T2, except for 
cognitive functioning. 
After correction for baseline HRQoL, the relationship of satisfaction with the received 
information remained only significant for role functioning (ß=0.17, p<0.05) and global 
quality of life (ß=0.14, p<0.05). Subanalyses for survivors <2 years since diagnosis showed 
the same relationships.
Stable satisfied survivors (56%) reported better HRQoL and lower levels of anxiety and 
depression at T2 compared to survivors who were unsatisfied (13%) or with changing 
satisfaction levels over time (30%; Figure 3). Multivariate linear regression analyses 
corrected for baseline HRQoL and covariates showed that the stability of satisfaction with 
received information predicted emotional, cognitive and social functioning (ß ranging from 
-0.09- -0.13, p<0.05).
dIsCussIOn
This population-based study among lymphoma and MM survivors showed that survivors with 
high levels of satisfaction with received information had the highest HRQoL and lowest anxiety 
and depressive symptom levels. The perceived receipt of information decreased slightly 
over time (mostly among short-term survivors), while HRQoL, anxiety and depression levels 
did not change over time. The receipt of more disease-related information was associated 
with lower levels of anxiety and depression, while the receipt of more information about the 
treatment and other services was associated with worse HRQoL and higher levels of anxiety 
and depression. Satisfaction with the received information at baseline was associated with 
HRQoL 2-years later, however after correction for baseline HRQoL the relationships partly 
disappeared. Satisfaction with the received information at both time points was associated 
with better emotional, cognitive and social HRQoL compared to fluctuating satisfaction 
levels or constant dissatisfaction with the received information.
The perceived levels of information about treatment and especially about other services 
were low at both assessment periods. The negative associations of information about 
treatment and other services with HRQoL, anxiety and depression could therefore indicate 
that this information was not enough, possibly leading to more uncertainty or confusion. 
This is confirmed by our finding that the most frequently mentioned topics survivors wanted 
more information about were possible side- and long-term effects of their treatment, late 
effects of cancer on different aspects of life and aftercare. However, patients with a higher 
stage disease might indicate to receive more information, but still have worse HRQoL and 
higher levels of anxiety and depressive symptoms as a consequence of their disease severity.
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figure 3: HRQoL at T2 according to the stability of sati sfacti on with the received informati on over ti me.
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Functioning scales of EORTC QLQ-C30 at T2 stratified to stability of



























Sati sfacti on with received informati on was associated with bett er HRQoL and lower levels of 
anxiety and depression. Although levels of received informati on (quanti ty) determine part 
of the sati sfacti on levels of cancer survivors, the quality of informati on (the degree to which 
informati on needs are met) is even more important. For some survivors the topics they 
wanted more informati on about were constant over ti me, possibly indicati ng that these 
needs remained unmet. Other survivors reported changing needs over ti me. HCPs must be 
aware of the possible (changing) needs of cancer pati ents, however studies show that there 
is a discrepancy between the actual informati on needs of the pati ent and the percepti on of 
HCP about the needs of the pati ents 25.  
The relati onship between sati sfacti on with received informati on and HRQoL, anxiety and 
depression largely disappeared aft er correcti on for baseline levels. A limitati on of these 
analyses is that they focus on mean diff erences and not on individual changes. Given the large 
standard deviati ons of the informati on provision scales, there is a high degree of variati on 
between individuals. Therefore we decided to make a disti ncti on between survivors who 
remained stable sati sfi ed or dissati sfi ed or pati ents who had fl uctuati ng sati sfacti on levels. 
Our results show that stable sati sfi ed survivors had the highest levels of mental HRQoL 
also aft er adjusti ng for baseline levels. These positi ve mental health outcomes can be the 
direct result of conversati ons between HCP and pati ent from which pati ents feel recognized, 
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validated, trusted, worthy, reassured and comforted 26, 27 and indirectly through diagnosis 
and treatment of mental problems (anxiety and depression) and strengthened social 
support. Alternatively, it is possible that patients with higher levels of HRQoL and lower 
levels of distress naturally report higher levels of satisfaction with the received information, 
independent of the information they actually received. 
Our results suggest that it is important to satisfy the patient and to keep the patient satisfied 
with respect to information. The best way to unravel the information needs of a patient is to 
consult the patient him or herself, however this is rarely done 28. Furthermore, HCPs often 
do not check the understanding of the patient 29.  Recently, some strategies were devised 
to address the information needs of cancer survivors. First, survivorship care plans provide 
cancer survivors with a summary of their treatment as a formal document that also includes 
recommendations for subsequent cancer surveillance, management of late effects, and 
strategies for health promotion 30 29. Second, feedback of patient reported outcomes (PRO) 
to the HCP has the potential to help detect unmet needs and symptoms, leading to better 
control and monitoring of such issues, serve as a guide for HCP to discuss HRQoL issues, act 
as patients’ voice, and facilitate individualized information provision and care 31 32.  Last, a 
recent founded Working Group of haematologists, radiation oncologists, epidemiologists 
and internists aimed to establish survivorship clinics with the goal to improve survivors’ 
HRQoL by informing survivors about long-term risks, advice preventive measures, suggest 
screening and improve aftercare by providing rehabilitation programs 33. Participation of 
survivors could be an efficient solution to address the unmet information needs.
The present study has limitations that should be mentioned. First, although the response 
rate at baseline was high and information was present concerning socio-demographic and 
clinical characteristics of the non-respondents and patients with unverifiable addresses, 
whether non-respondents declined to participate in the study because of poor health 
remains unknown. Secondly, a large part of the survivors did not respond to the second 
questionnaire, these non-responders had worse HRQoL scores at T1, which possibly caused 
some selection bias at T2. Third, the mean time since diagnosis was almost 4 years, which 
could influence the recall effect of information received.  However we did not found 
differences in the perceived receipt of information among short- and long-term survivors 
and the majority of patients was still under active follow-up. Fourth, the EORTC QLQ-INFO25 
only measures the information patients indicated to have received, it is not clear how much 
information was actually provided. It would therefore be interesting to compare data on 
actual information provision with data from questionnaires. Patient information delivery 
and perception are part of a complex process that is influenced by many factors including 
preexisting patient-related psychological and behavioral patterns, which can influence our 
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results. Finally, since the EORTC QLQ-INFO25 is not a measure of clinical outcomes it was not 
possible to determine clinically meaningful diff erences. The declines in perceived receipt 
of informati on over ti me were stati sti cal signifi cant but small, while HRQoL, anxiety and 
depression did not change over ti me. It is therefore diffi  cult to determine causal associati ons. 
An interventi on study which aims to improve informati on provision could provide more 
insight into the causality of these relati ons.
Despite the limitati ons noted, the present study showed that sati sfacti on with the received 
informati on among lymphoma and MM survivors was associated with bett er HRQoL and 
lower levels of anxiety and depression. Survivors who were sati sfi ed with the received 
informati on on both ti me points report bett er mental HRQoL. HCPs should provide pati ents 
with informati on adapted to pati ents needs in order to sati sfy survivors and also to keep them 
sati sfi ed. The eff ecti veness of PRO feedback, survivorship care plans and the foundati on of 
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CHaPTer 8
rising incidence, no change in survival and 
decreasing mortality from thyroid cancer in
 The netherlands since 1989
O. Husson, H.R. Haak, L.N. van Steenbergen, W.A. Nieuwlaat, B.A.C. van Dijk, 
G.A.P. Nieuwenhuijzen, H. Karim-Kos, J. Kuijpens, L.V. van de Poll-Franse, J.W.W. Coebergh




background: The incidence of thyroid cancer (TC) is increasing worldwide, partly due to 
increased detection. We therefore assessed combined trends in incidence, survival and 
mortality of the various types of TC in The Netherlands between 1989 and 2009.
methods: We included all patients ≥ 15 years with TC, diagnosed in the period 1989–2009 
and recorded in The Netherlands Cancer Registry (N = 8021). Information on age, gender, 
date of diagnosis, histological type of tumour and TNM classification was recorded. Mortality 
data (up to 1 January 2010) were derived from Statistics Netherlands. Annual percentages of 
change in incidence, mortality, and relative survival were calculated.
results: Since 1989 the incidence of TC increased significantly in The Netherlands (estimated 
annual percentage change (EAPC) = +1.7%). The incidence rates increased for all age groups 
(except for females ≥ 65 years), papillary tumours (EAPC = +3.6%), T1 and T3 tumours (EAPC 
= +7.9% and +5.8% respectively). Incidence rates decreased for anaplastic (EAPC = -1.9%) 
and T2 and T4 tumours (EAPC = -1.1% and -2.3% respectively). Five-year relative survival 
rates remained stable, however appeared to be somewhat higher for papillary (93%) and 
follicular (87%) TC, all age groups and T1-T3 tumours (95%, 94% and 80% respectively) 
and somewhat lower for T4 (52%) and medullary tumours (68%) in the 2004-2009 period 
compared to earlier periods. Mortality due to TC decreased (EAPC = -1.9%).
Conclusion: TC detection and incidence has been rising in The Netherlands, while mortality 
rates are decreasing and survival rates remained stable.
8
TRENDS IN THYROID CANCER INCIDENCE, MORTALITY AND SURVIVAL
121
InTrOduCTIOn
In recent years, the incidence of thyroid cancer (TC) has increased drasti cally in the US and 
most European countries 1, 2. TC is the most common endocrine malignancy 3. The higher 
incidence rates are oft en att ributed to increased environmental radiati on exposure 4, 
radiati on therapy for the treatment of the head and neck areas 5, lower iodine nutriti on 6 or 
higher prevalence of obesity 7. The exact eti ology of TC remains unclear. It is also  suggested 
that increasing use of more precise diagnosti cs, like cervical ultrasound and fi ne needle 
aspirati on biopsy (FNAB), contribute to an increased identi fi cati on of subclinical disease 2 8. 
Although  a larger porti on of small tumours then appears to have been detected,  slightly 
increased incidence rates of larger tumours are also observed 8. Contrary to the increasing 
incidence, mortality from TC remained stable  in north America 2 and decreased  (–23% and 
–28%, for men and women respecti vely) in the European Union 9 and prognosis is  good 
(except for the anaplasti c type of tumour).
The combined measurements of TC burden (i.e., incidence, mortality and survival) could 
indicate whether and where progress had been made in cancer diagnosis and treatment and 
where improvements might be needed. As none of the previous studies described all three 
determinants of TC burden in combinati on, we assessed long-term trends in incidence, 
mortality, and survival of TC in The Netherlands between 1989 and 2009. We hypothesized 
that in the absence of a clear patt ern of eti ological/environmental exposures the rising 
incidence might be largely due to increased diagnosti c scruti ny, leading to an increased 
detecti on of small tumours. If the incidence of small tumours would increase, due to its 




Populati on-based data were used from the nati on-wide Netherlands Cancer Registry (NCR), 
which was started in 1989 and combines data from eight Dutch regional cancer registries, 
currently merged into two. The NCR is based on noti fi cati on of all new diagnosed malignancies 
in The Netherlands by the automated pathological archive (PALGA), supplemented by 
noti fi cati ons from the nati onal registry of hospital discharge, various clinical chemistry 
laboratories and radiotherapy insti tuti ons. Informati on on pati ent (sex, date of birth) and 
tumour characteristi cs (date of diagnosis, histology, locati on, stage (TNM (Tumour-node-
metastasis) classifi cati on 10-12) were routi nely obtained from the medical records 6-12 
months aft er diagnosis. 
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Vital status was actively obtained on a regular basis from the municipal registries and from 
the database of deceased persons of the Central Bureau for Genealogy (date of last follow-
up: 1st January 2010). Survival time was calculated as the time from diagnosis to death or to 
1st January 2010 or to date of emigration.
Topography and histology were coded according to the International Classification of 
Diseases for Oncology (ICD-O-3) 13. All tumours with an ICD-O-3 topography code thyroid 
(C73) diagnosed in the period 1989-2009 were included this study (n= 8021). The following 
histological categories were used: papillary cancer (morphology codes 8050, 8201, 8260, 
8340-8344, 8350, 8504; and differentiation grade = 1 or 2), follicular cancer (8290, 8330-
8332, 8335; and differentiation grade = 1 or 2), poorly differentiated TC (8010, 8012; and 
differentiation grade = 3; or 8050, 8140, 8201, 8260, 8290, 8330-8332, 8335, 8340-8344, 
8350, 8337, 8504; and differentiation grade = 3 or 4; 8337), medullary cancer (8345, 
8510-8512), anaplastic cancer (8010, 8012; and differentiation grade = 4; or 8020-8035, 
8041, 8575, 8980) and other. T stage was based on pathological T stage. For cases where 
pathological stage was unknown, clinical stage was used. 
Patients <15 years and >95 years were excluded from the survival analysis, as well as cases 
diagnosed at autopsy. Age at diagnosis was divided into four groups (<45; 45-59; 60-74; 
≥75 years). The study period was divided into four categories of 5 years and one of 6 years: 
1989-1993, 1994-1998, 1999-2003, and 2004-2009. Incidence rates were calculated per age 
group, sex, histological type and T stage. 
statistical analyses
Annual incidence and mortality rates for the period 1989-2009 were calculated per 100,000 
person-years, using the mid-year population size as obtained from Statistics Netherlands. 
Rates were age-standardized to the European standard population (European Standardized 
Rates (ESR)). Trends in incidence were evaluated by calculating the estimated annual 
percentage change (EAPC) and the corresponding 95% confidence intervals (95% CI). To 
calculate this, a regression line was fitted to the natural logarithm of the rates, using the 
calendar year as regressor variable (i.e. y = ax + b where y = ln (rate) and x = calendar year, 
then EAPC = 100 * (ea - 1)). This calculation assumes that the rates increased or decreased 
at a constant rate over the entire period. Joinpoint analyses were performed to discern 
significant changes in the trend and, if present, when they occurred 14.
Relative survival was used as an estimation of disease-specific survival. It was derived as the 
ratio of observed survival of the cancer patients and the expected survival of a comparable 
age- and sex-matched group of the general population while using the Ederer method 15. 
Traditional, cohort-based, relative survival analysis was used to calculate 5-year relative 
survival. For the 5-year relative survival estimates of the last period (2004-2009) only the 
patients diagnosed in 2004 had 5-year follow-up. Recent changes in survival might therefore 
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not be accurately represented by standard cohort 5-year survival esti mates. Period-based 
relati ve survival analysis should provide the most-up-to-date esti mates for recent ti me 
periods.
Survival trends were quanti fi ed as the mean period percentage change (MPPC) within the 
period 1989-2009 esti mated by a linear regression model. A positi ve value of the mean 
period change implies an upward trend in survival (i.e. improving) and a negati ve value 
implies a negati ve trend (i.e. deteriorati on). 
Multi variate relati ve survival analyses, using Poisson regression modeling, were carried out 
to esti mate relati ve excess risk (RER) of dying adjusted for follow-up interval and age group. 




In The Netherlands 8021 new TC cases were registered between 1989 and 2009. Mean 
age at diagnosis was 53 ± 19 (standard deviati on (SD)) years. The female to male rati o was 
2.4:1. The proporti on male pati ents <45 years decreased steadily from 38% in 1989-1993 to 
32% in 2004-2009. In females, 40% were < 45 years of age at diagnosis. Furthermore, the 
proporti on pati ents 45-59 years increased (Table 1). 
The overall incidence rate increased from 2.0 in 1989 to 2.9 per 100,000 person years in 
2009 (EAPC= +1.7%; 95% CI: 1.2-2.3), corresponding to an increase from 315 cases in 1989 
to 537 in 2009. For females the incidence rate increased from 3.1 in 1989 to 4.1 per 100,000 
person years in 2009 (EAPC= +1.7%; 95% CI: 1.1-2.4). The EAPC for females changed from 
+0.1% (95% CI: -0.9-1.2) before 2001 to +4.7% (95% CI: 2.7-6.7) aft er 2001. For males the 
incidence rate increased from 1.0 in 1989 to 1.7 per 100,000 person years in 2009 (EAPC= 
+1.6%; 95% CI: 1.2-2.3). Incidence rates increased for all age groups, except for females ≥ 65 
years (Figure 1a).
The percentage of papillary TC cases increased for males from 47% in 1989 to 61% in 2009 
and for females from 51% in 1989 to 67% in 2009 (p<0.01; Table 1). The overall incidence 
rate increased for papillary TC from 1.0 in 1989 to 2.1 per 100,000 person years in 2009 
(EAPC = +3.6%; 95% CI: 3.0-4.2). The EAPC for papillary TC changed from +0.7% (95% CI: 
-1.9-3.3) before 1996 to +4.9% (95% CI: 3.8-5.9) aft er 1996, this trend was only found for 
females (Figure 1b). The incidence of follicular and medullary TC remained relati vely stable 
and the incidence of anaplasti c TC decreased slightly over ti me (EAPC = -1.9%; 95% CI: -3.3 
- -0.5) for both sexes.
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Table 1: Age, histology, and T stage of thyroid cancer patients in The Netherlands, 1989-2009 (n=8021) 



































<45 38 34 33 32 40 40 43 39
45-59 28 26 29 29 19 23 23 26
60-74 23 25 23 26 26 22 18 19
≥75 12 15 15 13 15 15 15 16
Histology
Papillary carcinoma 47 49 55 61 51 56 62 67
Follicular carcinoma 22 20 20 19 25 22 19 16
Poorly differentiated 
carcinoma
6 7 4 4 5 4 5 4
Medullary carcinoma 14 14 11 10 7 8 5 5
Anaplastic carcinoma 8 8 8 4 9 8 7 6
Other 3 2 3 2 3 3 2 3
T stage
1 12 16 16 29 14 15 19 36
2 35 29 31 20 40 43 41 25
3 13 14 16 27 11 12 12 20
4 22 21 20 14 21 18 18 12
X 18 20 16 10 14 12 10 7
# 6-year period
For T1 disease, the incidence rate increased from 0.2 in 1989 to 1.1 per 100,000 person years 
in 2009 (EAPC= +7.9%; 95% CI: 5.8-10.0) and for T3 disease the incidence rate increased 
from 0.2 in 1989 to 0.7 per 100,000 person years in 2009 (EAPC= +5.8%; 95% CI: 4.1-7.6). 
The EAPC for T1 changed from +2.1% (95% CI: -1.3-5.6) before 2002 to +14.3% (95% CI: 3.5-
26.3) after 2002 and T3 changed from +0.2% (95% CI: -2.6-3.1) before 2002 to +9.5% (95% CI: 
5.9-13.1) after 2002, these jointpoints were only found for females (Figure 1c). The overall 
incidence rate of T2 disease remained stable from 0.8 in 1989 to 0.7 per 100,000 person 
years in 2009 (EAPC= -1.1%; 95% CI: -2.2 - - 0.02). For females, the EAPC for T2 changed 
from +1.6% (95% CI: 0.2-3.0) before 2002 to +3.9% (95% CI: 3.5-26.3) after 2003 (with and 
decrease of -49.6% between 2002 and 2003 due to the change in TNM classification; Figure 
1c). This trend was not found for males (EAPC= -1.3% (95% CI:-3.4-0.9)). The incidence rate 
for T4 disease decreased by -2.3% (95% CI: -3.3 - -1.4) per year between 1989-2009; and 
changed from -0.2% (95% CI: -2.4-2.0) before 2002 to -2.4% (95% CI: -5.6-1.0) after 2002.
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Incidence (ESR) TC for males by age
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Incidence (ESR) TC for females by age
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figure 1a: Three-year moving average of age-standardized incidence rates (ESR) of thyroid cancer in 







































































































Incidence (ESR) TC for males by histology
In the Netherland 1989
-
2009
Incidence (ESR) TC for females by histology
In the Netherland 1989-2009
figure 1b: Three-year moving average of age-standardized incidence rates (ESR) of thyroid cancer in 
The Netherlands 1989-2009 according to gender and histology.
8
TRENDS IN THYROID CANCER INCIDENCE, MORTALITY AND SURVIVAL
127
Incidence (ESR) TC for males by T stage






































































































Incidence (ESR) TC for females by T stage




































































































figure 1c: Three-year moving average of age-standardized incidence rates (ESR) of thyroid cancer in 
The Netherlands 1989-2009 according to gender and T stage.
Verti cal line represents the change in TNM classifi cati on in 2003. UICC 5th editi on:  T1 tumour size maximal 1 cm; 
T2 tumour size > 1 cm and ≤ 4 cm; T3 tumour size > 4 cm limited to the thyroid; T4 any tumour with extrathyroid 
extension 11. UICC 6th editi on: T1 tumour size maximal 2 cm; T2 T2 tumour size > 2 cm and ≤ 4 cm;  T3 tumour size 
> 4 cm limited to thyroid or minimal extrathyroid extension; T4 tumour extends beyond thyroid capsule 12
relati ve survival
Overall, fi ve-year relati ve survival from TC remained stable, although appeared to increase 
in males from 74% in 1989-1993 to 82% in 2004-2009 and in females from 78% to 81% (Table 
2). While in 1989-2003, 5-year relati ve survival was bett er for females than in males, this 
discrepancy disappeared aft er 2003. Five-year relati ve survival decreased with increasing 
age at diagnosis, being  ~98% for <45 years, ~88% for 45-59 years, ~61% for 60-74 years and 
~42% for 75+ years in the enti re study period, and increased non-signifi cantly for all age 
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groups over time. Survival decreased with increasing stage of disease, with 5-year relative 
survival of ~95% for T1 disease in the entire period 1989-2009, while the 5-year relative 
survival for T2, T3, T4 disease were respectively, ~94%, ~80%, and ~52% in the entire study 
period. A non-significant increase over time was seen in survival of T1, T2, T3 thyroid cancer, 
while survival from T4 appeared to decrease over time. Five-year survival rates remained 
more or less stable for papillary TC (~93%) and follicular TC (~87%) over the entire study 
period and appeared to decrease slightly for medullary TC from 68% to 64% in 2004-2009. 
The 1-year relative survival for anaplastic thyroid cancer decreased from 16.2% in 1989-
1993 to 14.5% in 2004-2009. 
Table 2: Five-year relative survival (standard error) by period of diagnosis, T stage, and age





Male 74 (2.5) 74 (2.4) 74 (2.3) 82 (2.1) 2.5 (-3.2-8.2) 0.20
Female 78 (1.4) 81 (1.3) 83 (1.2) 81 (1.4) 1.1 (-1.7-3.9) 0.23
age (years)
<45 97 (0.8) 97 (0.7) 98 (0.5) 98 (0.7) 0.5 (-0.3-1.4) 0.11
45-60 86 (2.1) 86 (1.8) 89 (1.6) 90 (1.6) 1.5 (-0.2-3.2) 0.06
60-75 59 (2.8) 58 (2.9) 59 (2.9) 67 (3.1) 2.5 (-4.4-9.4) 0.26
75+ 36 (4.4) 48 (4.8) 40 (4.2) 42 (4.9) 1.1 (-11-13) 0.78
T stage
1 94 (2.2) 95 (1.8) 95 (1.5) 97 (1.0) 1.0 (-0.6-2.6) 0.12
2 92 (1.5) 95 (1.2) 94 (1.1) 94 (1.8) 0.6 (-2.4-3.5) 0.51
3 76 (4.2) 79 (3.6) 84 (3.0) 80 (3.1) 2.0 (-3.5-7.4) 0.26
4 59 (3.2) 56 (3.2) 56 (3.0) 39 (3.7) -5.8 (-17-5.7) 0.16
Xb 45 (4.2) 43 (3.9) 37 (4.0) 37 (5.5) -2.9 (-6.4-0.6) 0.07
Histology
Papillary carcinoma 93 (1.2) 93 (1.1) 94 (1.0) 93 (1.1) 0.2 (-1.0-1.3) 0.61
Follicular carcinoma 87 (2.2) 88 (2.4) 88 (2.2) 86 (3.2) -0.3 (-2.6-2.0) 0.63
Poorly differentiated 
carcinoma
27 (5.3) 20 (5.1) 35 (5.7) 44 (7.7) 6.6 (-6.5-20) 0.16
Anaplastic carcinoma 0 0 0 0 0 n.a.
Medullary carcinoma 68 (4.5) 78 (3.8) 62 (4.9) 64 (5.8) -2.8 (-17-11) 0.46
Other n.a. n.a. n.a. n.a. n.a. n.a.
a based on period analyses
b primary tumour cannot be assessed
n.a. not available
Multivariable relative survival analyses showed an increased risk of death for older patients, 
patients with a higher stage disease and a poorly differentiated, anaplastic or medullary 
tumour type, however no effect for period was found (Table 3). 
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Table 3: Relati ve excess risk (RER) of dying for thyroid cancer pati ents in The Netherlands






















Follicular carcinoma 1.0 0.8-1.3
Poorly diff erenti ated carcinoma 6.5* 5.2-8.1
Anaplasti c carcinoma 16.9* 13.9-20.7
Medullary carcinoma 3.9* 3.0-4.9
Other 5.9* 4.4-7.9
* P<0.05; Adjusted for follow-up interval































Mortality (ESR) TC by sex




figure 2: Three-year moving average of age-standardized mortality rates of thyroid cancer in The 




Mortality decreased with -1.9% (95% CI:-2.8- -0.9) per year between 1989 and 2009 (Figure 
2), more in males (-2.2%) than in females (-1.7%). In absolute numbers we observed a slight 
increase from 98 deaths in 1989 to 105 deaths in 2009. 
dIsCussIOn
Our study shows that since 1989 the incidence of TC increased significantly in The 
Netherlands, while mortality from TC decreased. This increase was due to papillary tumours 
only. Five-year relative survival remained stable and appeared to be somewhat higher for 
both sexes, all age groups and T1-T3 tumours and somewhat lower for T4 and medullary 
tumours in the period 2004-2009 compared to earlier periods. The one-year survival rate of 
anaplastic tumours remained low. 
The rising age-standardized incidence of TC in The Netherlands is in concordance with 
patterns observed in many other European countries and the US 1. The increase in our study 
was mainly due to the increased number of detected early stage tumours (T1) of papillary 
histological subtype. This shift to the detection of more early stage papillary tumours can 
partly be explained by the change in TNM classification in 2002, however the T1 incidence 
rates were already increasing before 2002 16 and incidence rates for T2 were also increasing 
after 2002. The incidence rates started to increase at a younger age in women than in men, 
possibly related to greater use of health care services by young and middle-aged women 
compared to men of the same age 17. Also, the incidence rate of papillary TC increased 
more steeply among women than men, likely because of the higher number of biopsies 
performed in this population 18.
The main question debated in the literature is whether or not the observed increase in TC 
incidence is the result of a real increase in number of cases or of improved detection? A 
recent study in the US showed a significant decrease in tumour size over time and concluded 
that the apparent increase in TC incidence was largely  due to more detection of subclinical 
disease 8. It has been shown that TC can exist as subclinical entity since at least one third 
of the adults have subclinical TC at autopsies 19. Improved detection by the increased 
use of and improved (resolution of) diagnostic tools and medical surveillance might be 
responsible for the detection of more subclinical disease and could also have resulted in 
a shift in detection from more advanced tumours to early stage tumours 18. Nevertheless, 
incidence rates also increased for T3 tumours, and this increase was larger than the 
decrease in incidence rates of T4 tumours. This increasing trend might be less related to the 
improved detection and increased surveillance. True increases in incidences of TC have been 
8
TRENDS IN THYROID CANCER INCIDENCE, MORTALITY AND SURVIVAL
131
associated with diff erent risk factors like exposure to ionizing radiati on (fallout, diagnosti c 
tests like computed tomography scans and treatments like radiotherapy), low iodine intake 
6 20 and overweight 7. However, none of these factors have been proven as risk factors in 
The Netherlands. Therefore more research into the events involved in the initi ati on and 
progression of thyroid cancer is needed.
Five-year relati ve survival rates for diff erenti ated TC were high and within the range of 
rates described for the US 21 and Europe 22. The small diff erences suggest corresponding 
diff erences in the availability of diagnosti c and treatment opti ons, and in the eff ecti veness 
of healthcare systems. The non-signifi cant decrease in fi ve-year relati ve survival rates for T4 
tumours could be explained by the decrease in incidence of the slowly growing T4 tumours, 
indicati ng that those tumours are earlier detected as T3 tumours. Furthermore, since 
2002 any tumour with minimal extrathyroidal extension is registered as T3 instead of T4 
and anaplasti c tumours are also registered as T4, leaving the truly advanced cancers with a 
worse prognosis as T4, which could explain the decrease in survival rates for these tumours.
Five-year relati ve survival rates for anaplasti c (5.6 – 11.4% depending on race) and 
medullary cancer (73.5 – 88.7% depending on race) were higher is the US compared to 
The Netherlands 21. The low incidence rates of both tumours have limited the development 
of clinical experti se and conducti on of randomized clinical trials 23. The American Thyroid 
Associati on recently came up with evidence-based management guidelines for medullary 
23 and anaplasti c TC 24. Disseminati on of standardized guidelines to Europe is important to 
ensure opti mal treatment for these pati ents. Recently, a study showed improved disease-
specifi c survival for a subpopulati on of anaplasti c TC pati ents who were treated by aggressive 
multi modal regimes based on a prognosti c index 25. Applicati on of this prognosti c index in 
The Netherlands could possibly lead to some improvements in survival rates for this most 
lethal tumour. 
The increased incidence of TC was not accompanied by a concurrent increase in TC mortality 
which even decreased for both men and women, equal to other studies in Europe 9 and the 
US 26. Many of the detected tumours were indeed small treatable cancers. The detecti on of 
these small tumours could have preceded development of more advanced cancers (T4) or 
tumours with more unfavourable prognosis such as medullary and anaplasti c cancers whose 
incidence decreased and whose prognosis remained stable or decreased. 
Since a large part of the increased incidence in our study can be ascribed to the detecti on 
of small (subclinical) tumours, overdiagnosis of clinically irrelevant cancer might be 
occurring 27. Indeed, most pati ents with cytological indeterminate nodules are referred 
for diagnosti c thyroid surgery, but the majority (66%) prove to have benign disease 28 
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and for these patients surgery is unnecessary 29. It has been hypothesized that increased 
detection of low risk tumours can lead to an overestimation of treatment efficacy and a 
subsequent rise in use of treatment 30. Up to now, there is a lack of randomized controlled 
trials to support management decisions for small and low-risk tumours. For patients with 
early-stage differentiated TC whose primary tumour is > 1 cm the guidelines recommend 
total thyroidectomy and radioactive iodine treatment to be selectively considered 9. 
Nevertheless, treatment with radioactive iodine is of uncertain benefit for patients with 
low-risk disease 31. In addition, the majority of patients with early-stage differentiated TC will 
have a favorable outcome and many of these tumours would remain asymptomatic during 
lifetime 32 However a small proportion of these patients will experience recurrent disease 
with increased morbidity 33. There is a need to improve the preoperative evaluation of low-
risk thyroid nodules in order to prevent potential overtreatment and in addition to this a 
more conservative surgical approach without radioiodine therapy should be considered for 
low risk patients 33.  A complete understanding of the various prognostic factors is important 
to  advise the patient accordingly on the best treatment and long-term surveillance 26. This 
is important since we recently showed that problems and symptoms of TC and its treatment 
can be detected up to 20 years after diagnosis 34. These late symptoms were mostly related 
to thyroid dysregulation (neuromuscular, concentration, sympathetic, psychological and 
sensory problems) and not so much to specific morbidities as a consequence of surgery (voice 
problems, throat/mouth problems and problems with scar). Long term health problems are 
becoming more important since the prevalence of TC survivors who received more or less 
aggressive/invasive treatment is increasing and will probably lead to an increased burden on 
health care in the coming years.
By combining the three epidemiologic determinants of TC burden (i.e., incidence, mortality 
and survival) with essential prognostic determinants we achieved a more comprehensive 
assessment of the progress against TC, however also quality of life assessments should be 
added 35. Some limitations of this study require consideration. Despite the rather clinical 
nature of the Netherlands Cancer Registry (NCR), lack of details regarding applied primary 
treatments in our population-based registry limited the potential to explore and elucidate 
specific reasons for the observed changes in survival. Also, information on the exact tumour 
size is lacking in the NCR. Thirdly, to calculate 5-year relative survival, we used two different 
methods, i.e., cohort- and period-based survival analyses. However, the cohort- and period-
based 5-year relative survival estimates exhibited relatively small differences. 
In conclusion, TC detection and incidence has been rising in The Netherlands, while mortality 
rates are decreasing and survival rates remained stable and appeared to be somewhat 
higher except for advanced tumours of which the frequency decreased markedly. 
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Health-related quality of life among thyroid 
cancer survivors: a systemati c review
O. Husson, H.R. Haak, W.A. Oranje, F. Mols, P.H.M. Reemst, L.V. van de Poll-Franse




background: Treatment and follow-up care procedures of thyroid cancer impose great 
challenges on survivors and could potentially affect their health-related quality of life 
(HRQoL).
methods: Two authors systematically reviewed the available literature on HRQoL of thyroid 
cancer survivors. A PubMed literature search for original articles published until February 
2011 was performed. Twenty-seven articles, conducted between 1997 and 2010, which met 
the predefined inclusion criteria, were subjected to a quality checklist.
results: All selected studies, except one, were of adequate or good quality. Surgery had a 
negative impact on short-term HRQoL scores, but these scores returned to preoperational 
levels when time since surgery increased. Long-term thyroid hormone therapy (levothyroxine) 
can lead to abnormalities like hyperthyroidism. HRQoL was most affected during thyroid 
hormone withdrawal for radioiodine remnant ablation or follow-up procedures. The use of 
recombinant human thyroid stimulating hormone instead of hormone withdrawal leads to 
considerable improvements in HRQoL during follow-up testing. The results for (long-term) 
survivors were contradicting. While most (long-term) survivors report some specific long-
lasting health problems, some studies found a lower HRQoL for thyroid cancer survivors 
compared with a healthy population or other reference groups, whereas other studies 
found similar HRQoL levels.
Conclusion: This review indicates that thyroid cancer survivors generally have a similar or 
slightly worse HRQoL compared to the normative population, however they report some 
specific medical problems after cancer treatment and follow-up tests which have a direct 
negative impact on their current HRQoL and could affect their long-term HRQoL. Specific 
longitudinal survivorship studies are lacking.
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InTrOduCTIOn
The incidence of thyroid cancer is rising worldwide. As the mortality rate remains relati vely 
stable, the number of thyroid cancer survivors is growing, with over 430,000 people with 
a history of thyroid cancer in the United States in 2007 1, 2. Treatment of thyroid cancer 
mostly involves surgery (total thyroidectomy or hemithyroidectomy with or without 
lymphadenectomy) followed by radioiodine ablati on therapy. These aggressive surgical 
and postoperati ve treatments are associated with toxicity and long-term physical and 
psychological morbidity 3.The removal of the total thyroid gland is accompanied by a lifelong 
dependence on exogenous thyroid hormone (levothyroxine). Despite the effi  cacy of these 
primary treatments and the high long-term survival rates, the disease can recur even 
decades later. Therefore long-term follow-up (neck ultrasonography; serum thyroglobulin 
(Tg) measurement following TSH sti mulati on; iodine-131 whole body scanning (WBS)), is 
necessary and associated with physical and psychological discomfort. In case of recurrence, 
additi onal radioiodine treatment or surgery is indicated. The treatment and follow-up care 
procedures impose great challenges on thyroid cancer survivors and could potenti ally aff ect 
their health-related quality of life (HRQoL).
The aim of cancer treatment is not only to increase survival but also to preserve HRQoL 4. 
HRQoL is a multi dimensional construct that covers the pati ents’ percepti ons of his or her 
physical, emoti onal, social, and cogniti ve functi ons. HRQoL assessment is an important 
aspect of cancer care. It gives a good overview of cancer pati ents’ subjecti ve experiences 
with cancer, its treatment, and follow-up procedures 5. Cancer survivors oft en deal with 
adaptati on problems and assessment of their HRQoL could help to improve aft ercare 6. The 
recent availability of recombinant human thyroid sti mulati ng hormone (rhTSH or thyrogen) 
as a less burdensome alternati ve for thyroid hormone withdrawal in the follow-up procedure 
sti mulated the research into the HRQoL of thyroid cancer pati ents. However, litt le is known 
about the impact of primary treatment and follow-up therapies on the HRQoL of (long-
term) cancer survivors.  The US Nati onal Coaliti on for Cancer Survivorship defi nes a person 
as a survivor from the moment of diagnosis through the balance of his or her life 7. The term 
‘long-term cancer survivors’ refers to those who are living 5 years or more beyond a cancer 
diagnosis. The goal of this review is to provide a complete overview of the literature on the 






A computerized search of the literature through the search engine Pubmed was performed 
on February 7, 2011. The search strategy combined the term ‘thyroid cancer’ or ‘thyroid 
carcinoma’ with other key terms: ‘quality of life’, ‘QoL’, ‘health-related quality of life’, 
‘HRQoL’, ‘health status’ and ‘well-being’. The reference lists of all identified publications 
were checked to retrieve other relevant publications. There were no restrictions with regard 
to the year of publication. The search yielded 371 hits.
selection criteria
Studies that met the following criteria were included: (1) if the objective was to describe 
HRQoL of thyroid cancer patients (2) if the publication was an original article (3) if the article 
was a full report published in English and (4) if it was published in a peer-reviewed journal. 
Studies were excluded for the following reasons: (1) if the study focused on terminally ill 
patients (life expectancy of less than 6 months) or children with thyroid cancer (<18 years of 
age), (2) if the study focused on patients with other thyroid diseases such as hypothyroidism 
without having thyroid cancer or other cancers as head-neck cancer or nasopharyngeal 
cancer, (3) if the study focused on risk groups with a (genetic) predisposition for thyroid 
cancer, (4) if the study only described experienced symptoms instead of HRQoL outcomes 
(5) if the objective was to describe the relation of HRQoL with other variables such as mood 
states, without the description of HRQoL itself.
The described inclusion and exclusion criteria were applied to our initial 371 hits. Based 
on their titles and abstracts, 37 articles met our criteria. The hard copies were obtained 
and reviewed by two investigators (OH and LP). After careful review, 27 articles fulfilled our 
selection criteria and were included in this review. The flow-chart of this selection procedure 
is shown in Figure 1.
Quality assessment
The methodological quality of each of the selected articles was independently assessed by 
the two investigators based on established criteria for systematic reviews (Table 1) 8. Each 
item of a selected study, that matched our criteria, was assigned one point. If an item did not 
meet our criteria or was described insufficiently or not at all, zero points were assigned. The 
highest possible score was 12. Studies scoring 10 points or more were arbitrarily considered 
to be of ‘high quality’. Studies scoring between 6 and 10 points were rated as ‘adequate 
quality’. Studies scoring less than 6 points were considered to be of ‘low quality’.
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Figure 1 Flow -chart of selection procedure 
 






Computerized search of databases and 
reference checking 
371 articles  found 
  
371 hits 
334 articles  excluded due to selection criteria 
and removal of duplicate articles 
37 articles potentially applicable 
Hard copies were obtained for more detailed 
evaluation of our selection criteria 
27 articles  were finally selected for this 
review 
After applying our selection criteria to the 
hard copies 10 articles  were excluded 
because they: 
- described symptoms instead of 
HRQoL measures (5)  
- were written in Polish (1) and 
German (1) 
- focused on patients with other 
thyroid diseases (2) 
- described the relation of HRQoL 
with other variables, without the 
description of HRQoL (1)  
figure 1: Flow-chart of selecti on procedure
Table 1: List of criteria for assessing the methodological quality of studies on quality of life of thyroid 
cancer pati ents
Positi ve if with respect to
HRQoL assessment
1. A valid (health-related) quality of life and/or health status questi onnaire is used.
Study populati on
2. A descripti on is included of at least two socio-demographic variables (e.g., age, employment status, 
educati onal status).
3. A descripti on is included of at least two clinical variables of the described pati ent populati on (e.g., tumour 
stage at diagnosis).
4. Inclusion and/or exclusion criteria are described.
5. Parti cipati on and response rates for pati ent groups have to be described and have to be more than 75%.
6. Informati on is given about the degree of selecti on of the pati ent sample (informati on is given about the rati o 
respondents versus non-respondents.
Study design
7. The study size is consisti ng of at least 50 pati ents (arbitrarily chosen).
8. The collecti on of data is prospecti vely gathered.
9. The process of data collecti on is described (e.g., interview or self-report etc.).
Results
10. The results are compared between two groups or more (e.g., healthy populati on, groups with diff erent 
treatment or age) and/or results are compared with at least two ti me points (e.g., longitudinally versus 
post-treatment).
11. Mean, median, standard deviati ons or percentages are reported for the most important outcome measures.





In total, 27 studies were included, all published between August 1997 and September 2010. 
HRQoL was the primary outcome in all studies. Eight studies focused on the impact of a 
specific treatment on HRQoL, 11 studies on the impact of follow-up procedures on HRQoL 
(3 of these also focused on some aspects of treatment) and 11 studies evaluated HRQoL 
among (long-term) cancer survivors. Prospective, cross-sectional, observational as well 
as intervention studies were included. The SF-36 9 was the most frequently used HRQoL 
questionnaire. The main findings are summarized in Table 2. 
methodological quality
The evaluation of the methodological quality of the studies by the two reviewers yielded 
disagreement on 11 items (3.3%), mostly due to differences in interpretation. These were 
solved through discussion in a consensus meeting. The quality scores ranged from 2 to 12 
points (Table 2) and the mean quality score was 8.8. One of the studies had a low quality 
according to our criteria and 10 studies had a high quality. The remaining 16 studies had an 
adequate quality. General shortcomings of the included studies were a lack of description of 
inclusion and/or exclusion criteria, response rates below 75%, a cross-sectional design, and 
a lack of information on the degree of selection of the patient sample. The studies will be 
discussed in order of their aim, starting with the effects of specific treatments and follow-up 
procedures on HRQoL, and ending with the HRQoL of (long-term) thyroid cancer survivors in 
general. Terminology is not consistent over the included articles, therefore ‘HRQoL’ is used 
throughout this manuscript to overcome illegibility.
Thyroid cancer treatments
Surgery
Three studies, two prospective 10, 11 and one cross-sectional 12, focused on the effects of 
surgery on HRQoL of thyroid cancer patients. 
The first prospective study showed that thyroid cancer patients who underwent (hemi)
thyroidectomy had worse scores on social functioning, mental health and role limitation due 
to physical and emotional problems in comparison with the general population of the United 
States 10. However, there was a trend towards recovery when time since surgery increased up 
to 12 months after operation. There were no differences in HRQoL scores between patients 
who underwent total thyroidectomy and patients who underwent hemithyroidectomy at any 
time point. The second prospective study demonstrated that postoperative HRQoL scores 
(12 months after surgery) on the domain of eating and emotional functioning, for patients 
who underwent tracheal resection for locally invasive thyroid cancer, were significantly 
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bett er than those of a comparison group composed of pati ents undergoing treatment for 
oropharynx cancer 11. Baseline HRQoL scores were lacking in this prospecti ve study. 
In a cross-secti onal study (pati ents’ median ti me since treatment was 2 years), pati ents 
submitt ed to modifi ed radical neck dissecti on reported worse chewing and shoulder scores 
than pati ents submitt ed to selecti ve paratracheal lymph node dissecti on and pati ents who 
only underwent total thyroidectomy 12. A mild dysfuncti on of the shoulder of pati ents 
undergoing neck dissecti on was also found in a study aimed to investi gate HRQoL of long-
term thyroid carcinoma survivors 13.
In summary, surgery for thyroid cancer leads to worse mental and physical HRQoL scores 
compared to the scores of the general populati on, however there is a trend towards recovery 
in ti me.  The size of the eff ect of HRQoL depends on the type of surgery.
Radioiodine remnant ablati on
Two randomized controlled trials focused on the eff ects of radioiodine ablati on with or 
without recombinant human TSH (rhTSH) 14, 15 on HRQoL. In both studies, HRQoL of euthyroid 
pati ents on L-thyroxine treatment receiving rhTSH was preserved compared to a drop in 
HRQoL for hypothyroid pati ents withdrawing L-thyroxine treatment to prepare for remnant 
ablati on. In the Italian study, scores of seven of the eight scales of the SF-36 improved for 
the euthyroid group from baseline (within 14 days aft er thyroidectomy) to one month aft er 
ablati on (week 4), while these same scores deteriorated for the hypothyroid group 14. In the 
French study, physical well-being, functi onal well-being, and fati gue were aff ected in the 
hypothyroid group at t1 (leaving the hospital aft er remnant ablati on) compared to baseline 
(one day aft er thyroidectomy). However, HRQoL was preserved in the euthyroid pati ents 
aft er remnant ablati on. Aft er 3 (t2) and 9 months (t4), the groups were no longer stati sti cally 
signifi cant diff erent on HRQoL 15.
A cross-secti onal study found that postoperati ve radioacti ve iodine treatment was the 
most important predictor of HRQoL in pati ents with thyroid cancer, aff ecti ng the domains 
chewing, speech, taste, saliva and anxiety 12. This study also concluded that pati ents who 
received higher doses (more than 150 mCi) of radioacti ve iodine reported signifi cantly 
worse HRQoL compared to pati ents who received lower doses.
In summary, radioiodine remnant ablati on aff ects some, mainly physical, domains of HRQoL, 
however rhTSH preserves HRQoL bett er than withdrawing levothyroxine treatment. 
Thyroid hormone therapy
Four studies, three prospecti ve 16-18and one cross-secti onal study 19, focused on the eff ects 
of lifelong thyroid hormone treatment on HRQoL.
The fi rst prospecti ve study found that pati ents under chronic suppressive levothyroxine 
treatment (chronic mild or subclinical hyperthyroidism) had an impaired HRQoL compared 
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with healthy age-matched controls 18. The total score and the emotional, sleep, energy and 
social scales of the Nottingham Health Profile and mental health, general health and social 
function of the SF-36 were lower in the thyroid cancer patient group at baseline (under usual 
levothyroxine dose). After 4 to 7 days of withdrawal of levothyroxine, necessary for whole 
body scanning, HRQoL scores were better than under levothyroxine treatment although one 
day before scanning (hypothyroid state) the HRQoL scores were worse.
In a randomized controlled trial it was investigated whether restoration to euthyroidism 
by decreasing levothyroxine dose improved HRQoL parameters. After 6 months, all 
HRQoL parameter values of the low TSH-group were the same as the baseline values. 
For the euthyroid group, only the role limitations as a result of physical problems (SF-36) 
deteriorated after 6 months 17. The authors concluded that restoration of euthyroidism in 
general does not affect HRQoL.
Another prospective study found that patients on thyroid hormone treatment, before 
rhTSH, were not significantly different from the US norm population on four of the eight 
SF-36 scales (physical functioning, vitality, social functioning and role emotional) and on 
the mental component scale. However, patients on thyroid hormone therapy scored better 
than the US norm population on two scales (role physical function and bodily pain) and the 
physical component scale whereas they scored worse on the general and mental health 
scale 16.
A cross-sectional study evaluated the effects of chronic suppressive doses of levothyroxine 
on HRQoL. Compared with the German general population, patients scored lower on seven 
of eight SF-36 domains (not bodily pain) and on the mental component scale 19. However, 
patients using levothyroxine scored better on physical functioning, role-physical, bodily pain, 
vitality and role-emotional scales and the mental and physical component scores compared 
to patients under short-term hypothyroidism 19.  
In summary, levothyroxine treatment results in similar or slightly impaired HRQoL compared 
to the general population.  
Thyroid cancer follow-up tests
Thyroid hormone withdrawal for Tg measurement and/or whole body scanning
Four prospective studies found a negative effect of thyroid hormone withdrawal on several 
aspects of HRQoL 18, 20-22. The first study found a significant reduction of HRQoL from the week 
before the radioiodine scan to peak thyroid hormone withdrawal, while there was a gradual 
improvement from peak withdrawal to 4 weeks after the scan at normal levothyroxine 
therapy. The main differences in HRQoL between peak withdrawal and normal levothyroxine 
therapy were seen on the physical, psychological and social well-being scales, both for the 
thyroid specific HRQoL and the general HRQoL (FACT-G)  20. Besides this, the second study 
also found a reduction in the spiritual domain between baseline (prior to withdrawal) and 
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aft er the 3 week withdrawal period. Four weeks aft er resumpti on of the thyroid hormone 
therapy the HRQoL domains were similar to baseline levels 21. The third prospecti ve study 
found that HRQoL worsened with the ti me of levothyroxine withdrawal. In the fi rst 2 weeks 
of levothyroxine withdrawal there was a signifi cant worsening of the physical domain and 
total HRQoL score of the FACT-G, and additi onally aft er 4 weeks of withdrawal the emoti onal 
and social domains were also signifi cantly aff ected compared with the start of withdrawal 
22. Another study found that pati ents in profound hypothyroidism aft er withdrawing 
levothyroxine treatment for whole body scanning had worse scores on all HRQoL indexes of 
the SF-36 and Notti  ngham Health Profi le compared to euthyroid controls 18.
One prospecti ve study searched for HRQoL eff ects of a short (3 week) levothyroxine 
withdrawal instead of a long (4 weeks) levothyroxine withdrawal for thyroglobulin screening. 
There was a signifi cant reducti on in 6 of the 8 HRQoL scales of the SF-36 (physical functi on, 
role-physical, vitality, social functi on, role-emoti onal and mental health) from the ti me of 
withdrawal to the ti me of peak TSH. Four weeks aft er resumpti on of levothyroxine therapy 
HRQoL returned to prewithdrawal levels for all categories. In comparison with the general 
populati on SF-36 scores, except vitality, did not fall below 50% of the general populati on 
scores 23.
A qualitati ve cross-secti onal study found that changes in physical well-being due to 
withdrawal from thyroid hormone medicati on infl uenced psychological en social well-being 
24. The other two cross-secti onal studies evaluated the eff ects of short-term hypothyroidism 
in pati ents hospitalized for radioiodine therapy or whole body scanning 5, 19. The hypothyroid 
pati ents scored worse in seven of eight domains of the SF-36 in the fi rst study 19 and on 
all domains in the second study compared with the German general populati on 5. The 
mental component score of the SF-36 was also signifi cantly lower in both studies for the 
hypothyroid pati ents and the physical component score was worse in the second study for 
the hypothyroid group. 
In summary, thyroid hormone withdrawal causes signifi cant reducti ons in physical and 
mental HRQoL. Aft er resumpti on of the levothyroxine treatment HRQoL levels will return to 
prewithdrawal levels.
Thyroid hormone withdrawal vs. rhTSH for Tg measurement and/or WBS
Three prospecti ve studies were conducted to assess HRQoL diff erences between rhTSH and 
thyroid hormone withdrawal in thyroglobulin measurement and/or whole body scanning 
16, 25, 26. The fi rst prospecti ve multi center study found that aft er rhTSH administrati on, 7 of 
8 domains of the SF-36 were at or above the level of the US reference group; only general 
health was signifi cantly lower for the rhTSH group. In contrast, aft er hormone withdrawal 
the pati ents scored signifi cantly worse on all 8 domains compared to the US reference group 
16. The same was found in the other two studies where rhTSH pati ents reported signifi cantly 
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better HRQoL scores on performance of physical activities, problems with daily activities as 
a result of physical health, bodily pain, and emotional problems compared to hypothyroid 
patients. The physical component score of the SF-36, but not the mental component score, 
was also higher for rhTSH patients 25, 26.
In summary, the use of rhTSH instead of thyroid hormone withdrawal prevents HRQoL 
deterioration accompanied by the withdrawal. 
Thyroid cancer survivors
Eleven studies, 2 prospective 27, 28 and 9 cross-sectional 13, 29-36, focused on the HRQoL of 
(long-term) thyroid cancer survivors. One prospective study found no significant differences 
in SF-36 scores between thyroid cancer patients (14  years since the primary operation) 
and a healthy Swedish reference population 27. However, the other prospective study found 
significant differences in HRQoL between patients with differentiated thyroid cancer (DTC) 
(diagnosed from < 1 to 23 years earlier) and a control group of subjects with non-toxic 
multinodular goiter (enlargement of the thyroid that is not associated with overproduction 
of thyroid hormone or malignancy) on levothyroxine therapy 28. DTC patients scored worse 
on anxiety, depression, somatisation, hostility. A second evaluation with a subset of the 
thyroid cancer patients after 8-14 months showed a slight improvement in overall sum 
scores and on the somatisation scale.
Four cross-sectional studies found worse HRQoL scores for thyroid cancer survivors 
compared with healthy reference groups 29-31, 35. Thyroid cancer patients (5 months - 
27 years after diagnosis) had lower scores on all domains of the SF-36 except for social 
functioning compared to the general Singaporean population. Older patients (≥ 50 years) 
scored worse on physical functioning, higher educated patients (>12 years) scored better 
on mental health, and employed patients scored better on role physical emotional domains 
compared to their counterparts 29. Compared with German reference values, patients 
with non-metastatic thyroid cancer under levothyroxine therapy (mean period since the 
diagnosis of thyroid cancer was 5.5 years) reported significantly lower vitality, role-physical, 
mental health, role-emotional and social functioning domains of the SF-36 during their 
first year after diagnosis. After this first year, the SF-36 domains increased correlating with 
the time since initial diagnosis, except for vitality and role-emotional functioning 30. When 
compared with Dutch controls, selected by patients themselves, thyroid cancer survivors 
(median time after initial treatment was 6.3 years) scored worse on social functioning and 
general health of the SF-36. When compared with age- and gender-matched controls from 
other HRQoL-studies, physical functioning and role limitations due to physical problems 
were also negatively affected in the patient group. Better scores on the social functioning, 
role limitations due to physical problems and general health scales were correlated with 
a longer time since initial treatment 31. Disease-free survivors of DTC showed decreased 
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HRQoL compared with age-matched controls from the Korean general populati on on fi ve 
functi onal domains (physical, role, cogniti ve, emoti onal and social) of the EORTC-QLQ-C30 
35. A lower HRQoL was associated with higher scores on anxiety, depression and fati gue.
One cross-secti onal study found no signifi cant diff erences in total HRQoL scores on the 15D 
between thyroid cancer survivors (mean 12.4 years aft er initi al treatment) and an age- and 
gender-standardized general Finnish populati on. The survivors scored worse on the sleeping, 
speech and distress domains of the 15D and bett er on the discomfort and symptom items 
compared to the general populati on. Older age at ti me of initi al treatment was associated 
with worse HRQoL 32.
Four cross-secti onal studies without a reference group found that thyroid cancer survivors 
reported good long-term health 33 and scored very high on all domains of the EORTC-
QLQ-C30 34, but also reported thyroid specifi c, lasti ng medical problems due to cancer and 
its treatment33, 34. The mean score of general health was 3.1 on a 5-point scale for pati ents 
who underwent total thyroidectomy 13. This was lower than expected when compared with 
other forms of cancer. The last study found that fati gue, high impact of operati onal scar, and 
chills (cold intolerance) were negati vely associated with HRQoL, while social support was 
positi vely correlated with HRQoL 36. Contradictory, they also showed that pati ents at 19-36 
months aft er thyroidectomy had lower HRQoL scores compared with those pati ents within 
18 months of operati on 36.
In summary, (long-term) thyroid cancer survivors score similar or worse on HRQoL scales 
compared to the general populati on. Thyroid cancer survivors report some specifi c long-
lasti ng problems.
dIsCussIOn
Thyroid cancer survivors report severe (long-term) impairments of HRQoL aft er treatment 
and follow-up procedures. Surgery had a negati ve impact on short-term HRQoL scores, but 
HRQoL scores recovered when the ti me since surgery increased. Based on one study, no 
diff erences were found between total thyroidectomy and hemithyroidectomy, more research 
is needed. The exact infl uence of surgery on HRQoL cannot be determined, because most 
pati ents received radioiodine shortly aft er the operati on which distorts the infl uence of 
surgery. Lifelong thyroid hormone therapy can lead to slightly impaired HRQoL scores, this 
impairment was not found in studies with higher quality. HRQoL was most aff ected during 
thyroid hormone withdrawal for radioiodine remnant ablati on or follow-up procedures. The 
use of rhTSH instead of hormone withdrawal leads to considerable improvements in HRQoL 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Studies that focused on (long-term) thyroid cancer survivors showed contradictory 
results. While most patients report some specific long-lasting health problems, most high 
quality studies found a lower HRQoL for thyroid cancer survivors compared with a healthy 
population or other reference groups, whereas lower quality studies found no differences 
with the normal population. However, long-term survivorship studies are lacking and also 
the influence of developing a metastasis on HRQoL is underreported. Comparison of the 
results of the included survivorship studies using the SF-36 as HRQoL questionnaire 27, 29-31, 
with data from studies with patients with chronic disorders showed that thyroid cancer 
survivors reported better HRQoL scores on all SF-36 subscales compared to patients with 
chronic heart failure, chronic obstructive pulmonary disease, fibromyalgia and depression 
38-40. Thyroid cancer survivors scored better or similar on the physical scales (physical 
functioning, bodily pain, general health, role-physical) and worse on vitality and the mental 
scales (social functioning, role-emotional, mental health) compared to diabetes mellitus 
patients 39, 41.
The results of the studies discussed in this review should be handled with caution. Most 
included studies were of adequate quality. However there were several methodological 
issues that impede drawing strong conclusions on the HRQoL of thyroid cancer survivors. 
First, there is a lack of a valid, thyroid cancer specific instrument to assess HRQoL 12, 42. Most 
studies used a general HRQoL questionnaire, which cannot capture the specific complaints 
associated with thyroid cancer and its treatment. Also, many different questionnaires were 
used to assess HRQoL which makes it difficult to compare the results of the different studies. 
Other problems were small sample sizes (less than 100 patients) 10, 11, 13-15, 17, 18, 20, 22, 24, 28, 34, lack 
of (healthy) control groups 12, 13, 20-24, 34, 36 and use of cross-sectional designs 5, 12, 13, 19, 24, 29-34, 36. 
Most studies focused on survivors between 1 and 5 years after diagnosis while the negative 
effects of cancer and its treatment can still fluctuate years thereafter.
The diagnosis and treatment of thyroid cancer significantly impacts the lives of survivors 43. 
Radical surgical treatment and toxicities of treatment can create chronic long-term health 
problems and late effects like vocal cord paralysis, hoarseness, fatigue, insomnia, chills 
(cold intolerance), tetany and tingling around the mouth 36. Because the thyroid gland is 
(partially) removed, most health problems are endocrine related and caused by the hyper- 
and hypothyroid states. Frequently reported symptoms are peripheral edema, difficulty 
concentrating, memory loss, insomnia, intolerance of cold, temperature sensitivity, weight 
gain, sleep disturbances, skin dryness, muscle cramping, constipation, hoarseness, slow 
movements, anxiety, puffy face and hands, and loss of libido 3, 19, 44. The fluctuating thyroid 
hormone levels could cause the different results for the effect of levothyroxine on HRQoL. 
Some patients experience hyperthyroid symptoms accompanied by more energy and better 
well-being, while others experience more hypothyroid symptoms accompanied by more 
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negati ve distress and worse well-being.  It is important for pati ents to undergo regular 
medical check-ups, not only to check the recurrence status, but also to adapt the dose of 
levothyroxine.  The use of rhTSH in follow-up care leaded to a reducti on in health problems 
and consequently maintenance of HRQoL. The recent trend in management of thyroid 
cancer towards individualizing treatment and avoiding aggressive interventi ons in low risk 
cases 45 is expected to have a positi ve impact on HRQoL of thyroid cancer survivors. 
Besides direct treatment and follow-up related eff ects, HRQoL can also be aff ected 
negati vely by fear and uncertainty related to a cancer diagnosis, feelings of diagnosis 
being dismissed as not seriously or “having a good cancer (prognosti cally)”, receiving 
confl icti ng messages, or even no informati on about treatment-related side-eff ects 43. There 
is a need for multi disciplinary aft er care leading to an improved HRQoL 30.The fi rst step for 
multi disciplinary aft er care will be recogniti on, recording and acknowledgment of specifi c 
(long-term) health problems of thyroid cancer pati ents by both primary and secondary 
health care professionals. Thereaft er, development and evaluati on of eff ecti ve interventi ons 
is needed to address the needs of thyroid survivors. These interventi ons should not only be 
directed to adequate management of long-term problems, but also to adequate informati on 
provision. Thyroid pati ents perceive their illness on a subjecti ve, emoti onal basis unrelated 
to its actual severity therefore inclusion of a psychologist in the multi disciplinary team 
could help to improve illness representati ons 46. Another good opportunity would be the 
implementati on of a survivorship care plan 47, which aims at providing a cancer survivor 
with a summary of their course of treatment, management of late eff ects, and strategies for 
health promoti on. Another component of such a plan is an ongoing care plan so that cancer 
survivors receive coordinated care from team members knowledgeable about the disease 
process and treatment-related side-eff ects. 
Concluding, thyroid cancer has a big impact on survivors and multi disciplinary monitoring 
is therefore recommended. Future studies on HRQoL in thyroid cancer survivors should be 
prospecti ve in design, include larger number of parti cipants and include a thyroid cancer 
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background: To date, no valid instrument is available that focuses on specific health-related 
quality of life (HRQoL) issues that affect thyroid cancer survivors. Objective of this study was 
to develop and pretest a thyroid cancer specific HRQoL questionnaire that can be used in 
addition to the more general European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30).
material and methods: Potentially relevant issues were identified by a systematic literature 
review, a focusgroup meeting, and an issue list completed by 6 health care professionals 
(HCP) and 18 thyroid cancer survivors. Resultant issues were analyzed on importance and 
relevance (Phase I). The issues were formulated into a long provisional list of questions 
(Phase II). These questions were administered in combination with the EORTC QLQ-C30 to 
306 Dutch thyroid cancer survivors to pretest the hypothesized scale structure (Phase III). 
Although the development of this questionnaire was not set up as an international study, 
phase I-III are in agreement with the methodology of the EORTC guidelines.
results: The literature search, focusgroup and issue list completed by HCP and survivors 
resulted in 75 issues. These were reduced to create a 30 item provisional list. Pretesting led 
to a selection of 24 items with a good range of response. This resulted in the THYCA-QoL 
containing 24 items and seven conceptual scales.
Conclusion: The THYCA-QoL in combination with the EORTC QLQ-C30 is ready for a large 
(international) scale validation study, and will assess HRQoL issues of most relevance and 





The incidence of thyroid cancer is rising worldwide 1. Since the mortality rate of pati ents 
suff ering from diff erenti ated thyroid cancer remains relati vely stable, and survival rates are 
high (5-year survival rates around 97% in 2007)2, the number of thyroid cancer survivors is 
growing. In the United States in 2007, over 430,000 people have a history of thyroid cancer 
2, 3. Treatment of thyroid cancer mostly involves surgery, predominantly total thyroidectomy 
with or without lymphadenectomy, followed by radioiodine treatment to ablate the 
remaining thyroid ti ssue 4. Dependent on staging of the thyroid cancer hemithyroidectomy 
could suffi  ce. These aggressive surgical and postoperati ve treatments are associated with 
long-term physical and psychological morbidity 5. The removal of the whole thyroid gland 
is accompanied by a lifelong dependence on pharmacotherapy with thyroid hormone 
(levothyroxine) with dosing regimes suppressing TSH producti on. Despite the effi  cacy of 
these primary treatments and the high long-term survival rates, the disease has the potenti al 
to recur even decades later. Therefore, intensive long-term periodical follow-up, is necessary 
and associated with physical and psychological discomfort. In case of recurrence, additi onal 
radioiodine treatment or surgery is indicated. The treatment and follow-up care procedures 
impose great challenges on thyroid cancer survivors and could aff ect their health-related 
quality of life.
Health-related quality of life (HRQoL) is a multi dimensional construct that covers the pati ents’ 
percepti ons of his or her physical, emoti onal, social, and cogniti ve functi ons. HRQoL gives a 
good overview of cancer pati ents’ subjecti ve experiences on cancer and its treatment and 
follow-up procedures 6. Cancer pati ents oft en deal with adaptati on problems. Assessment 
of their HRQoL could help to improve aft ercare 7. However, to date litt le is known about 
the impact of primary treatment and follow-up therapies on the HRQoL of thyroid cancer 
survivors. The US Nati onal Coaliti on for Cancer Survivorship defi nes a person as a survivor 
from the moment of diagnosis through the balance of his or her life 8. The long-term HRQoL 
of thyroid cancer survivors is also underexposed. A recent systemati c review indicated that 
thyroid cancer survivors generally have a similar or slightly worse HRQoL compared to the 
normati ve populati on 9. Nevertheless,  thyroid cancer survivors do report some specifi c 
medical problems during and aft er cancer treatment and follow-up tests which have a direct 
negati ve impact on their current HRQoL and could possibly aff ect their long-term HRQoL 9. 
The main problem of previous studies is the lack of a valid, specifi c instrument to assess the 
HRQoL of thyroid cancer survivors. Most studies used a general HRQoL questi onnaire, which 
cannot unveil specifi c thyroid cancer related complaints. In a limited number of studies, 
some thyroid cancer specifi c items were added to a more general HRQoL questi onnaire 
10-13. However, these items were never validated, nor do they cover the whole spectrum of 
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health problems associated with thyroid cancer.  The European Organization for Research 
and Treatment of Cancer (EORTC) developed a core cancer quality of life questionnaire 
(EORTC QLQ-C30) consisting of 30 items 14. The core questionnaire was intended to be 
supplemented by additional modules to assess specific disease and treatment related 
quality of life issues in particular patient groups 15. To the best of our knowledge, no module 
existed for thyroid cancer, nor did any other validated disease-specific questionnaire exist 
for this patient population. 
Aim of this study was to develop a thyroid cancer specific HRQoL questionnaire applicable 
in combination with the core measure (EORTC QLQ-C30), in order to assess treatment and 
cancer specific side-effects of thyroid cancer. We describe the first three out of four phases 
of the development of a thyroid cancer specific module to supplement the EORTC QLQ-C30.
maTerIal and meTHOds
study design
Preparation and development of the thyroid cancer specific HRQoL questionnaire followed 
the guidelines published by the EORTC QOL Group for phase I-III 15-17, however our 
questionnaire is not an EORTC QOL group product and the development of this questionnaire 
was not set up as an international study. The module development process has four distinct 
phases, aimed at ensuring validity and reliability. 
Phase I: 
Phase I was aimed at compiling an exhaustive list of relevant HRQoL issues for thyroid cancer 
survivors. Extensive literature searches through PUBMED (February 2010) were conducted 
to identify all relevant HRQoL issues using the keywords: “quality of life”, “health-related 
quality of life”, and “complaints” in addition to “thyroid cancer” or “thyroid carcinoma”. The 
retrieved provisional list with issues was then translated into Dutch.
A focus group with thyroid cancer survivors (N=4) was composed in order to discuss relevant 
HRQoL issues in general, with respect to their phase of disease. An estimation of the impact 
of these issues to the survivors was explored. With this information issues that were lacking 
in the provisional list were added to this list. The provisional list was then presented to 
health care providers (HCP; N=6) for feedback on appropriateness of content and breadth 
of coverage. Missing issues were added to the list. The health care providers were asked 
to rate the issues from 1 (not relevant for thyroid cancer survivors) to 4 (very relevant for 
thyroid cancer survivors on a Likert scale (relevance rating) and to select the 25 core issues 
which must be definitely included in the questionnaire (priority rating). The same was asked 




(mean score ≥ 1.5) for both health care providers and survivors and high priority rati ngs for 
inclusion in the module (rati ngs ≥ 25%) for both health care providers and survivors were 
added to the fi nal list of issues. 
Phase II:
The fi nal list of HRQoL issues was operati onalised into questi ons compati ble with the EORTC 
QLQ-C30 in terms of format (response categories: ‘not at all’, ‘a litt le’, ‘quite a bit’ and ‘very 
much’) and ti me frame (one week for all items, except  four weeks for the sexuality items). 
Where possible, issues which had been constructed into items in previous EORTC modules 
were used or adapted to provide comparability of data. This was done using the EORTC 
QOL Item Bank 18, which comprises all existi ng EORTC QOL questi onnaire items and their 
translati ons19.
Phase III:
Phase III of the module development was divided into two parts. In the fi rst part the fi nal 
list was pretested in a group (N=8) of thyroid cancer survivors (who did not parti cipate in 
phase I). The objecti ve was to identi fy problems relati ng to the phrasing and clarity of items. 
Survivors were asked to complete the EORTC QLQ-C30 and the thyroid specifi c items and 
underwent cogniti ve debriefi ng, indicati ng if they found any questi ons annoying, confusing, 
upsetti  ng or intrusive, and if so, they were asked to re-phrase the questi on. Survivors were 
asked whether or not questi ons were irrelevant or additi onal issues should be included in 
the module. The questi onnaire was adapted to the responses on these debriefi ng questi ons.
In the second part of phase III, the resultant fi nal questi onnaire was pretested in a sample 
of survivors (N=306) to test the scale structure. 
stati sti cal analyses
Descripti ve stati sti cs were used to calculate relevance and priority rati ngs of the issue list of 
phase I and to analyze the debriefi ng questi ons of the fi rst part of phase III. For the second 
part of phase III, item descripti ve stati sti cs and the response distributi ons for each item 
were calculated, in order to examine central tendency, variability and symmetry. 
To support construct validity, factor analysis was used to determine the underlying 
constructs, which explain signifi cant porti ons of the variance. The factor loadings were 
examined in order to explain the meaning of each construct. 
Multi -trait scaling analysis was employed to confi rm the scale structure (found aft er 
exploratory factor analyses) of the questi onnaire. To test for item-scale convergent validity, 
correlati ons of 0.40 or greater were sought between an individual item and its scale, 
corrected for overlap. Item-scale discriminant validity was examined by comparing the 
correlati on of each item with its own scale versus other scales. An item was expected to 
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correlate significantly higher with its own scale than with other scales. 
Additionally, reliability was tested via Cronbach’s alpha coefficients, which ranges between 
0 and 1. The higher the score, the more reliable the generated scale is. A minimum score 
of 0.70 is preferred 20. Furthermore, convergent and divergent validity was examined by 
evaluating Pearson’s correlations between the various scales of the EORTC QLQ-C30 and 
found scales of the thyroid cancer specific questionnaire. It was expected that scales that are 
conceptually related correlate moderately to highly with one another (r≥0.40). Conversely, 
scales with a less conceptual relation are expected to show weak correlations (r<0.40) 20
All analyses were performed using SPSS software, version 17.0 (SPSS Inc., Chicago IL)  
resulTs
Phase I:
Twenty-seven papers on HRQoL of thyroid cancer survivors were identified 9, and one 
non-validated thyroid cancer specific questionnaire was identified 10. This non-validated 
questionnaire did not cover the whole spectrum of health problems associated with thyroid 
cancer because it only added four thyroid cancer specific items to a more general HRQoL 
questionnaire for cancer survivors. A list of 64 relevant issues related to thyroid cancer was 
derived from these 27 articles. The focusgroup with four thyroid cancer survivors (mean age 
of 53 years, 2-19 years since diagnosis, 3 survivors with differentiated thyroid carcinoma 
and 1 with medullary thyroid carcinoma) resulted in 11 additional issues relevant for thyroid 
cancer survivors. 
The rating (mean scores, range, prevalence and proportions of priority ratings) of the 
75-issues by health care providers (N=6; three internist-endocrinologists, two surgeons and 
one MD specialized in nuclear medicine) and 18 thyroid cancer survivors (mean age of 49 
years, 1-18 years since diagnosis, all differentiated thyroid cancer) resulted in removal of 
37 issues. Additionally, eight issues of the remaining 38 issues were already covered by the 
EORTC QLQ-C30 (sleeping troubles (item 11), constipation (item 16), tiredness (item 18), 
difficulty concentrating (item 20), irritability (item 23), difficulty with remembering (item 
25), troubles with family life (item 26), troubles in social life (item 27). This resulted in a list 
of 30 issues, relevant for thyroid cancer survivors.
Phase II:
A provisional questionnaire of 30 thyroid cancer specific items was constructed. Seventeen 
existing items from the EORTC QOL Item Bank (comprising all items used in disease-specific 





Eight survivors reviewed the 30 items for clarity of wording and overlapping of items 
(debriefi ng questi ons), none of the items was excluded. The ti me for survivors’ self 
completi on of the EORTC QLQ-C30 and provisional thyroid cancer module was ≤ 10 minutes 
for four survivors (50%), between 11 and 15 minutes for three survivors (37.5%) and > 15 
minutes for one survivor.
Table 1: Thyroid cancer pati ent characteristi cs (n=306)
age at ti me diagnosis - Mean(SD) 46.3 (14.9)
age at ti me of survey - Mean(SD) 56.4 (14.5)
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The EORTC QLQ-C30 and the provisional thyroid cancer specific list were completed by 
306 survivors (Table 1). Response information is provided in Table 2, which displays the 
items descriptive statistics. Valid responses were high for all items. Six items with >80% of 
the answers falling in one answer category (floor effects) were excluded for factor analysis 
(different taste (item 6), trembling hands (item 13), cramps in arms (item 14), hair loss (item 
19), hyperactivity (item 27), and depressive feelings (item 29)).
Table 2: Item descriptive statistics of 306 thyroid cancer survivors
Item description Valid (%) mean (sd)
distribution of valid 
responses (%)
1 2 3 4
1 Have you had a dry mouth? 98 1.5 (0.8) 63 27 6 4
2 Have you had trouble swallowing? 97 1.3 (0.6) 74 21 3 2
3 Have you been hoarse? 97 1.3 (0.6) 76 19 3 1
4 Have you had a weak voice? 97 1.4 (0.7) 72 20 6 2
5 Have you had a lump in your throat? 97 1.3 (0.7) 74 19 6 1
6 Did food and drink taste different as normal? * 97 1.1 (0.5) 89 9 1 1
7 Did the scar in your neck bother you? 97 1.3 (0.7) 78 15 3 3
8 Have you felt chilly? 97 1.8 (0.9) 48 33 10 9
9 Have you had difficulty tolerating heat? 97 1.5 (0.8) 66 20 11 3
10 Have you had hot flushes? 97 1.6 (0.9) 60 25 9 6
11 Have you had pain in your muscles and/or joints? 97 2.0 (1.0) 36 36 19 10
12 Have you had tingling hands and/or feet? 97 1.5 (0.8) 67 23 6 4
13 Have you had trembling hands?* 97 1.2 (0.6) 83 12 3 1
14 Have you had cramps in your arms?* 96 1.2 (0.6) 84 12 3 1
15 Have you had cramps in your legs? 97 1.6 (0.8) 57 26 14 3
16 Have you felt slowed down? 97 1.5 (0.7) 63 26 8 2
17 Have you gained weight? 96 1.3 (0.6) 71 26 3 1
18 Have you had painful, irritated or dry eyes? 96 1.4 (0.7) 67 24 6 3
19 Have you had hair loss?* 96 1.3 (0.6) 80 15 4 1
20 Have you had skin problems (e.g. itchy, dry)? 96 1.5 (0.7) 66 26 6 3
21 Have you suffered from palpitations? 96 1.3 (0.6) 74 20 5 1
22 Have you had headaches? 96 1.5 (0.7) 59 30 10 2
23 Have you had abrupt attacks from tiredness? 96 1.7 (0.9) 50 30 17 3
24 Have you had troubles with thinking? 96 1.5 (0.7) 59 32 7 2
25 Have you had attention problems? 96 1.4 (0.7) 67 26 6 2
26 Have you felt restless or agitated? 96 1.4 (0.7) 69 22 8 1
27 Have you felt hyperactive?* 96 1.2 (0.5) 85 10 5 0
28 Have you felt anxious? 96 1.2 (0.5) 79 18 3 0
29 Have you felt depressive?* 96 1.3 (0.6) 81 13 4 1
30 To what extent were you interested in sex? 87 1.8 (0.7) 37 47 15 2
1= Not at all
2= A little
3= Quite a bit
4= Very much




The suitability of the data (remaining 24 items) for factor analysis was tested via the Kaiser-
Meyer-Olkin (KMO) measure of sampling adequacy, which tests the parti al correlati ons 
among the items. The KMO value should be higher than 0.5 for a sati sfactory analysis to 
proceed 21. The KMO measure in this study was 0.84. Items with initi al communaliti es < 
0.10 should be deleted for further analyses; none of the items were deleted based on this 
criterium. Based on Catt ell’s scree plot and the Kaiser-Gutt man rule (which states that an 
eigenvalue (the amount of the total variance explained by that factor) must be greater than 
one) 7 factors were identi fi ed. Oblique rotati on, which assumes that the factors could be 
correlated with each other, simplifi ed their interpretati on by minimizing the items with high 
loadings on each factor. The seven factors cumulati vely accounted for 46% of variati on in 
all items (respecti vely 25%, 6%, 4%, 4%, 3%, 2%, 2%). Oblique rotati on generates a patt ern 
matrix with factor loadings and a structure matrix with correlati ons between items and 
components in a structure matrix (Table 3). A cut-off  point of 0.35 for factor loadings was 
adopted, i.e. only those items scoring higher than this threshold were retained for further 
analyses. Six items were dropped based on this criterium and were treated as single items. 
The multi -trait scaling analysis showed that scaling assumpti ons were adequately met for 
four of the seven scales (Table 4).  Cronbach’s alpha coeffi  cients range from 0.45-0.82, four 
of the seven scales scored higher than the preferred 0.70 level.  
Most scales of the thyroid specifi c questi onnaire were weakly correlated (r<0.40) with the 
QLQ-C30 (Table 5).  
The resulti ng questi onnaire, consisti ng of 24 items, was named THYCA-QoL (Att achment).
dIsCussIOn
The THYCA-QoL has been methodologically developed using standard guidelines 15-17. It is 
designed for use in combinati on with the EORTC QLQ-C30 core instrument to assess all 
major dimensions of HRQoL in thyroid cancer survivors. The content of the questi onnaire 
has been determined by an extensive literature search, and by interviews with HCP and 
thyroid cancer survivors. The next step of development (phase IV) involves administrati on 
in a large internati onal group of thyroid cancer survivors to provide additi onal psychometric 
properti es of the questi onnaire.
Content validity was addressed in phase I to enlarge confi dence that the instrument measures 
the aspects it was designed for. The content of our items is in agreement with the items of 
the non-validated Thyroid Cancer City of Hope Questi onnaire (TCCHQ) 10-12, however our 
questi onnaire covers the whole spectrum of health problems thyroid cancer survivors’ are 
dealing with. The TCCHQ adds four thyroid cancer specifi c questi ons to a more general HRQoL 
questi onnaire, while our questi onnaire adds 24 relevant items to the EORTC QOL-C30. Also, 
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scoring of the TCCHQ produces four general subscale scores (physical, psychological, social, 
spiritual), giving little specific information of how HRQoL is affected by thyroid cancer and its 
treatment. Because thyroid cancer survivors were extensively involved in the development 
of the questionnaire, our questions are more adapted to the terminology used by thyroid 
cancer survivors. Furthermore, the initial validation of the Thyroid Cancer Module of the M. 
D. Anderson Symptom Inventory is based on a small sample (n=60) of survivors who were 
not very symptomatic and were not representative for thyroid cancer survivors in general 13. 
Table 3: Rotated component matrix (factor loadings)
Item description Pattern matrix structure matrix
1 2 3 4 5 6 7 1 2 3 4 5 6 7
first factor: neuromuscular 
15 Cramps legs 0.523 0.600







3 Hoarseness 0.860 0.854
4 Weak voice 0.716 0.724




24 Difficulty thinking -0.588 -0.731
fourth factor: sympathetic 
10 Hot flushes 0.832 0.862
9 Sensitive heat 0.541 0.664




5 Lump in throat 0.414 0.534
1 Dry mouth 0.400 0.478
sixth factor: Psychological 
28 Anxious 0.602 0.552
26 Restless 0.572 0.713
21 Palpitations 0.498 0.600
23 Abrupt tiredness 0.360 0.627
seventh factor: sensory 
18 Eye problems 0.548 0.601
20 Skin problems 0.528 0.514
Items 7 (scar), 8 (chilly), 12 (tingling hands/feet), 17 (gained weight), 22 (headaches), 30 (interested in sex) were 









































































































































































































































































































































































































































































































































































































































































































































































































Some limitations of the module development should be acknowledged. First, the results 
confirmed the hypothesized scale structure and reliability of 4 of 7 of the multi-item scales 
(voice, concentration, sympathetic and psychological problems), with reliability estimates 
between 0.72 and 0.82. In contrast, the reliability of the neuromuscular, throat/mouth 
and sensory problem scales was suboptimal (0.63, 0.62 and 0.45, respectively). The lower 
reliability observed for these scales may reflect the limited variability observed in the scores of 
the items comprising these scales. The lower reliability estimates will not necessarily negate 
the value of the scales, since survivors and HCP rated the items as relevant during phase I of 
the development process. Given that the found scales were in line with the expectations we 
had after reviewing the literature and a scale structure could improve clinical interpretability, 
we preferred to keep the scale structure rather than treating those items as single ones. 
Since we also used the same patient sample for the factor analysis as well as for the multi-
trait analysis, our hypothesized scale structure must be further confirmed in another large 
(international) sample of diverse thyroid cancer survivors. Statistical techniques from the 
Item Response Theory (IRT) will be used for the final validation of the questionnaire and its 
hypothesized scales. 
Second, during phase III, the provisional module was tested in a group of 306 survivors of 
which almost half (45%) was diagnosed more than 10 years ago, creating a potential for 
bias (floor/ceiling effects). Results from the focus group indicated that the kind of problems 
thyroid cancer survivors are dealing with do not differ across the cancer continuum, 
only the severity of the problems changes over time. In the next phase of questionnaire 
development, the method of known-groups validation must be used to assess the ability 
of the THYCA-QoL to distinguish between subgroups of thyroid cancer survivors with 
regard to years since diagnosis, disease stage, treatment, and histology. The study sample 
of the next development phase should include more medullary thyroid cancer patients, 
since the number of those patients was too low in the provisional test phase to test the 
applicability of the questionnaire within this group. Also, as is recommended by the EORTC, 
the responsiveness to change and the cross-cultural validity need to be tested in the last 
phase of questionnaire development 15-17.
The THYCA-QoL is the first thyroid cancer specific HRQoL questionnaire developed using 
standard methodologically proven guidelines. This questionnaire can be of value in the 
treatment and after care of thyroid cancer survivors. It will make medical doctors more 
aware of the potential HRQoL issues thyroid cancer survivors are dealing with. Also, this 
questionnaire helps doctors to provide survivors with adequate information on HRQoL 
and thereby improve survivors’ experiences of their illness. After the phase IV validation is 
completed, the questionnaire can be used in future trials of new and existing treatments for 
thyroid cancer survivors. It may also be of value in the longitudinal follow-up of survivors 
in order to find survivors who are most vulnerable for health problems and to arrange 
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att achment: Final 24 items of the THYCA-QoL questi onnaire
1. Have you had a dry mouth?
2. Have you had trouble swallowing?
3. Have you been hoarse?
4. Have you had a weak voice?
5. Have you had a lump in your throat?
6. Did the scar in your neck bother you?
7. Have you felt chilly?
8. Have you had diffi  culty tolerati ng heat?
9. Have you had hot fl ushes?
10. Have you had pain in your muscles and/or joints?
11. Have you had ti ngling hands and/or feet?
12. Have you had cramps in your legs?
13. Have you felt slowed down?
14. Have you gained weight?
15. Have you had painful, irritated or dry eyes?
16. Have you had skin problems (e.g. itchy, dry)?
17. Have you suff ered from palpitati ons?
18. Have you had headaches?
19. Have you had abrupt att acks from ti redness?
20. Have you had troubles with thinking?
21. Have you had att enti on problems?
22. Have you felt restless or agitated?
23. Have you felt anxious?
24. To what extent were you interested in sex?
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background: Given the longevity of thyroid cancer patients, any impairment in health-
related quality of life (HRQoL) during the follow-up period is of considerable concern. 
Therefore, the first aim of this study was to assess (thyroid cancer specific) HRQoL among 
long-term thyroid cancer survivors and to compare this with the HRQoL of an age- and sex-
matched normative population. Secondly, our aim was to investigate which clinical and 
socio-demographic characteristics and thyroid cancer specific problems were associated 
with HRQoL.
material and methods: All patients diagnosed with thyroid cancer between 1990-2008, as 
registered in the Eindhoven Cancer Registry, received a survey on HRQoL (EORTC QLQ-C30) 
and disease-specific symptoms (THYCA-QoL). The scores were compared with age-and-sex-
matched cancer free controls (n=800). A series of multiple linear regression analyses were 
conducted to investigate the independent associations between clinical, socio-demographic 
and thyroid cancer specific factors with HRQoL.
results: A total of 306 patients (86%) responded to the invitation. Thyroid cancer survivors 
had significantly lower scores on physical, role, emotional, cognitive and social functioning 
(p<0.001) compared to the normative population after adjusting for comorbidities. 
Sympathetic problems (feeling chilly (52%), hot flushes (40%)), neuromuscular problems 
(cramp legs (43%) and pain joints/muscles (64%)) and abrupt attacks of fatigue (50%) were 
the most often reported thyroid cancer specific complaints.
Thyroid cancer specific neuromuscular, concentration, sympathetic and psychological 
problems explained 41-58% of the variance in HRQoL. Clinical and socio-demographic 
factors explained a small part of the variance in (thyroid cancer specific) HRQoL (1-27%).
Conclusion: Thyroid cancer survivors experience symptoms and deteriorated HRQoL 
long after diagnosis. Thyroid cancer specific neuromuscular, sympathetic, concentration 
and psychological symptoms are stronger associated with HRQoL than clinical and socio-
demographic factors alone. Awareness of these specific determinants of HRQoL could help 
health care practitioners to provide better supportive care.
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InTrOduCTIOn
In the Netherlands, the incidence of thyroid cancer (TC) is 3.1 cases per 100.000 people per 
year. Each year 570 pati ents are diagnosed with TC 1.  Worldwide incidence rates are rising 
2. The incidence is 2.5 ti mes higher in women than in men. The papillary and follicular type 
account for about 80-90% of all cases, and poorly diff erenti ated (medullary and anaplasti c) 
TCs for about 10-20%. As a result of the very good prognosis of papillary or follicular TC 
(exceeding >90% 5-year survival rates) the number of TC survivors is growing 3. 
Treatment of TC involves surgery, predominantly (near-)total thyroidectomy with or without 
lymphadenectomy, followed by radioiodine (iodine-131) therapy to ablate the remaining 
thyroid ti ssue. Depending on type and size of the tumour hemithyroidectomy could suffi  ce. 
The removal of the whole thyroid gland is accompanied by a lifelong dependence on 
supplement therapy with thyroid hormone (levothyroxine), in the fi rst years with dosing 
regimes suppressing thyroid sti mulati ng hormone (TSH) producti on 4. Despite the effi  cacy 
of these primary treatments and the high long-term survival rates, 15-35% of the pati ents 
develop a locoregional recurrence or distant metastases, even decades later 5. Therefore, 
intensive long-term periodical follow-up is necessary. 
Given the longevity of TC pati ents, possible impairments in health-related quality of life 
(HRQoL) during the follow-up period are of considerable concern.  There is a limited number 
of studies focusing on HRQoL among TC survivors that moreover show contradictory 
results 6. A few studies found a lower HRQoL for TC survivors compared with a reference 
group, whereas other studies found similar HRQoL levels 6. The main problem of previous 
studies is the lack of a valid, specifi c instrument to assess the HRQoL among TC survivors. 
Therefore, we recently developed a TC specifi c HRQoL questi onnaire to unveil specifi c TC 
related complaints 7.  Furthermore, most other studies were inconclusive because they 
had  small sample sizes and focused on short-term TC survivors (<2 years aft er diagnosis) 6. 
Consequently litt le is known about long-term HRQoL in TC pati ents. Therefore, the primary 
objecti ve of our study was to assess general and TC specifi c HRQoL of long-term TC survivors 
and to compare this with an age- and sex-matched normati ve populati on. To be able to 
tailor supporti ve care to the individual needs of TC pati ents, it is important to obtain insight 
into the factors infl uencing HRQoL. Therefore our second aim was to investi gate which 






This study is a population-based survey among TC survivors registered within the Eindhoven 
Cancer Registry (ECR) of the Comprehensive Cancer Centre South (CCCS). The ECR compiles 
data of all individuals newly diagnosed with cancer in the southern part of the Netherlands, 
an area with 10 hospitals serving 2.3 million inhabitants 8. All individuals diagnosed with TC 
between 1990-2008 as registered in the ECR were eligible for participation (N=568) (Figure 
1). We excluded patients who had cognitive impairment or were too ill at time of the study 
(N=31), had unverifiable addresses (N=90), or died prior to the start of the study (according 
to the ECR, hospital records, and the Central Bureau for Genealogy (N=6). One hospital 
declined to participate (N=86). The study was approved by the Medical Ethics Committee of 














568 patients diagnosed and registered with thyroid cancer between 
January 1990 and August 2008 (and still alive on November 1st 2010), 
diagnosed within the Eindhoven Cancer Registry 
-One general hospital declined to 
participate (86 patients) 
- Six patients deceased shortly before the 
study started 
- 90 addresses could not be verified. 
-31 patients were too ill or incompetent 
due to cognitive impairment or language 
barriers 
A questionnaire was sent to the remaining patients (N=355; 100%). 
 
306 (86%) patients returned a completed questionnaire  49 (14%) patients did not complete the 
questionnaire, some had a known reason: 
-Actively refused  
-Did not confirm they had cancer  
 
figure 1: Flow-chart of the data collection process
data collection
Data collection was conducted in November 2010 within PROFILES (Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship). PROFILES 
is a registry for the study of the physical and psychosocial impact of cancer and its treatment 
from a dynamic, growing population-based cohort of both short and long-term cancer 
survivors. PROFILES contains a large web-based component and is linked directly to clinical 
data from the ECR. Survivors were informed about the survey via a letter from their (ex)-
attending specialist. The letter explained that by completing the questionnaire (online 
or by pencil-and-paper), patients consented to participate and agreed to the linkage of 
the questionnaire data with their disease history in the ECR. Further details of the data 
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collecti on method have been described previously 9. Data from the PROFILES registry will 
be available for non-commercial scienti fi c research, subject to study questi on, privacy and 
confi denti ality restricti ons, and registrati on (www.profi lesregistry.nl).
study measures
Socio-demographic and clinical characteristi cs
Clinical informati on of the survivors was available from the ECR. The ECR routi nely collects 
data on tumour characteristi cs, including date of diagnosis, disease stage, primary treatment, 
and pati ent background characteristi cs including date of birth. 
Questi ons on marital status, educati onal level, and current occupati on were added to the 
questi onnaire. Comorbidity at the ti me of survey was categorized according to an adapted 
Self-administered Comorbidity Questi onnaire (SCQ) 10, including heart disease, stroke, high 
blood pressure, long disease, diabetes, ulcer or stomach disease, kidney disease, anemia 
or other blood disease, depression, osteoarthriti s, back pain, rheumatoid arthriti s and a 
questi on on other medical problems. 
EORTC-QLQ-C30
HRQoL was measured by the European Organisati on for Research and Treatment of Cancer 
Quality of Life Questi onnaire (EORTC-QLQ-C30) 11.This 30-item HRQoL questi onnaire 
consists of fi ve functi onal scales (physical, role, cogniti ve, emoti onal and social), a global 
quality of life scale, 3 symptom scales (fati gue, pain, nausea and vomiti ng) and a number of 
single items assessing common symptoms (dyspnoea, loss of appeti te, sleep disturbance, 
consti pati on and diarrhea) and perceived fi nancial impact of the disease. The ti me frame 
of the questi ons is the previous week, and each item is scored on a 4 point response scale 
ranging from 1, ‘not at all’ to 4, ‘very much,’ with the excepti on of the global QoL scale, 
which is scored on a 7-point modifi ed linear analogue scale ranging from 1, ‘very poor’ to 
7, ‘excellent’. Aft er linear transformati on, all scales and single item measures range in score 
from 0-100. A higher score on the functi onal scales and global QoL means bett er functi oning 
and HRQoL, whereas a higher score on the symptom scales means more complaints. 
Thyroid cancer specifi c HRQoL (THYCA-QoL)
TC specifi c HRQoL was measured by a self-developed questi onnaire (THYCA-QoL) to assess 
side-eff ects due to TC or its treatment 7. We developed and validated the TC specifi c HRQoL 
questi onnaire according to the methods of the European Organisati on for Research and 
Treatment of Cancer (EORTC) Quality of Life group. The questi onnaire consists of 24 items, 
with a ti me frame of the previous week (except for the sexual interest item which is four 
weeks) and each item is scored on a 4 point response scale ranging from 1, ‘not at all’ to 
4, ‘very much’. The THYCA-QoL consists of seven symptom scales (neuromuscular, voice, 
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concentration, sympathetic, throat/mouth, psychological and sensory problems) and six 
single items (problems with scar, felt chilly, tingling hands/feet, gained weight, headaches, 
interest in sex). Scores were linear transformed to a 0-100 scale. A higher score on this scale 
means more symptoms. 
normative population
Normative population data was obtained from CentERpanel, an online household panel that 
is representative of the Dutch population. The process of the annual data collection, which 
started in 2009 by our study group, is described elsewhere 12. The data wave in 2009 included 
assessment of HRQoL (EORTC QLQ-C30). From the 1731 members  ≥18 years who responded 
(78%), an age-and-sex-matched normative cancer-free sample (n=800) was selected for this 
study to reflect the age and sex distribution of the TC sample. Socio-demographic data were 
also collected for this group.  
statistical analyses
Differences in clinical and socio-demographic characteristics between respondents, non-
respondents and patients with unverifiable addresses and between TC patients and the 
normative population were compared using chi-square statistics for categorical variables 
and t-tests or analysis of variance (ANOVA) for continuous variables. 
ANCOVA was used to compare the mean scores on the individual EORTC QLQ-C30 scales 
between TC survivors and the normative population, controlled for the number of 
comorbidities. In addition, 
clinical meaningfulness of the differences was determined according to the guidelines of 
the EORTC Quality of Life Group 13. Differences in (TC specific) HRQoL between subgroups 
of survivors (<5 years; 5-10 years; > 10 years since diagnosis) were analyzed using ANOVA.
A series of multiple linear regression analyses (enter method) were conducted to investigate 
the independent associations between clinical (disease stage, primary treatment, 
comorbidity) and socio-demographic characteristics (age, sex, partner, educational level) 
with subscale scores of the EORTC-QLQ-C30 and THYCA-QoL. Also, independent associations 
of the TC specific problems with the subscales of the EORTC QLQ-C30 were analyzed with 
multiple linear regression analyses and were adjusted for clinical and socio-demographic 
variables (determined a priori).
All statistical analyses were performed using SPSS version 17.0 (Statistical Package for Social 
Sciences, Chicago, IL, USA) and P values <.05 were considered statistically significant.
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resulTs
Pati ent and tumour characteristi cs
Three hundred and six pati ents returned a completed questi onnaire (response 86%). 
A comparison between respondents, non-respondents and pati ents with unverifi able 
addresses indicated that pati ents with unverifi able addresses were younger compared to 
non-respondents and respondents. No diff erences between groups were seen regarding 
sex, type of TC, stage of the disease or primary treatment.
The mean age at diagnosis was 46 (SD=15) years (Table 1). Average ti me since diagnoses was 
9.6 (SD= 5.5) years. More than half of the pati ents were diagnosed with stage I disease (57%). 
Surgery (99%) was followed by iodine-131 ablati on therapy in 69% and by radiotherapy in 
3% of the cases. More than three quarters (78%) of the pati ents had one or more comorbid 
conditi ons. The most common comorbiditi es were backache (36%), high blood pressure 
(29%), arthrosis (28%) and cardiovascular problems (12%). 
TC pati ents reported more oft en the presence of comorbid conditi ons and more oft en had 
a lower educati onal level compared to the normati ve populati on (Table 1). No diff erences 
between groups were seen in age, sex, partnership and occupati on.
HrQol of TC survivors compared with normati ve populati on
HRQoL of TC survivors as measured by the EORTC-QLQ-C30 was compared with an age-
and-sex-matched normati ve sample from the general Dutch populati on (Figure 2a/2b). The 
survivors had signifi cantly lower scores on physical (83 vs. 89), role (82 vs. 88), emoti onal (83 
vs. 88), cogniti ve (82 vs. 92) and social functi oning (85 vs. 93; all p<0.001) compared to the 
normati ve populati on aft er adjusti ng for comorbiditi es. No diff erences were seen in global 
health. According to the guidelines of the EORTC Quality of Life Group, the diff erences 
between TC survivors and normati ve populati on were of small clinical importance for 
the subscales physical, role and social functi oning and medium for cogniti ve functi oning. 
The clinical importance of the diff erence for the emoti onal functi oning scale could not be 
determined 13.
TC survivors had signifi cantly more symptoms of fati gue (28 vs. 18), dyspnoea (14 vs. 8), 
insomnia (22 vs. 16), appeti te (6 vs. 4), consti pati on (10 vs. 6; all p<0.001), diarrhea (7 vs. 
4; p<0.01) and had higher scores on fi nancial diffi  culti es (10 vs. 3; p<0.001) compared to 
the normati ve populati on aft er adjusti ng for comorbiditi es. No diff erences were seen for 
nausea and pain. The diff erences were of small clinical importance for fati gue, dyspnoea, 












age at time survey in years (mean (±sd)) 56.4 (14.5) 55.1 (13.5) 0.15
Years since diagnosis 9.6 (5.5) - -
25th percentile 4.7 -
Median 9.0 -
75th percentile 13.5 -
sex 0.95
Male 76 (24.8%) 200 (25.0%)
Female 230 (75.2%) 600 (75.0%)
Type of thyroid cancer -
Papillar 217 (70.9%) -
Follicular (including Hurthle cell) 73 (23.8%) -
Medullary  13 (4.2%) -
stage -
I 172 (57.1%) -
II 59 (19.6%) -
III  48 (15.9%) -
IV 20 (6.6%) -
Primary treatment -
Surgery 83 (27.1%) -
Surgery + iodine-131 ablation 212 (69.3%) -
Surgery + radiotherapy 9 (2.9%) -
Other 2 (0.7%) -
Comorbidity (self-report) <0.001
None 68 (22.2%) 319 (39.9%)
1 70 (22.9%) 208 (26.0%)
≥ 2 168 (54.9%) 273 (34.1%)
Partnership 0.48
Partner 238 (77.8%) 606 (75.8%)
No partner 68 (22.2%) 194 (24.3%)
educational level 0.01
High 80 (26.2%) 261 (32.7%)
Middle 192 (63.0%) 491 (61.6%)
Low 33 (10.8%) 45 (5.6%)
Current occupation 0.20
Employed 154 (51.3%) 376 (47.0%)
Not employed 146 (48.7%) 424 (53.0%)
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Global health Physical functioning Role functioning Emotional functioning Cognitive functioning Social functioning
Thyroid cancer survivors Norm population
figure 2a: HRQoL of thyroid cancer survivors compared to normati ve populati on
Mean EORTC-QLQ-C30 functi oning subscale scores (0-100) of survivors in comparison with a Dutch normati ve 
populati on. A higher scores means bett er functi oning. An asterisk above the bar indicates a group diff erence 

















Fatigue Nausea Pain Dyspnoea Insomnia Appetite Constipation Diarrhoea Financial 
difficulties
Thyroid cancer survivors Norm population
figure 2b: HRQoL of thyroid cancer survivors compared to normati ve populati on
Mean EORTC-QLQ-C30 symptom subscale scores (0-100) of survivors in comparison with a Dutch normati ve 
populati on. A higher score indicates more symptoms. An asterisk above the bars indicates a group diff erence 
(ANCOVA, p < 0.05, adjusted for comorbidity). 
Thyroid cancer specifi c HrQol
The majority of TC survivors experienced disease specifi c symptoms during the past week. 
Sympatheti c problems (feeling chilly (52%), hot fl ushes (40%)), neuromuscular problems 
(cramp legs (43%) and pain joints/muscles (64%)) and abrupt att acks of fati gue (50%) were 
the most oft en reported complaints.
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Table 2: Mean scores (±SD) of thyroid cancer survivors on EORTC QLQ-C30 and THYCA-QoL scales (0-
100) and single items according to years since diagnosis.
survivors <5 years 
since diagnosis
n = 81
survivors 5-10 years  
since diagnosis
n=86





Global health 73.8 (18.2) 74.4 (21.2) 77.6 (20.2) 0.3
Physical functioning 82.0 (19.7) 83.5 (19.7) 83.0 (19.5) 0.9
Role functioning 79.8 (26.8) 84.3 (24.6) 81.1 (28.3) 0.5
Emotional functioning 83.6 (16.3) 81.1 (22.8) 84.9 (20.2) 0.4
Cognitive functioning 80.4 (20.4) 79.5 (27.3) 84.7 (20.1) 0.2
Social functioning 85.8 (22.1) 82.1 (29.7) 86.6 (22.9) 0.4
eOrTC QlQ-30 symptoms++
Fatigue 30.9 (24.6) 29.0 (28.3) 26.0 (23.8) 0.4
Nausea 4.3 (11.1) 5.8 (14.1) 3.1 (8.4) 0.2
Pain 17.5 (25.4) 17.5 (25.9) 16.8 (24.1) 0.9
Dyspnoea 14.8 (21.7) 14.9 (22.8) 12.7 (22.2) 0.7
Insomnia 27.2 (29.9) 21.3 (29.7) 20.1 (28.5) 0.2
Appetite 9.1 (21.7) 6.3 (20.4) 3.9 (13.4) 0.1
Constipation 11.9 (21.9) 8.7 (18.0) 9.5 (19.8) 0.6
Diarrhea 7.0 (18.0) 7.9 (20.4) 5.4 (14.2) 0.5
Financial difficulties 10.3 (19.5) 11.5 (26.1) 8.4 (20.7) 0.6
THYCa-Qolscales ++
Neuromuscular 27.7 (22.1) 23.8 (23.3) 22.1 (20.7) 0.2
Voice 16.0 (22.7) 12.1 (20.6) 7.3 (14.1) 0.01
Concentration 19.6 (21.5) 18.5 (25.2) 12.1 (18.9) 0.02
Sympathetic 23.3 (29.2) 21.8 (28.3) 14.0 (20.1) 0.02
Throat/mouth 19.3 (20.1) 13.2 (18.1) 8.9 (13.1) <0.01
Psychological 16.9 (17.1) 15.8 (18.7) 11.9 (14.6) 0.07
Sensory 17.5 (19.2) 14.3 (19.8) 14.2 (19.9) 0.5
THYCa-Qolsingle items ++
Problems with scar 16.5 (26.9) 9.1 (23.3) 8.0 (20.1) 0.03
Felt chilly 31.7 (32.9) 26.8 (31.6) 23.4 (30.6) 0.2
Tingling hands/feet 17.7 (27.4) 17.9 (25.1) 11.6 (24.0) 0.1
Gained weight 12.2 (18.6) 12.9 (20.6) 9.4 (17.7) 0.3
Headaches 18.8 (24.8) 19.8 (26.4) 16.4 (23.5) 0.6
Less interest in sex+ 24.2 (23.3) 35.6 (25.8) 24.4 (24.4) <0.01
+ Higher scores indicate better functioning; ++ Higher scores indicate more symptoms
# P-value of ANOVA for differences between the three groups (results of post-hoc tests are described in text)
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Clinical and socio-demographic factors associated with (thyroid cancer specifi c) HrQol 
When strati fi ed by years since diagnosis (<5 years; 5-10 years; > 10years since diagnosis) 
no diff erences between the groups were seen in functi oning and symptom scales of the 
EORTC QLQ-C30. TC survivors >10 years since diagnosis reported less TC specifi c voice, 
concentrati on, sympatheti c, throat/mouth problems compared to survivors <5 years since 
diagnosis (Table 2). Survivors < 5 years since diagnosis reported more problems with their 
scar compared to survivors 5-10 years and >10 years since diagnosis. 
Table 3: Standardized betas of multi variate linear regression analyses evaluati ng the associati on of 
independent variables with the HRQoL scales.












age -0.01 -0.21 ** -0.05 0.19** 0.06 0.11
Years since dx 0.09 0.01 -0.02 -0.02 0.10 -0.03
sex 0.07 -0.03 0.02 0.07 0.10 0.06
Type of cancer
Papillar Ref Ref Ref Ref Ref Ref
Follicular -0.05 -0.07 -0.01 0.01 0.04 -0.01
Medullary -0.05 -0.09 -0.07 0.03 -0.02 -0.01
Primary treatment -0.06 -0.01 0.01 0.02 -0.11 -0.05
stage -0.01 -0.05 -0.05 -0.19** -0.02 -0.08
Comorbidity -0.24** -0.24 ** -0.17** -0.18** -0.06 -0.07
Partner -0.21** -0.24** -0.21** -0.12 -0.13* -0.23**
educati on -0.13* -0.14* -0.17** -0.06 -0.14* -0.12
r2 0.14 0.27 0.14 0.08 0.06 0.08
*<0.05; **<0.01
+ Higher score indicates bett er functi oning
Abbreviati ons: dx = diagnosis
Age and Years since dx were conti nuous variables in the multi variate model.
Other variables were sex: male vs. female; type of cancer: papillar vs. follicular and papillar vs. medullary; primary 
treatment: surgery vs. surgery + ablati on; disease stage: stage I/II vs. stage III/IV; comorbidity: no comorbid 
conditi ons vs. one or more comorbid conditi ons; partner: partner vs. no partner; educati onal level: high vs. low.
Multi variate linear regression analyses showed that clinical factors (type of cancer, primary 
treatment, stage of disease, years since diagnosis) were not associated with the functi onal 
and symptom scales of the EORTC QLQ-C30, except for disease stage which was negati vely 
associated with emoti onal functi oning (Table 3). Having one or more comorbiditi es was 
associated with worse global health and physical, role and emoti onal functi oning and more 
fati gue (Beta = 0.24; p<0.05), pain (Beta = 0.25; p<0.05), dyspnoea (Beta =0.18; p<0.05), 
insomnia (Beta = 0.17; p<0.05) and less appeti te (Beta= 0.15; p<0.05). Higher age was 
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associated with worse physical functioning and better emotional functioning. Absence of a 
partner and lower educational level were associated with worse functioning (Table 3) and 
more symptoms (Betas ranging from 0.12 – 0.24; p<0.05). 
Most clinical variables were not associated with TC specific problems (neuromuscular, 
psychological and sensory problems; feeling chilly, tingling hands/feet, gaining weight, 
headaches, interest in sex; Table 4). However fewer years since diagnosis was associated 
with more voice, throat and scar problems (Beta = -0.14; p<0.05). Medullar TC and a higher 
stage disease were associated with more sympathetic problems. More comorbidities, 
absence of a partner and lower educational level were associated with more TC specific 
symptoms (Table 4). The explained variance (R2) of clinical and socio-demographic variables 
ranged from 1% to 27%.
Table 4: Standardized betas of multivariate linear regression analyses evaluating the association of 








age 0.08 0.12 -0.19** -0.01 0.05 -0.11 -0.02
Years since dx -0.07 -0.17** -0.08 -0.11 -0.23** -0.10 -0.05
sex -0.01 0.09 -0.11 0.16** 0.02 0.04 -0.02
Type of cancer
Papillar Ref Ref Ref Ref Ref Ref Ref
Follicular -0.05 -0.01 -0.07 0.04 0.02 0.02 0.09
Medullar 0.01 0.02 0.01 0.13* -0.02 -0.06 0.07
Primary treatment 0.10 0.02 0.10 0.07 -0.05 0.06 0.06
stage 0.05 0.16* 0.13 0.15* 0.16* 0.10 -0.01
Comorbidity 0.26** -0.02 0.09 0.09 0.17** 0.20** 0.20**
Partner 0.14* -0.04 0.18** 0.09 -0.03 0.16** 0.01
education 0.20** 0.03 0.17** 0.06 0.10 0.09 0.05
r2 0.19 0.10 0.11 0.11 0.15 0.11 0.06
*<0.05; **<0.01
+ Higher score is more symptoms
Abbreviations: dx = diagnosis
Age and Years since dx were continuous variables in the multivariate model.
Other variables were sex: male vs. female; type of cancer: papillar vs. follicular and papillar vs. medullary; primary 
treatment: surgery vs. surgery + ablation; disease stage: stage I/II vs. stage III/IV; comorbidity: no comorbid 
conditions vs. one or more comorbid conditions; partner: partner vs. no partner; educational level: high vs. low.
Multivariate linear regression analyses, corrected for socio-demographic and clinical 
characteristics showed that more neuromuscular problems were associated with worse 
global health (Beta = -0.23; p<0.05), physical (Beta = -0.35; p<0.01), role (Beta = -0.31; 
p<0.01), emotional (Beta = -0.16; p<0.05) and social functioning (Beta = -0.36; p<0.01). 
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More concentrati on problems were associated with worse cogniti ve (Beta = -0.73; p<0.01) 
and social functi oning (Beta = -0.23; p<0.01), while more sympatheti c problems were 
associated worse global health (Beta = -0.17; p<0.05). More psychological problems were 
associated with worse physical (Beta = -0.25; p<0.05), emoti onal (Beta = -0.53; p<0.01) and 
social functi oning (Beta = -0.22; p<0.01) and worse global health (Beta = -0.19; p<0.05).The 
explained variance (R2) ranged from 41% for global health and 58% for cogniti ve functi oning.
dIsCussIOn
Our fi ndings showed that TC survivors report stati sti cal signifi cant and clinical relevant lower 
levels of physical and psychosocial functi oning, and signifi cantly more symptoms compared 
to an age- and sex matched normati ve populati on. TC specifi c neuromuscular, concentrati on, 
sympatheti c and psychological problems were most strongly associated with worse physical 
and psychosocial functi oning. 
Primary treatment was not associated with HRQoL, which is in agreement with an earlier 
study that found no diff erences in HRQoL scores between pati ents who underwent total 
thyroidectomy and hemithyroidectomy respecti vely 14. A recent study showed that those 
pati ents submitt ed to higher doses of radioacti ve iodine are at risk for poor HRQoL 15. For 
part of the pati ents there may be overtreatment, since low risk pati ents are unlikely to 
benefi t from radioacti ve iodine therapy aft er initi al surgery 16. Unfortunately, no data on 
doses of radioacti ve iodine were available in the present study. Furthermore, the recent 
use of recombinant human thyroid sti mulati ng hormone (rhTSH) as alternati ve for thyroid 
hormone withdrawal preserved HRQoL during radioacti ve iodine ablati on6.
Disease stage and ti me since diagnosis were not related to HRQoL, although high disease 
stage and short ti me since diagnosis were related to more TC specifi c voice and throat/
mouth problems, indicati ng the severity of surgery. Our results show that TC specifi c 
problems related to thyroid dysregulati on (neuromuscular, concentrati on, sympatheti c, 
psychological and sensory problems) were most strongly associated with HRQoL. Although 
TC specifi c symptoms diminish over ti me, they remain present long aft er initi al treatment. 
The high doses of replacement therapy (TSH < 0.1 mU/L) in the fi rst years of follow-up, for 
pati ents who underwent ablati on therapy or had high risk of recurrence, and the subsequent 
TSH suppression may cause symptoms of subclinical hyperthyroidism. Aft er the fi rst years 
the doses of replacement therapy will be lowered for low risk survivors (TSH level around 
median (1 mU/L)), however the lower doses might not be the opti mal (pre-operati ve) level 
for the specifi c pati ent and in that case the symptoms are a result of the supplemental 
thyroid hormone treatment 17. Furthermore, long-term exposure to excess thyroid hormone 
CHAPTER 11
186
can lead to (irreversible) changes of the autonomous nervous system, which could not be 
reversed by restoration to euthyroidism 18. These changes possibly influence the well-being 
of a patient and might be an explanation for the symptoms patients experience even long-
term after diagnosis. 
Having one or more comorbidities was associated with worse functioning and more (TC 
specific) symptoms. Comorbid conditions could affect the presentation and recognition of 
symptoms and result in worse HRQoL on their own. Since 78% of the survivors reported 
one or more comorbidities, it is unclear whether comorbidity is associated with lower 
HRQoL or whether it is the disease itself, or their collaborative effect that negatively impacts 
HRQoL. Since the prevalence of comorbidities in the normative population (natural aging 
effects) was significantly lower compared to TC survivors, this might indicate that part of the 
comorbid diseases developed after primary treatment for TC and their development might 
be related to the treatment procedures 15. Studies suggest that subclinical hyperthyroidism 
(due to suppressive hormone therapy) has potential harmful effects on bone metabolism 
and the cardiovascular system 19 and is even associated with increased mortality due to 
cardiovascular diseases 20. More research is needed into the type, severity and impact of 
comorbid conditions in TC survivors, the development over time and the associations with 
treatments 21.
Our finding that partnered patients and patients with a higher educational level had higher 
HRQoL scores are in line with previous research 22, 23. Partnered patients experience more 
social support 23 and higher educated patients possibly receive more information by asking 
more questions, are more satisfied, choose the best doctor for their feeling and have a better 
understanding of the disease 22, that might lead to lower levels of anxiety and depression 
and better coping strategies. 
The strengths of our population-based study are the high response rate, the inclusion of 
long-term TC survivors (2-20 years after diagnosis), the large sample size, the availability of 
normative data of the EORTC QLQ-C30 and the use of a TC specific HRQoL questionnaire. 
However, the present study has the following limitations. First, detailed follow-up treatment 
data was lacking because the cancer registry registers only the primary treatment 
procedure.  Secondly, patients with unverifiable addresses were younger and more often 
had stage I papillary tumour compared to the respondents. Therefore our findings cannot 
be generalized to this younger group of patients with papillary tumours. Furthermore, 
people from the normative population more often had a higher educational level compared 
to the TC survivors, which could have influenced our results. The fourth limitation was 
the cross-sectional study design which limits the determination of causal associations. 
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Assessment of more specifi c biochemical (TSH levels and serum free T4, T3) and treatment 
parameters (levothyroxine dose, extent surgery, additi onal treatments) in combinati on with 
the assessment of THYCA-QoL over ti me is needed to draw defi niti ve conclusions about the 
exact mechanisms leading to a decreased HRQoL among long-term TC survivors.
As a consequence of the good prognosis for diff erenti ated TCs, pati ents are someti mes 
advised by HCP that TC is not a serious problem 24. This atti  tude trivializes the importance 
of the disease and causes pati ents to feel dismissed as not having a serious disease 25. 
Since survivors report decreased HRQoL and several TC specifi c symptoms long-term aft er 
diagnosis, there is a need for multi disciplinary aft ercare. The fi rst step for multi disciplinary 
aft ercare will be recogniti on, recording and acknowledgment of specifi c long-term health 
problems of pati ents with TC by HCPs. Our questi onnaire (THYCA-QoL) can be of value in 
the treatment and aft er care of TC survivors. It will make HCPs more aware of the potenti al 
HRQoL issues TC survivors are dealing with. HCPs can monitor changes in HRQoL (and its 
determinants) over ti me and provide conti nuous support for pati ents with TC during follow-
up surveillance. In additi on, HCPs could also help to improve HRQoL among pati ents with 
TC by showing them how to manage uncomfortable symptoms and by referring them for 
further services when necessary (for example physical acti vity programs or support groups).
In conclusion, TC survivors have a worse HRQoL compared to the normati ve populati on. 
TC specifi c neuromuscular, sympatheti c, concentrati on and psychological problems last 
up long-term aft er diagnosis and are more strongly associated with HRQoL than socio-
demographic and clinical factors alone.  Awareness of these specifi c determinants of HRQoL 
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fati gue among (long-term) thyroid cancer survivors: 
results from the populati on-based PrOfIles registry





aim: To obtain insight into the prevalence of fatigue among short-term and long-term thyroid 
cancer survivors, by comparing a sample of thyroid cancer survivors with an age- and sex-
matched normative population. Secondly, our aim was to investigate which demographic, 
clinical, and thyroid cancer specific characteristics were associated with fatigue.
methods: All patients diagnosed with thyroid cancer between 1990-2008, as registered 
in the Eindhoven Cancer Registry, received a cross-sectional survey on fatigue (FAS) and 
disease-specific symptoms (THYCA-QoL). The fatigue scores were compared with those 
of an age- and sex-matched normative population (n=530). Multiple linear regression 
analyses were conducted to investigate the independent associations between clinical and 
demographic variables and (thyroid cancer specific) HRQoL.
results: Eighty-six percent (n=306) responded. Short-term survivors and long-term 
thyroid cancer survivors (< 5 years: 22.6 ± 7.3; 5-10 years: 22.6 ± 8.5; 10-15 years: 20.9 ± 
6.6; >15 years: 20.5 ± 6.7) had statistically significant higher scores on fatigue compared 
to the normative population (18.7 ± 5.9; p<0.001). Anxiety (OR: 1.15, 95% CI: 1.03-1.28) 
and depression (OR: 1.43, 95% CI: 1.22-1.68) were associated with fatigue, as was also 
the case for thyroid cancer specific neuromuscular (OR: 1.03, 95%CI: 1.01-1.06, p<0.01), 
concentration (OR: 1.03, 95%CI: 1.01-1.06, p=0.01) and psychological problems (OR: 1.06, 
95%CI: 1.02-1.10, p<0.01).
Conclusion: Short-term and long-term thyroid cancer survivors report higher levels of 
fatigue compared to an age- and sex-matched normative population. Both thyroid cancer 
specific and mental health problems were strongly associated with fatigue. Future research 
is needed to determine the underlying mechanisms of fatigue among thyroid cancer 
survivors and identify possible treatment options.
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InTrOduCTIOn
Worldwide, the incidence of thyroid cancer is rising 1. As a result of the very good prognosis of 
papillary and follicular thyroid cancer (exceeding >90% 5-year survival) the number of thyroid 
cancer survivors is rising 2, 3. Treatment of thyroid cancer involves surgery, predominantly 
(near-)total thyroidectomy, followed by radioiodine (131-I) therapy to ablate the remaining 
thyroid ti ssue. Depending on type and size of the tumour hemithyroidectomy could suffi  ce. 
The removal of the thyroid gland is accompanied by a lifelong dependence on supplement 
therapy with levothyroxine, in the fi rst 2 years with dosing regimens suppressing thyroid 
sti mulati ng hormone (TSH) producti on 4, 5, causing subclinical hyperthyroidism. Despite the 
effi  cacy of these primary treatments and the high long-term survival rates, the disease can 
recur even decades later. Therefore, long-term follow-up is necessary. Given the longevity 
of thyroid cancer pati ents, the possible long-term eff ects of cancer and its treatment on 
pati ents’ well-being are of increasing importance.
Fati gue is a common problem among diff erent groups of cancer survivors, with prevalence 
rates ranging between 17% and 90% 6-8. High levels of fati gue are associated with low health-
related quality of life 9 and high levels of emoti onal distress 10. Research focusing on the levels 
of fati gue among thyroid cancer survivors is lacking. Nevertheless, fati gue is a frequently 
reported complaint among pati ents with (subclinical) hyperthyroidism 11. Since short-term 
thyroid cancer survivors receive suppressing doses of levothyroxine, causing subclinical 
hyperthyroidism, it can be expected that these survivors experience higher levels of fati gue 
compared to long-term thyroid cancer survivors who have returned to an euthyroid state.
The primary objecti ve of our study was to obtain insight into the prevalence of fati gue 
among short-term and long-term thyroid cancer survivors, by comparing a sample of 
thyroid cancer survivors with an age- and sex-matched normati ve populati on. Secondly, 
our objecti ve was to investi gate which demographic and clinical characteristi cs and which 
thyroid cancer-specifi c and mental health problems were associated with fati gue in thyroid 
cancer survivors.  Our hypotheses were 1) short-term thyroid cancer survivors report higher 
levels of fati gue compared to long-term survivors and the normati ve populati on; 2) long-
term survivors ‘return’ to normal levels of fati gue and therefore report similar fati gue 
levels compared to the normati ve populati on; 3) clinical and psychological variables are 





This study is a population-based survey among thyroid cancer survivors registered within 
the Eindhoven Cancer Registry (ECR) of the Comprehensive Cancer Centre South (CCCS). 
The ECR compiles data of all individuals newly diagnosed with cancer in the southern part of 
the Netherlands, an area with 10 hospitals serving 2.3 million inhabitants 12. All individuals 
diagnosed with thyroid cancer between 1990 and 2008 as registered in the ECR were eligible 
for participation (N=568). We excluded patients who had cognitive impairment or were too ill 
at time of the study (medical records and advice attending specialist N=31), had unverifiable 
addresses (N=90), or died prior to the start of the study (according to the ECR, the Central 
Bureau for Genealogy which collects information on all deceased Dutch citizens via the civil 
municipal registries, and hospital records; N=6). One hospital declined to participate (N=86). 
Questionnaires were send to the remaining 355 patients. This study was approved by the 
certified Medical Ethics Committee of the Maxima Medical Centre in Eindhoven. 
data collection
Data collection started in November 2010 and was done within PROFILES (Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship) 13. PROFILES 
is a registry for the study of the physical and psychosocial impact of cancer and its treatment 
from a dynamic, growing population-based cohort of both short and long-term cancer 
survivors. PROFILES contains a large web-based component and is linked directly to clinical 
data from the Eindhoven Cancer Registry (ECR). Details of the PROFILES data collection 
method have been previously described 13. In summary, survivors were informed of the 
study via a letter from their (ex-)attending specialist. The letter included a link to a secure 
website, a login name, and a password, so that interested patients could provide informed 
consent and complete questionnaires online. If the patient did not have access to internet, 
or preferred written rather than digital communication, (s)he could return our postcard 
by mail after which (s)he received our paper-and-pencil version of the informed consent 
form and questionnaire. Data from the PROFILES registry is available for non-commercial 
scientific research, subject to study question, privacy and confidentiality restrictions, and 
registration (www.profilesregistry.nl).
study measures
Sociodemographic and clinical characteristics
Survivors’ sociodemographic and clinical characteristics at time of cancer diagnosis were 
available from the ECR. The ECR routinely collects data on tumour characteristics, including 
date of diagnosis, tumour grade and stage according to the Tumour-Node-Metastasis clinical 
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classifi cati on 14, treatment, and pati ent background characteristi cs including date of birth 
and comorbidity at the ti me of diagnosis. Self-reported comorbidity at the ti me of survey 
was categorized according to the adapted Self-administered Comorbidity Questi onnaire 
(SCQ) 15. The SCQ also assesses survivors’ perceived burden and medicati on use for each 
comorbid conditi on. Questi ons on marital status, educati onal level, and current occupati on 
were added to the questi onnaire.
Mental health
Mental health was assessed with the Hospital Anxiety and Depression Scale (HADS), with 
7 items each assessing anxiety and depression.16 Clinical level of anxiety or depressive 
symptoms was indicated with a score of ≥8 on each subscale.16, 17 
Thyroid-specifi c HRQoL 
Thyroid cancer specifi c HRQoL was measured by the THYCA-QoL which was developed to 
assess side-eff ects due to thyroid cancer or its treatment.18The questi onnaire consists of 24 
items, with a ti me frame of the previous week, except for the sexual interest item which is 
four weeks. Each item is scored on a 4 point response scale ranging from 1, ‘not at all’ to 4, 
‘very much’. The THYCA-QoL consists of seven scales (neuromuscular, voice, concentrati on, 
sympatheti c, throat/mouth, psychological and sensory problems) and six single items. 
Scores were linear transformed to a 0-100 scale. A higher score on this scale means more 
complaints.
Fati gue
Fati gue was assessed with the Fati gue Assessment Scale (FAS), a questi onnaire consisti ng of 
10 items: fi ve questi ons refl ecti ng physical fati gue and fi ve questi ons for mental fati gue. The 
response scale is a 5-point scale (1 never to 5 always) and scores can range from 10 to 50. 
The psychometric properti es are good 19 20 and the questi onnaire has been used with cancer 
pati ents before 21.
normati ve populati on
Normati ve populati on data was obtained from CentERpanel, an online household panel that 
is representati ve of the Dutch populati on. The process of the annual data collecti on, which 
started in 2009 by our study group, is described elsewhere 22. The most recent data wave in 
2011 also included an assessment of fati gue with the FAS. From the 2040 (82%) members of 
18 years and older, an age- and sex-matched normati ve sample (n=530) was selected for this 
study to refl ect the age and sex distributi on of the thyroid cancer sample. Sociodemographic 




Demographic and clinical data of respondents, non-respondents and patients with 
unverifiable addresses were compared using chi-square statistics for categorical variables 
and analysis of variance (ANOVA) for continuous variables. The non-parametric Wilcoxon 
test was applied when normality and homogeneity assumptions of continuous variables 
were violated.
ANOVA was furthermore used to compare the mean scores of the thyroid cancer sample 
(stratified by years since diagnosis: short-term <5 years; long-term 5-10 years; long-term 
10-15 years; long-term >15 years) on the FAS items and total score with those of the Dutch 
normative population. 
Logistic regression models were conducted to identify associations of demographic and 
clinical variables, mental health and thyroid cancer specific problems with fatigue. The 
models were composed as follows: 1) demographics; 2) demographics + clinical variables; 
3) demographics + clinical variables + mental health; 4) demographics + clinical variables + 
thyroid specific HRQoL. 
The total FAS score was divided into two groups, 10 to 21 (not fatigued), 22-50 (fatigued) as 
previously done 23. 
Clinically meaningful differences were determined with Norman’s ‘rule of thumb’, whereby 
a difference of ≈0.5 SD indicates a threshold of discriminant change in scores of a chronic 
illness 24. All statistical analyses were performed using SPSS version 17.0 (Statistical Package 
for Social Sciences, Chicago, IL, USA) and P values <.05 were considered statistically 
significant.
resulTs
Patient and tumour characteristics
Three hundred and six patients returned a completed questionnaire (response 86%). A 
comparison of respondents, non-respondents and patients with unverifiable addresses 
indicated that patients with unverifiable addresses were younger compared to non-
respondents and respondents (mean 52, 56 and 54 years respectively) 25. No differences 
between groups were seen regarding sex, type of thyroid cancer, stage of the disease or 
primary treatment. 
The mean age at time of the survey was 56 (SD=15) years. Average time since diagnoses was 
9.6 (SD= 5.5) years. More than half of the patients were diagnosed with stage I disease (57%). 
Surgery (99%) was followed by iodine-131 ablation therapy in 69% and by radiotherapy in 
3% of the cases. More than three quarters (78%) of the patients had one or more comorbid 
conditions. 
12
FATIGUE AMONG THYROID CANCER SURVIVORS
197
Table 1: Clinical and socio-demographic characteristi cs of thyroid cancer survivors strati fi ed by ti me 





















Mean age at ti me of survey 
(±SD)
55.6 ± 16.0 54.5 ± 14.8 56.8 ± 13.1 59.6 ± 13.4 55.8 ± 14.6 0.26
Mean years since initi al 
diagnosis (±SD)
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Comorbidity at ti me of study
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Some variables exceed 100% due to rounding off ; some variables do not add up to 100% due to missing data.
a Educati on: Low (no or primary school); Medium (lower general secondary educati on or vocati onal training); High 




Table 2: Mean scores (± SD) of thyroid cancer specific problems and mental health problems stratified 


































































HADS anxiety 5.2 ± 3.6 5.1 ± 4.4 4.1 ± 3.2 4.2 ± 3.7 3.7 ± 3.3 0.001
HADS depression 3.6 ± 2.9 3.7 ± 3.5 3.0 ± 2.6 3.4 ± 3.2 3.6 ± 3.3 0.66
% above the ≥8 clinical cut-off 16, 17
HADS anxiety 19 (24) 20 (24) 8 (12) 8 (14) 64 (12) 0.004
HADS depression 11 (14) 13 (16) 5 (7) 7 (12) 7 (12) 0.60
n.a.: these items were not assessed in the normative population
Comparisons on clinical and socio-demographic characteristics, thyroid cancer specific 
and mental heath problems of respondents stratified by years since diagnosis showed that 
short-term survivors were more likely to be diagnosed with a higher stage disease compared 
to long-term survivors (Table 1). Furthermore, survivors <5 years since diagnosis were more 
likely to report voice, sympathetic and throat/mouth problems compared to survivors >15 
years since diagnosis and higher levels of anxiety compared to survivors ≥10 years since 
diagnosis (Table 2). There was a trend toward diminishing thyroid cancer specific problems 
over time.
The normative population was more likely to be higher educated, reported less comorbidities 
and were less likely to have anxiety compared to short-term and long-term thyroid cancer 
survivors (Tables 1 and 2).
fatigue of thyroid cancer survivors compared with a normative population
In general, short-term survivors reported the highest levels of mean fatigue scores and the 
normative population, the lowest (Table 2). 
The normative population was significantly less likely than the survivors group to report 
being bothered by fatigue, getting tired quickly, not being able to do much, feeling exhausted 
physically and mentally, problems with starting things and thinking clearly, and no desire to 
do anything. Also, the FAS total score was significantly lower for the normative population 
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compared to the thyroid cancer survivors. No signifi cant diff erences were found between 
short- and long-term survivors.
Clinically meaningful diff erences between the normati ve populati on and the short-term 
survivors were found for the items getti  ng ti red very quickly, feeling physically exhausted, 
problems with thinking clearly and the FAS total score. Furthermore, a clinically meaningful 
diff erence was found between long-term survivors (5-15 years aft er diagnosis) and the 
normati ve populati on for the item getti  ng ti red very quickly. Comparison between short- 
and long-term survivor groups showed no clinically meaningful diff erences in fati gue scores 
(Table 3).  
When strati fi ed by ti me since diagnosis and divided into three fati gue groups; not fati gued 
(as defi ned by a score of 10 to 21 on the FAS), fati gued (22 to 34), and  very fati gued (35 
to 50) as previously done 23, signifi cant diff erences were noted between all the survivors 
(Figure 1) and the normati ve populati on (p<0.001). Survivors were more oft en classifi ed 
as fati gued or very fati gued (short-term: 43%; long-term 5-10 years: 44%; long-term 10-
15 years: 47%; long-term > 15 years: 39%) compared to the normati ve populati on (25%). 
Furthermore long-term survivors >15 years aft er diagnoses reported less fati gue compared 
to the other three survivor groups, and survivors <10 years aft er diagnosis reported more 
































figure 1: Fati gue levels of thyroid cancer survivors compared to an age and sex-matched normati ve 
populati on
% Thyroid cancer survivors strati fi ed by years since diagnosis (short-term: <5 years; long-term: ≥5 years), and 
normati ve populati on who are fati gued. Category cut-off s were based on FAS total scores: not fati gued (10-21), 
fati gued (22-34), very fati gued (35-50).
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logisti c regression
Logisti c regression models were conducted to identi fy associati ons of demographic and 
clinical variables, mental health and thyroid cancer specifi c problems with fati gue. Model 
1 consisti ng of only demographic variables showed that lower educati on (odds rati o (OR): 
2.79, 95% confi dence interval (CI): 1.55-5.04, p<0.01) was associated with a higher risk for 
fati gue (Table 4). 
With the inclusion of clinical variables in Model 2, educati on remained signifi cantly associated 
with fati gue, while  partnership became signifi cant in this model, whereby absence of a 
partner was associated with more fati gue (OR: 1.94, 95% CI: 1.05-3.58, p=0.04). Having 
comorbid conditi ons (OR: 2.60, 95% CI: 1.42-4.74, p<0.01) was also signifi cantly associated 
with fati gue. 
In Model 3, anxiety (OR: 1.15, 95%CI: 1.03-1.28, p=0.01) and depression (OR: 1.43, 95%CI: 
1.22-1.68, p<0.01) were signifi cantly associated with fati gue. Following the inclusion of 
these psychological factors, only comorbidity (OR: 2.39, 95%CI: 1.14-5.00, p=0.02) remained 
signifi cant in this model. 
In Model 4, neuromuscular (OR: 1.04, 95%CI: 1.02-1.06, p<0.01), concentrati on (OR: 1.03, 
95%CI: 1.01-1.06, p=0.01) and psychological problems (OR: 1.05, 95%CI: 1.02-1.28, p<0.01) 
were signifi cantly associated with fati gue, whereby more problems indicated higher levels 
of fati gue. All clinical variables were not signifi cantly associated with fati gue anymore, while 
age at survey (OR: 0.97, 95%CI: 0.94-1.00, p=0.05) and educati onal level (OR: 2.57, 95%CI: 
1.06-6.62, p=0.04) were also signifi cant, whereby an older age and higher educati onal level 
were associated with less fati gue. The single items of the thyroid cancer specifi c HRQoL 
questi onnaire (problems with scar, felt chilly, ti ngling hands and/or feet, headaches, gained 
weight) were not related to fati gue, except for sexual functi oning (OR: 0.98, 95%CI: 0.97-
1.00, p=0.05), whereby less interest in sex was related to higher levels of fati gue.
dIsCussIOn
This large populati on-based study among survivors of thyroid cancer showed that 
fati gue remains a problem long-term aft er diagnosis. In general, regardless of ti me since 
diagnosis, thyroid cancer survivors reported stati sti cally signifi cant higher levels of fati gue 
when compared with an age- and sex-matched normati ve populati on, although clinically 
meaningful diff erences were only found between short-term survivors and the normati ve 
populati on. Levels of fati gue decreased with increasing ti me since diagnosis, but these 
diff erences were not signifi cant. Thyroid cancer specifi c (neuromuscular, concentrati on and 
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Our results are consistent with fi ndings of a recent German study showing that thyroid 
cancer pati ents at the beginning of inpati ent rehabilitati on do suff er from higher levels of 
fati gue than the general populati on 26, as was also found in a Korean study among short-
term thyroid cancer survivors (median 2.7 years aft er diagnosis) 27. A Dutch study among 
cured diff erenti ated thyroid cancer pati ents (median durati on of cure of 6.3 years) showed 
that a longer durati on of cure was correlated with bett er scores on general, mental and 
physical fati gue 28. Our results also show decreasing levels of fati gue with increasing years 
since diagnoses, however levels of fati gue of long-term survivors were higher compared to 
the normati ve populati on albeit not clinical relevant higher.
The high doses of replacement therapy (TSH < 0.1 mU/L) in the fi rst years of follow-up, for 
pati ents who underwent ablati on therapy or had high risk of recurrence, and the subsequent 
TSH suppression, may cause symptoms of (subclinical) hyperthyroidism.  Subclinical 
hyperthyroidism is a reversible cause of fati gue 11. However, aft er the fi rst years, the doses 
of replacement therapy will be lowered for low risk survivors (TSH level around median 
(1 mU/L)) to restore euthyroidism and fati gue levels are therefore expected to decrease. 
This might explain the decrease in fati gue levels for long-term survivors compared to short-
term survivors in our study. However, the long-term survivors sti ll had stati sti cally signifi cant 
higher fati gue levels compared to the normati ve populati on. This is in contrast with another 
Dutch study showing that thyroid cancer pati ents (n=24) under long-term subclinical 
hyperthyroidism (> 10 years) do not diff er in the levels of general, mental and physical 
fati gue compared to an age- and sex matched reference group 29. Our fi nding that thyroid 
cancer specifi c problems were associated with fati gue could indicate that the TSH level of 
around 1 mU/L, might not be the opti mal (pre-operati ve) level for the specifi c pati ent 30, and 
that the pati ent therefore does not feel well.
Another explanati on of our fi ndings could be the presence of cancer-related fati gue (CRF). 
Fati gue levels of thyroid cancer survivors (43%) are comparable to those observed in other 
cancer survivor populati ons (17-90%)6, 8, 31. According to the guidelines of the Nati onal 
Comprehensive Cancer Network (NCCN), cancer-related fati gue is defi ned as a distressing, 
persistent, subjecti ve sense of physical, emoti onal, and/or cogniti ve ti redness or exhausti on 
related to cancer or its treatment that is not proporti onal to recent acti vity and interferes 
with usual functi oning 32. The underlying mechanisms involved in cancer-related fati gue 
are not well understood. Possible mechanisms include eff ects of cancer or its treatment 
on the central nervous system, muscle energy metabolism, sleep rhythms 33, mediators of 
infl ammati on and stress 34, immune acti vati on 35, and hormonal changes related to eff ects 
on the hypothalamic– pituitary axis 7. A Norwegian study showed that type or intensity of 
cancer treatment is unrelated to the level of cancer-related fati gue and more related to 
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mental and somatic health problems 36. This finding is in line with the results of a Dutch 
study showing that levels of fatigue of thyroid cancer survivors (median duration of cure 
of 6.3 years) were not affected by initial tumour stage, total activity of radioiodine, tumour 
recurrence, and replacement therapy dose 28. In addition to this, our own results show no 
associations between clinical factors and fatigue (except for comorbidity), while thyroid 
cancer specific and mental health problems were most strongly associated with fatigue. 
Due to the high prevalence of fatigue and the profound effect that it can have on a patient’s 
daily life, healthcare providers should be encouraged to inquire about the presence of 
this symptom 37. Both non-pharmacologic and pharmacologic treatments are available for 
the treatment of cancer-related fatigue. Currently, the best treatments are psychosocial 
interventions and exercise 37. Other non-pharmacologic and pharmacologic interventions 
have less supporting evidence but still may be effective for some patients. Recently, an 
Internet-based education program based on NCCN guidelines showed good results to help 
patients manage cancer-related fatigue 38. Further research is needed to determine if an 
intervention for fatigue can reduce the high levels of fatigue among long-term thyroid 
cancer survivors.
The present study has some limitations that should be mentioned. Although demographic 
and clinical information of non-respondents and survivors with unverified addresses were 
available for comparison, the health status of these survivors and its possible effects on 
current results remain unknown. In addition, the cross-sectional study design limits the 
determination of causal association between cancer-related factors and fatigue. A logistic 
regression model including mental health and thyroid cancer specific problems could not be 
performed, since there is a high correlation between the thyroid cancer specific psychological 
problem scale and the anxiety scale of the HADS. Therefore, it was not possible to determine 
which of the factors was most strongly associated with fatigue.
Nevertheless, the present study provides an important contribution to the limited data 
available on fatigue of (long-term) thyroid cancer survivors. Since our study has a high 
response rate, extrapolating these results to the larger population of thyroid cancer 
survivors seems justified. Furthermore, we were able to compare fatigue levels with an 
age- and sex-matched normative sample. Future research with longitudinal designs should 
make use of an additional reference group, namely a group of patients with hyperthyroidism 
without thyroid cancer, to see whether it is the history of thyroid cancer accompanied by 
CRF or (subclinical) hyperthyroidism that causes the higher levels of fatigue compared to the 
normative population. 
In conclusion, about 40% of the thyroid cancer survivors report a high level of fatigue up till 
20 years after diagnosis. Short-term and long-term thyroid cancer survivors report higher 
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levels of fati gue compared with the normati ve populati on. Thyroid cancer specifi c and 
mental health problems were highly associated with fati gue. Further research is needed 
to explore the underlying determinants of fati gue and the opti mal treatment opti ons for 
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summarY Of resulTs 
In this chapter, the main fi ndings of this thesis are summarized, and put into a perspecti ve, 
whereby conceptual and methodological considerati ons and implicati ons for clinical practi ce 
and future research will be discussed.
Part I: Informati on provision and pati ent reported outcomes
The summary of part I will be guided by the conceptual model presented in the general 
introducti on (Figure 1). At the centre of the conceptual model is the perceived level of, and 
sati sfacti on with the received informati on. Throughout this thesis informati on provision was 
defi ned as all cancer-related informati on provided by the health care provider (HCP) in oral, 
writt en or any other form. Our fi rst aim was to assess the levels of received informati on 
and the sati sfacti on with this informati on among melanoma cancer survivors (Chapter 2). 
We used the internati onally validated EORTC QLQ-INFO25 to assess informati on provision 
1. Melanoma survivors indicated that they received no informati on about diff erent aspects 
of their disease (9-37%), treatment (38%), and aft ercare (84-94%). More than half of the 
survivors (61%) were not or only a bit sati sfi ed with the amount of informati on received; a 
quarter of the pati ents indicated that they wanted to receive more informati on. 
 
      
 
 
Perceived level of, and 
satisfaction with, 
information received 
Patient (including personality), 
tumour (including disease stage), 
treatment and hospital 
characteristics 
Health-related quality of life 






Chapters 5, 6 
Background characteristics Information provision Outcomes 
figure 1: Conceptual model of relati ons between informati on provision and clinical, socio-demographic, 
psychological and pati ent reported outcomes.
The left  part of our conceptual model indicates that several background characteristi cs might 
be associated with the perceived level of and sati sfacti on with the received informati on. 
Among melanoma survivors the perceived receipt of informati on was associated with a 
higher disease stage, less years since diagnosis, a higher educati onal level and younger 
age, while sati sfacti on with informati on was associated with hospital of treatment, a higher 
educati onal level and use of the internet (Chapter 2).
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Besides the associations of clinical and socio-demographic factors with information 
provision, psychological factors like personality can also affect the perceived level of 
received information. Therefore the effects of the personality traits negative affectivity 
(NA) and social inhibition (SI) and their combined effect (Type D personality) on satisfaction 
with received information among a diverse group of 3080 cancer survivors were examined 
(Chapter 3). The perceived receipt of information, and the satisfaction with and usefulness 
of the received information were all lower for cancer survivors with a Type D personality 
compared to cancer survivors without a Type D personality or survivors with high scores for 
NA or SI only, also after controlling for clinical and socio-demographic characteristics.
In the right part of our conceptual model it is hypothesized that several patient reported 
outcomes (PROs) could have a bidirectional relationship with the perceived level of, and 
satisfaction with the received information. In Chapter 4, the literature on the relationship 
between information provision and health-related quality of life (HRQoL), anxiety and 
depression was systematically reviewed. This review showed that satisfied patients, patients 
with fulfilled information needs, and patients who experience less information barriers, in 
general have a better HRQoL and lower levels of anxiety and depression. Most of these 
findings are based on observational studies. Only one intervention study which aimed to 
improve information provision showed a positive relation with HRQoL, while the other 
seven intervention studies did not found an association. 
To investigate potential pathways between information provision and PROs as observed 
in the systematic review we hypothesized that illness perception might play an important 
role. It has been reported that illness perception is a major determinant of HRQoL 2 and is 
possibly associated with information provision, which was examined in Chapter 5. Results 
showed that among a diverse group of 3080 cancer survivors the perceived receipt of more 
disease-specific information was associated with more control and a better understanding 
of the illness, while the perceived receipt of more information about other services was 
associated with more negative consequences of the illness on the patients’ life, longer 
perceived duration of illness, less treatment control, more symptoms attributable to the 
illness, less understanding of, and stronger emotional reaction to the illness. Satisfaction 
with the received information was associated with better illness perception on all subscales, 
except for personal control. 
In Chapter 6, we brought together the associations between information provision, illness 
perception and PROs among colorectal cancer (CRC) patients. It was shown that the 
perceived receipt of information was quite comparable between CRC patients with and 
without metastasis, except for information about treatments which was higher for patients 
with metastasized disease. Issues related to disease course and supportive care were 




receive more informati on about. Only 60% of the pati ents with metastati c CRC were (quite) 
sati sfi ed with the received informati on. For pati ents with metastasized CRC the perceived 
receipt of more disease informati on and informati on about other services was associated 
with worse PROs (illness percepti on, HRQoL, anxiety and depression), while sati sfacti on 
with the received informati on was not associated with PROs.
Most studies described in our systemati c review had a cross-secti onal design. Therefore, we 
prospecti vely examined the relati onship between informati on provision and HRQoL, anxiety 
and depression among lymphoma and multi ple myeloma (MM) (Chapter 7). We observed 
that the perceived receipt of informati on decreased slightly over ti me (mostly among short-
term survivors), while HRQoL, anxiety and depression levels did not change. Sati sfacti on 
with the received informati on at baseline predicted HRQoL 2 years later, however aft er 
correcti on for baseline HRQoL the relati onship largely disappeared. Stability of sati sfacti on 
with the received informati on was associated with bett er mental HRQoL compared to 
fl uctuati ng sati sfacti on levels or stable dissati sfacti on with the received informati on, also 
when adjusted for baseline HRQoL levels.
Part II: Thyroid cancer survivors: an understudied group
Long-term trends in incidence, mortality, and survival of thyroid cancer (TC) in The 
Netherlands between 1989 and 2009 were examined in Chapter 8. Since 1989 the incidence 
of TC increased signifi cantly in the Netherlands, while mortality from TC decreased. Five-
year relati ve survival rates remained stable and appeared to be somewhat higher in the 
2004-2009 period compared to earlier periods, except for advanced tumours of which the 
frequency decreased markedly. Due to the increasing incidence and good prognosis of 
diff erenti ated TC, the number of (long-term) TC survivors is rapidly increasing. The results 
of this study therefore support the need for research into the long-term HRQoL of TC 
survivors and possible physical and psychosocial problems survivors’ are dealing with aft er 
the completi on of primary treatment.
In Chapter 9, the available literature was systemati cally reviewed to provide a complete 
overview on the current knowledge about HRQoL of TC survivors. This review showed that 
TC survivors report severe impairments of HRQoL aft er treatment (surgery, radioacti ve 
iodine ablati on, supplemental thyroid hormone therapy) and follow-up procedures. 
Studies focusing on long-term TC survivors showed contradictory results. Therefore, strong 
conclusions on the HRQoL among long-term TC survivors could not be drawn from the 
studies included in our systemati c review. The main problem of included studies was the 
absence of a valid, TC specifi c instrument to assess HRQoL. Most studies used a general 
HRQoL questi onnaire, which cannot capture the specifi c complaints associated with TC and 
its treatment. This fi nding resulted in the need to develop a thyroid cancer specifi c HRQoL 
questi onnaire, which was described in Chapter 10. Potenti ally relevant issues were identi fi ed 
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by our systematic literature review, a focus group meeting, and an issue list completed by 
six health care providers (HCP) and 18 TC survivors. Resultant issues were analyzed on 
importance and relevance by HCP and patients which resulted in a provisional list of 30 
items formulated as questions according to the EORTC format. Pretesting by a large group 
of TC survivors led to a selection of 24 items with a good range of response. This resulted 
in the THYCA-QoL containing 24 items and seven conceptual scales (neuromuscular, voice, 
concentration, sympathetic, throat/mouth, psychological and sensory problems). 
The THYCA-QoL provided the possibility to assess TC specific HRQoL among long-term 
TC survivors. Using this questionnaire, the long-term HRQoL effects of TC and its various 
treatments was examined, by comparing a sample of TC survivors (2-20 years since diagnosis) 
with an age- and gender-matched normative population (Chapter 11). Our findings showed 
that TC survivors report lower levels of physical and psychosocial functioning, and more 
problems (fatigue, dyspnea, insomnia and financial) compared to an age- and gender 
matched normative population. Most differences were of small clinical importance. Clinical 
and socio-demographic factors explained only a small part of the variance in HRQoL, while TC 
specific neuromuscular, concentration, sympathetic and psychological problems explained a 
large part (41-58%) of the variance in HRQoL. 
Fatigue is a common problem among patients with (subclinical) hyperthyroidism 3, as is 
the case for TC survivors with suppressing doses of levothyroxine in the first years after 
surgery. Research focusing on the levels of fatigue among thyroid cancer survivors is lacking. 
Therefore, we examined the prevalence of fatigue among short-term and long-term TC 
survivors (Chapter 12). Our results showed that around 40% of the TC survivors report a high 
level of fatigue up till 20 years after diagnosis. Short-term and long-term TC survivors report 
higher levels of fatigue compared with the normative population, however differences were 
only clinically meaningful for short-term survivors compared with the normative population. 
TC specific (neuromuscular, concentration and psychological) and mental health (anxiety 





With the ongoing improvements in early detecti on and treatment of cancer along with the 
ageing of the populati on, the number of cancer survivors is rapidly increasing in the Western 
world. Therefore, achieving and maintaining opti mal well-being must be an important 
objecti ve of current cancer treatment, cancer rehabilitati on and aft ercare. Adequate 
informati on provision is one of the most important factors in the supporti ve care for cancer 
survivors and is associated with positi ve pati ent reported outcomes (bett er HRQoL, lower 
levels anxiety and depression, positi ve illness percepti on). Although the knowledge about 
cancer survivorship has grown in the past decade, survivors of rare tumours, like thyroid 
cancer (TC), so far received litt le att enti on in the cancer survivorship literature. 
growing number of thyroid cancer survivors
Since 1989 the incidence rates of TC increased signifi cantly in The Netherlands, while 
mortality from TC decreased. These trends caused a marked increase in the number of 
TC survivors (20-year prevalence of 2700 in 1990 vs. 5500 in 2010). There is an ongoing 
discussion in the literature about the questi on whether or not the observed increase in 
TC incidence is real or apparent. Since the beginning of the 1980’s there is an increase in 
use of more precise diagnosti cs, like ultrasonography and fi ne needle aspirati on biopsies 4, 
5,  and bett er medical surveillance 6. An American study showed a signifi cant decrease in 
tumour size over ti me and concluded that the apparent increase in TC incidence was due to 
increased detecti on of subclinical disease 7. This fi nding is supported by the fi nding of a 36% 
incidence of occult papillary tumours in Finnish adults at autopsies 8. It might therefore be 
possible that the increased incidence of TC in the Netherlands is partly due to overdiagnosis 
of clinically irrelevant cancer 9. Most pati ents with cytological indeterminate nodules are 
referred for diagnosti c thyroid surgery, but the majority prove to have benign disease 10 
and for these pati ents surgery is unnecessary 11.  The main problem of overdiagnosis is that 
pati ents cannot benefi t from “unnecessary” treatment, however this treatment can lead to 
morbiditi es and can aff ect the persons’ well-being for the rest of his/her life 9. Furthermore, 
increased detecti on of small tumours can lead to an overesti mati on of treatment effi  cacy 
and a subsequent rise in use of treatment 12 13. A recent study showed that implementati on 
of a gene-expression classifi er to identi fy a subpopulati on of pati ents with a low likelihood 
of cancer leads to a marked reducti on (74% to 7.6%) in the HCPs decision to operate on 
cytologically indeterminate thyroid nodules 11 14. More clinical strategies should be developed 
to minimize overdiagnosis.
The increase in incidence rates cannot be completely ascribed to improved detecti on. Real 
increases in incidences of TC have been associated with diff erent risk factors (radiati on 
exposure15-17, low iodine intake 18 and overweight 19), although the exact eti ology of TC 
remains unclear and needs to be explored 20.
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Current state of information provision among cancer survivors
As the number of cancer survivors is rapidly increasing, investigating the current state of 
information provision and the degree of satisfaction with received information is important. 
It reveals whether information provision is sufficient, or whether improvements are needed. 
Our studies among cancer survivors of different cancer types (melanoma, endometrial, 
colorectal, (non-)Hodgkin and multiple myeloma) indicate that survivors received quite a bit 
of information about their disease, medical tests and treatment 21, 22. However, a substantial 
percentage of the survivors stated that they were not or only a little informed about the 
cause of their disease and possible side effects of their treatment. Cancer survivors received 
the least information on topics related to aftercare, such as what to expect in their social 
and sexual life, where to go for additional help, rehabilitation, or psychological support, and 
how to cope with cancer at home, different care locations outside the hospital, or things 
to do to improve their health. Moreover, 15 - 28% of the survivors wanted to receive more 
information, and the most frequently mentioned topics were (psychosocial) aftercare, cause 
and course of the disease and late effects of treatment. Topics that survivors wanted to 
receive more information about changed over time, with  information about disease stage, 
treatment options and side-effects of treatment most frequently mentioned in the diagnosis 
and treatment phase, while post-treatment, patients report a continued need for treatment 
related information and also information about rehabilitation was important 23. 
Survivors who were not satisfied with the received information, indicated on all information 
provision subscales that they received less information and found the information less 
helpful than satisfied survivors. Moreover, unsatisfied survivors indicated that they wanted 
to receive more additional information than satisfied survivors. However, a small group of 
unsatisfied survivors indicated that they wanted to receive less information than satisfied 
survivors. Although most patients prefer to be fully informed 23, a minority of patients do not 
want to receive all available information 24.
Patient and clinical characteristics and perceived level of received information
Several factors contribute to differences in the perceptions of the received information (left 
part conceptual model; Figure 1).
Clinical factors associated with perceived levels of information
Levels of perceived information differed between survivors with different types of cancer, 
possibly due to differences in intensity of treatment and follow-up procedures. Survivors 
with a higher stage disease and survivors who underwent more advanced treatments 
(radiotherapy and chemotherapy) perceived to receive more information 21, 22. It is likely that 
HCPs provide more information to these patients, as the treatment is more complex and can 




undergoing more advanced treatment oft en receive informati on from more than one HCP.
In additi on, cancer survivors who were diagnosed and treated shortly before the start of 
our studies reported that they received more informati on compared to long-term survivors. 
Pati ents who are sti ll under supervision of a HCP might have a clearer picture of the 
informati on they received. The diminishing contacts of pati ents with their HCP aft er the 
completi on of treatment and follow-up could lead to less informati on exchange 25. It is also 
possible that recall bias infl uenced these fi ndings. Pati ents may forget informati on they 
received, because it is oft en complex and emoti onally charged 26. 
Except for melanoma survivors, cancer survivors with fewer comorbid conditi ons reported 
that they received more informati on and were more sati sfi ed with the informati on. One 
explanati on is that pati ents with more comorbid conditi ons have more specifi c informati on 
needs that are possibly not fulfi lled by the informati on provided to them. 
Moreover, the sati sfacti on and helpfulness of the received informati on and the amount of 
writt en informati on received varied between pati ents treated in diff erent hospitals in our 
area. This suggests that some hospitals and/or HCPs gave bett er pati ent-centred informati on 
or additi onal writt en informati on (pati ent informati on leafl ets), which promotes informati on 
recall and understanding.
Socio-demographic factors associated with perceived levels of informati on
An associati on between younger age and more perceived informati on was observed, 
which is consistent with previous research 27. Studies have shown that older pati ents tend 
to ask fewer questi ons during their visit with their HCP, and might therefore receive less 
informati on 28, 29. Older pati ents appear to be less interested in detailed informati on, but 
have a preference for informati on about the most important aspects of their disease and 
treatment 29. The acquisiti on of detailed disease informati on might not be the main goal of 
older pati ents. They oft en leave the provision of details up to their HCP and therefore have a 
more passive role, leading to a doctor-centred interacti on 30. Older pati ents have been found 
to have a greater reliance on informati on provided by their HCP 23. Health care providers 
might also be prejudiced against older pati ents; some HCPs seem to provide older pati ents 
with less informati on 31. Finally, older pati ents may have more diffi  culti es processing and 
remembering medical informati on they receive than younger pati ents 32. We did not fi nd a 
relati on between gender and levels of received informati on, while another study showed 
that women seek more informati on than men 23. 
Also, survivors with a high educati onal level indicated that they received more informati on 
than lower educated survivors. Previous studies have shown that higher educated pati ents 
want as much informati on on prognosis as possible 33, are more likely to seek informati on 
from a greater range of sources (like the internet) 23, obtain more informati on, and show 
more perceived uncertainty 34. For these reasons, higher educated survivors might ask their 
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HCPs for more explanation when the provided information does not yet meet their needs 28. 
It is also possible that HCPs (who are higher educated themselves) are more prone to give 
more information to patients with a similar educational level. Higher educated patients may 
also be better able to understand and remember the information. 
In addition, survivors who have a partner indicated that they received more information 
about their disease. Previous research indicates that accompanied patients are likely 
to benefit from the extra information that their companions remember 35. Discussing 
the received information with their partner may help patients to better understand and 
remember the information they receive from their HCP.  The presence of companions 
has been found to increase patient understanding, involvement in the consultation, and 
decision-making 36. 
Furthermore, another important issue not assessed in our studies, is the role of cross-
cultural differences in information provision. Truth telling and honest disclosure of cancer 
information appears to remain controversial in some southern countries 37-39. Awareness of 
a cancer diagnosis or prognosis is associated with more anxiety and depression, and poorer 
physical, social and emotional HRQoL in those countries 40-42. Future studies should pay 
more attention to the cultural background of the survivor to get insight into differences in 
the perceived levels of received information and satisfaction.
Personality and the perceived level of information received
Cancer survivors with a Type D personality (combined effect of negative affectivity and 
social inhibition) perceived to receive less information. There exists a strong positive 
relation between positive affect and memory 43, while negative affect is associated with 
difficulties to access, obtain, and understand cancer information 44. Individuals scoring high 
on neuroticism, a trait closely related to negative affectivity,  might have a preference for 
information that reassures them 45. Cancer related information might be judged as threatening 
by Type D cancer survivors and will probably be accompanied by the experience of more 
negative emotions. The experience of negative emotions requires energy and can distract 
attention and diminish concentration. The recall of received information could therefore be 
hindered. Also, individuals with a Type D personality tend to use a “disengagement coping 
strategy” which involves avoiding or denying threatening information, seeking distraction 
and distancing oneself from the stressor or related feelings 46, 47. Even if the HCP gives a 
large amount of information, it might be possible that the passive coping style leads to 
inadequate information processing, whereby the relevant information will not be picked up. 
Furthermore, previous studies show that one aspect of social inhibition is feeling insecure 
and less competent when communicating with others 48, 49. These feelings might result in 
more difficulties in communicating with the HCP and a lower willingness to ask questions 




benefi t from behavioural interventi ons that are aimed towards reducing maladapti ve coping 
strategies such as withdrawal 50. Such interventi ons should focus on the empowerment of 
Type D pati ents to increase their health control and to reduce negati ve emoti ons 51. Strategies 
targeti ng HCPs may focus on their facilitati ng behavior, since this has been associated with 
enhanced pati ent sati sfacti on in pati ents less confi dent in communicati ng with their HCP 52.
Informati on provision and pati ent reported outcomes
Health-related quality of life in TC survivors
In the past decade a growing number of studies have documented the high prevalence of 
short-term, long-term and late eff ects of cancer treatment. Up to now, most survivorship 
studies examining PROs have focused on survivors of common cancer types (e.g. breast, 
colorectal and prostate cancer). To date litt le is known about the long-term HRQoL among 
TC survivors. Our systemati c review showed that TC survivors report severe impairments of 
HRQoL aft er treatment (surgery, radioacti ve iodine ablati on, suppressive thyroid hormone 
therapy). However, the benefi ts of radioacti ve iodine ablati on and suppressive hormone 
therapy are of uncertain benefi t for low-risk TC survivors 53-57.These treatments have even 
been associated with harmful eff ects on bone metabolism and the cardiovascular system 58. 
Therefore, it is important to consider a more conservati ve therapeuti c approach for these 
pati ents 59. 
The results of our long-term survivorship study show that thyroid cancer survivors experience 
deteriorated HRQoL compared to a normati ve populati on and TC specifi c problems even 20 
years aft er primary diagnosis. In this study we did not fi nd a direct relati on between primary 
treatment type and long-term HRQoL, although it seems that problems related to surgery 
(voice, throat/mouth and problems with scar) were more oft en present in the fi rst years aft er 
diagnosis. The decreased HRQoL and high levels of fati gue in the fi rst years aft er diagnosis 
could be caused by the high suppressing doses of levothyroxine, resulti ng in subclinical 
hyperthyroidism. When doses of levothyroxine are then lowered to restore euthyroidism, 
symptoms related to thyroid dysregulati on were expected to disappear. However, the 
symptoms remained present. Therefore, a possible explanati on for the decreased HRQoL 
might be that these lower doses of levothyroxine aft er the high suppressing doses might not 
be the opti mal (pre-operati ve) level for the specifi c pati ent and in that case the symptoms 
are a result of the supplemental thyroid hormone treatment 60. Furthermore, long-term 
exposure to excess thyroid hormone can lead to (irreversible) changes of the autonomous 
nervous system, which could not be reversed by restorati on of euthyroidism 61. These 
changes possibly infl uence the well-being of a pati ent and might also be an explanati on for 
the symptoms pati ents experience even long-term aft er diagnosis. More research is needed 
into the exact mechanisms leading to the decreased HRQoL among TC survivors. 
Despite the experience of these symptoms, pati ents are someti mes advised by HCPs that 
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TC is not a serious problem, partly as a consequence of the good prognosis for papillary and 
follicular TC 62. This attitude trivializes the importance of the disease and causes patients to 
feel dismissed as not having a serious disease 63. The THYCA-QoL questionnaire can be of 
value in the evaluation of treatment effects and aftercare of TC survivors. It can make HCPs 
more aware of the potential HRQoL issues TC survivors are dealing with. HCPs can then 
provide TC survivors with information on (long-term) effects of TC and its treatment and 
care options and thereby possibly improve survivors’ HRQoL.
Patient reported outcomes and information provision: chicken or egg causality dilemma
Results of this thesis show positive associations between information provision and patient 
reported outcomes (right part conceptual model; Figure 1). Especially satisfaction with 
the received information was strongly associated with better HRQoL, less anxiety, less 
depression and more positive illness perceptions. Nevertheless these results cannot be 
interpreted univocally, since the causal direction of the associations is not clear.
On the one hand, adequate information provision can lead to improved PROs. The pathways 
through which information can influence PROs might be direct or indirect. A lack of 
information or too much information can directly lead to anxiety, depression or a decreased 
HRQoL. The positive influence of information on PROs appears to be mostly indirect. 
Recent studies identified several indirect pathways through which information can lead 
to better PROs including increased access to care, greater patient knowledge and (shared) 
understanding, higher quality medical decisions, enhanced therapeutic collaboration, 
strengthened social support, patient empowerment, better management of emotions and 
coping, better sense of control, health competence and better symptom management 
and treatment adherence 64-67. With respect to the mental health component, information 
exchange can work therapeutic in that a HCP can express empathy which may help the 
patient to experience more positive emotions (hope, optimism and self-worth) instead of 
negative emotions (fear and anxiety) 68, 69 70.  An example for the physical health component 
could be that information provision about the beneficial effects of physical activity on 
treatment-related symptoms (e.g. fatigue) may help to motivate survivors to increase their 
physical activity levels and consequently diminish their symptoms.
On the other hand, it is possible that patients with higher levels of HRQoL and lower levels 
of distress naturally report higher levels of satisfaction with the received information, 
independent of the information they actually received. Furthermore, high levels of anxiety or 
depression and low HRQoL can inhibit information processing; patients with a poorer mental 
health may have more difficulty to understand the information even when the information 




might indicate to receive more informati on, but sti ll have worse HRQoL and higher levels 
of anxiety and depressive symptoms as a consequence of their disease severity. For this 
group the message of informati on (with regard to prognosis) and the way the informati on is 
provided (empathy) are probably more important than the degree to which the informati on 
meets the informati onal needs 71. However, it is diffi  cult for HCPs to remain opti misti c while 
being honest about a poor prognosis 72.
methodological considerati ons
The studies presented in this thesis are subject to various strengths and limitati ons. Several 
methodological issues have been highlighted in the previous chapters. In this secti on, some 
general limitati ons of the studies will be considered.
study design
The studies included in this thesis, except for chapter 7, had a cross-secti onal design. This 
limits the potenti al for drawing causal inferences. The causati on may be reversed (e.g. 
chicken or the egg dilemma for informati on provision and PROs). Prospecti ve studies can 
give more insight into changes over ti me, but are sti ll limited in establishing causality. In 
additi on, other characteristi cs may confound the relati onship between the dependent and 
independent variables. Although we adjusted our analyses for potenti al confounders, some 
candidate confounders were lacking (e.g. cultural background, health literacy levels and 
biochemical data) and could not be taken into account. 
measurements
Clinical and physiological data and reference groups
Despite the rather clinical focus of the populati on-based Netherlands Cancer Registry, several 
important parameters were not registered for TC pati ents (e.g. extent of surgery, levothyroxine 
dose, applied treatments during follow-up, tumour size). Furthermore, informati on on 
biochemical parameters of TC (TSH levels and serum free T3 and T4) was lacking. Long-term 
assessment of biochemical and treatment parameters in combinati on with the assessment 
of TC specifi c HRQoL (THYCA-QoL) could give more insight into the mechanisms accounti ng 
for the decreased HRQoL among TC survivors. In additi on, comparison of a group of TC 
survivors with a group of pati ents with subclinical hyperthyroidism without cancer could be 
helpful to test whether or not the symptoms survivors experience are TC specifi c or related 
to thyroid dysfuncti oning in general.
Informati on provision: EORTC QLQ-INFO25
The majority of survivors parti cipati ng in our studies can be described as long-term (>5 years 
aft er diagnosis) cancer survivors, who are oft en out of the acute phase of medical treatment 
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and decision making. The EORTC QLQ-INFO25 is not specifically designed for assessment 
of information provision among this group. The questionnaire has been validated among 
newly diagnosed cancer patients receiving primary treatment and patients with recurrent/
metastatic disease starting a second line of treatment 1. The mean time since diagnosis was 
3 - 5 years in our studies, which could influence the recall effect of information received. 
Although the Cronbach’s alpha of the scales were good in all of our studies, further research 
is needed to test the psychometric properties of this questionnaire among long-term cancer 
survivors. 
Furthermore, the EORTC QLQ-INFO25 only assesses the information patients indicated to 
have received (self-report). Notwithstanding the fact that the perception of the patient is 
most important, comparing data on actual information provision with the subjective data 
from our questionnaire would be of additional value. Patients often forget a substantial 
amount of the information given because it is complex and emotionally charged. 
In addition, the EORTC QLQ-INFO25 does not measure who provided the information, 
and when the information was provided exactly. It would be interesting to assess which 
aspects of information patients receive from their different HCPs (i.e. radiation oncologist, 
medical oncologist, oncology nurse, general practitioner), at what point during their disease 
trajectory they receive the information, and whether these aspects are associated with 
usefulness of and satisfaction with the information received. 
Finally, since the EORTC QLQ-INFO25 is not a measure of clinical outcomes, it was not 
possible to determine clinical meaningful differences. Differences in the perceived receipt 
of information might be statistical significant yet considered as unimportant. In this respect, 
it would be interesting to study how patients define an important improvement/worsening 
of information provision. With this information HCPs could better interpret the importance 
of our research findings. 
future directions
Cancer survivorship studies show that many survivors, including survivors of rare tumours, 
like thyroid cancer, face continuing physical and psychosocial problems long after completion 
of primary treatment. Achieving and maintaining optimal well-being is an important 
objective of current cancer treatment and of cancer rehabilitation and aftercare. One of the 
most important aspects of cancer care is the provision of adequate information. Survivors 
who are satisfied with the received information report better PROs compared to survivors 
who are dissatisfied. However, several areas of information provision were experienced as 
insufficient. Therefore, future research should focus on strategies to improve the information 
provision. In this section we will discuss some strategies to improve information provision, 




unraveling the informati on needs of cancer survivors
The percepti ons of HCPs about pati ents’ needs should become in agreement with the actual 
needs of the pati ent. The best way to unravel the informati on needs of a pati ent is to consult 
the pati ent, but this is rarely done and research is limited 73. Also, a neglected aspect of a 
consultati on is checking the understanding of the pati ent 74.  It is necessary to regularly 
check what the pati ent has understood 75 and whether the informati on was helpful  76. When 
necessary, the HCP must repeat the informati on several ti mes, both between and within 
consultati ons 77. Cancer pati ents may not always be able to retain and process informati on 
because they may be emoti onally overwhelmed 78 79, impaired in their cogniti ve capability, or 
deny their illness  as a coping strategy to retain hope 80, 81. Therefore, the ti ming and the way 
informati on is provided are important factors to take into account. Furthermore, awareness 
of the background characteristi cs associated with the perceived receipt of informati on could 
help HCPs to provide more pati ent-centered informati on.
decision aid for TC survivors
TC survivors perceive to receive confl icti ng recommendati ons on radioacti ve iodine 
treatment from their HCP 63.  Informati on on rati onale, risks and uncertainti es relati ng to 
this treatment are perceived as insuffi  cient. Most of the ti mes no treatment choice was 
off ered and pati ents felt the treatment was imposed on them.  Since there is uncertainty 
about the eff ecti veness of radioacti ve iodine treatment and TSH suppression for low-risk TC 
pati ents, informed decision making and pati ent involvement should be improved. A decision 
aid intended to be used as an adjunct to individualized HCP counseling proved to increase 
medical knowledge and informed medical decision making in pati ents with early-stage 
papillary TC who were considering adjuvant radioiodine treatment 82, 83 84. Other studies 
showed that the use of decision aids can enhance pati ent sati sfacti on and understanding 
without increasing anxiety, even in pati ents with advanced cancer 85 86. 
survivorship Care Plan
A recent communicati on strategy devised to address the informati on needs of cancer 
survivors is a Survivorship Care Plan (SCP) 27, 87. Previous studies have shown that providing 
pati ents with writt en informati on increases their recall, knowledge and sati sfacti on with 
informati on 88, 89, although general writt en informati on is oft en not empowering.  A SCP 
provides cancer survivors with a summary of their course of treatment as a formal document 
87.  Essenti al in such a SCP is detailed informati on provision about diagnosis and treatment 
of cancer, possible long-term and late eff ects and management thereof, lifestyle and cancer 
surveillance recommendati ons, and available resources 90. The SCP is expected to be an 
empowering and enabling device 91, by facilitati ng bett er understanding and self-care by the 
pati ent. However, evidence concerning the eff ecti vity of the SCP to improve PROs is lacking 92.
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feedback of PrOs from patient to HCP
The most frequently reported unmet need among cancer survivors was information about 
long-term effects and aftercare. More than 60% of survivors report that their HCP lacked 
complete knowledge of how their HRQoL was affected by cancer and its treatment 93. A 
way to focus on key topics during a consultation is feedback of PROs. Feedback on HRQoL 
information to HCPs has the potential to help detect unmet needs and symptoms leading 
to better control and monitoring of such issues, serve as a guide for HCPs to discuss HRQoL 
issues, act as patients’ voice, and facilitate individualized information provision and care 
94.  Research shows that PRO feedback to HCPs was effective in initiating discussion of 
problematic HRQoL and was able to focus the conversation on topics relevant for the patient 
without extending the visit 95. However, another study showed that PRO feedback alone 
does not overcome the existing barriers that prevent HCPs from discussing HRQoL issues 
with their patients 94.
Future studies should investigate whether feedback of PROs directly to the patient is more 
effective in initiating a discussion than feedback of PROs to the HCP alone. One way to 
give PRO feedback directly to the patient is by a web-based intervention. An increasing 
number of patients participating in our PRO studies fill in the questionnaires online 96. When 
the raw online questionnaire data could be translated into easy interpretable graphical 
representations, this will give the patient insight into their own well-being compared to 
other cancer patients or a normative population. This PRO information may empower 
patients to initiate discussions about these topics with their HCP. The effectiveness of a 
web-based intervention, aimed at providing feedback on PROs directly to the patient, in 
increasing patient satisfaction with information and addressing unmet informational needs 
should be explored.
Concluding remarks
The number of cancer survivors is rapidly increasing in the Western world. The increasing 
incidence rates of TC can partially be explained by the improved diagnostics, possibly leading 
to overdiagnosis and accompanying overtreatment. Cancer survivors often experience a 
diminished HRQoL and higher levels of anxiety and depression as a result of cancer and 
its treatment. Recognition and monitoring (e.g. with the THYCA-QoL for TC survivors) of 
the specific health problems survivors’ are dealing with is important to provide optimal 
supportive care. Another important aspect of survivorship care is information provision. 
Satisfaction with received information is related to better PROs. However, several areas 
of information provision are experienced as insufficient. The identification of specific 
information needs could facilitate a more patient-tailored approach of informing patients. 
Besides, HCPs need to be aware of the clinical and socio-demographic factors associated with 




approach of informati on provision may contribute to improved sati sfacti on levels and PROs 
in cancer survivors. Strategies to improve informati on provision to cancer survivors, like 
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nederlandse samenVaTTIng (summarY In duTCH)
Inleiding
Toenemend aantal (ex-)kankerpatiënten
Door de vergrijzing van de bevolking en het dalende risico om aan kanker te overlijden, 
dankzij steeds vroegere opsporing en verbeterde behandeling, neemt het aantal (ex-)
kankerpatiënten fors toe: van 600.000 (ex-)patiënten in 2010 tot ongeveer 915.000 in 2020. 
Er wordt in toenemende mate onderzoek gedaan naar de late en langdurige effecten van 
kanker en de behandeling op het psychosociaal welbevinden van (ex-)kankerpatiënten. 
Studies tonen aan dat sommige (ex-)kankerpatiënten tot wel 15 jaar na diagnose nog een 
verminderde kwaliteit van leven hebben in vergelijking met een Nederlandse normpopulatie. 
Zorg voor (ex-)kankerpatiënten
Informatievoorziening is een van de belangrijkste aspecten van de ondersteunende zorg 
voor (ex-)kankerpatiënten. Op basis van goede informatie kan een patiënt beter beslissingen 
nemen over de behandeling, worden de behandelprocedures beter opgevolgd en heeft de 
patiënt het idee meer controle te hebben over de situatie. Uit eerder onderzoek blijkt dat 
(ex-)patiënten vaak niet in hun informatiebehoefte worden voorzien en daardoor ontevreden 
kunnen zijn over de hoeveelheid ontvangen informatie. Informatie met betrekking tot 
de ziekte en behandeling is mogelijk van invloed op andere patiënt gerapporteerde 
uitkomstmaten zoals de kwaliteit van leven van (ex-)kankerpatiënten. 
Schildklierkanker
Onderzoek naar het psychosociaal welbevinden heeft zich tot nu toe voornamelijk gericht 
op (ex-)kankerpatiënten met veelvoorkomende tumoren zoals prostaatkanker, borstkanker, 
longkanker en dikkedarmkanker. Er is nog relatief weinig bekend over de impact van kanker 
en de behandeling op de lange termijn kwaliteit van leven van (ex-)patiënten met minder 
vaak voorkomende tumoren zoals schildklierkanker. Elk jaar worden er 500-600 patiënten 
in Nederland gediagnosticeerd met schildklierkanker. Door de toenemende incidentie en 
goede prognose van de papillaire en folliculaire tumoren (5-jaarsoverleving >90%) neemt 
het aantal (ex-)schildklierkankerpatiënten snel toe. 
De primaire behandeling van schildklierkanker bestaat meestal uit het (geheel of gedeeltelijk) 
operatief verwijderen van de schildklier. Patiënten krijgen na een totale verwijdering van 
de schildklier een behandeling met radioactief jodium. Wanneer de schildklier volledig 
verwijderd is worden er geen schildklierhormonen meer aangemaakt. Daarom moeten (ex-)
patiënten de rest van hun leven schildklierhormonen slikken, in de eerste jaren vaak met 
een hoge dosis. Schildklierkanker kan na de behandeling terugkomen. Dit betekent dat (ex-)
schildklierkankerpatiënten ook regelmatig gecontroleerd moeten worden. Gezien de goede 
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prognose en de agressieve behandeling is het van groot belang te weten wat de effecten van 
schildklierkanker en de behandeling ervan zijn op de (lange termijn) kwaliteit van leven. Met 
dit inzicht kan de (na)zorg aangepast worden aan de behoeftes van (ex-)patiënten.
doel van dit proefschrift
Het doel van dit proefschrift was tweeledig. In deel I is getracht een beeld te krijgen van 
de hoeveelheid ontvangen informatie en tevredenheid daarmee bij verschillende groepen 
(ex-)kankerpatiënten in verschillende fasen van hun ziekte. De invloed van de hoeveelheid 
ontvangen informatie en de tevredenheid daarmee is vervolgens gerelateerd aan kwaliteit 
van leven, niveaus van angst en depressie. In deel II is de focus gelegd op de (lange termijn) 
kwaliteit van leven van (ex-)schildklierkankerpatiënten.
Voornaamste bevindingen van het proefschrift
Deel I: Informatievoorziening en patiënt gerapporteerde uitkomstmaten
In hoofdstuk 2 werd de hoeveelheid ontvangen informatie en de tevredenheid daarmee 
onder (ex-)melanoompatiënten in kaart gebracht. Van de (ex-)melanoompatiënten gaf 9 tot 
37 procent aan geen informatie te hebben ontvangen over verschillende aspecten van de 
ziekte en diagnose, terwijl 38 procent van deze patiënten rapporteerde geen informatie te 
hebben gehad over de behandeling. Met betrekking tot de nazorg en follow-up gaf 84 tot 
94 procent van de patiënten aan geen informatie te hebben gehad. Meer dan de helft van 
de (ex-)melanoompatiënten (61 procent) was niet tevreden met de hoeveelheid ontvangen 
informatie. Daarnaast gaf een kwart van de patiënten aan graag meer informatie te willen 
ontvangen van hun behandelend arts. 
Verder liet dit onderzoek ook zien dat patiënten met een hoog ziektestadium, hoog 
opleidingsniveau en jonge leeftijd bij diagnose aangaven meer informatie te hebben 
ontvangen van hun arts in vergelijking met patiënten met een laag ziektestadium, lager 
opleidingsniveau en hogere leeftijd ten tijde van de diagnose. Verder waren hoger opgeleiden 
en patiënten die gebruik maakten van het internet meer tevreden met de ontvangen 
informatie ten opzichte van lager opgeleiden en patiënten die geen gebruik maakten van 
internet. Een ander belangrijk punt was dat de tevredenheid over de ontvangen informatie 
sterk verschilde per ziekenhuis van diagnose en behandeling.
Naast relaties tussen informatievoorziening en klinische en demografische factoren, kunnen 
psychologische factoren zoals persoonlijkheid ook gerelateerd zijn aan de hoeveelheid 
ontvangen informatie en de tevredenheid daarmee. In hoofdstuk 3 werd daarom de 
relatie onderzocht tussen Type D persoonlijkheid en informatievoorziening bij 3080 (ex-)
kankerpatiënten. Iemand met een Type D persoonlijkheid heeft een combinatie van twee 
persoonlijkheidskenmerken: negatieve affectiviteit (de neiging om negatieve emoties te 
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ervaren) en sociale inhibitie (de neiging om jezelf of je emoties niet te uiten in het bijzijn van 
anderen). Patiënten met een Type D persoonlijkheid gaven aan minder informatie te hebben 
ontvangen, minder tevreden te zijn met de ontvangen informatie en de informatie ook 
minder bruikbaar te vinden in vergelijking met (ex-)patiënten zonder Type D persoonlijkheid. 
Deze resultaten werden ook gevonden na correctie voor klinische en socio-demografische 
factoren. 
In hoofdstuk 4 werd er door middel van systematisch literatuuronderzoek gekeken naar 
de relatie tussen enerzijds informatievoorziening aan patiënten en anderzijds kwaliteit van 
leven, niveaus van angst en depressie onder (ex-)kankerpatiënten. Het literatuuronderzoek 
werd uitgevoerd op basis van wetenschappelijke publicaties die tot februari 2010 
verschenen op PubMed. Vijfentwintig artikelen, alle geschreven tussen 1996 en 2009, die 
voldeden aan de vooraf gedefinieerde inclusiecriteria, werden beoordeeld op basis van 
een lijst met kwaliteitscriteria. Daaruit kwam naar voren dat tevreden patiënten, patiënten 
die zich voldaan voelden ten aanzien van hun informatievoorziening, en patiënten die 
geen belemmeringen hadden bij het verzamelen van informatie over het algemeen een 
betere kwaliteit van leven rapporteren en minder last hebben van angstige en depressieve 
gevoelens. Van de acht studies die gericht waren op interventies ter verbetering van de 
informatieverstrekking aan patiënten, bleek slechts één studie een positief verband te 
vinden tussen informatievoorziening en kwaliteit van leven. 
Uit eerder onderzoek is gebleken dat de ideeën en gedachten die patiënten hebben over hun 
ziekte (ziekteperceptie) sterk samenhangen met hun ervaren kwaliteit van leven. Mogelijk 
is er ook een relatie tussen ziekteperceptie en informatievoorziening, dit werd onderzocht 
in hoofdstuk 5. De resultaten lieten zien dat onder 3080 (ex-)patiënten (baarmoederkanker, 
dikkedarmkanker, lymfeklierkanker of multipel myeloom) de perceptie meer informatie 
over de ziekte te hebben ontvangen gerelateerd was aan een positievere ziekteperceptie 
van de kankerpatiënt (meer controle en beter begrip). Echter, de perceptie meer informatie 
te hebben ontvangen over nazorg was gerelateerd aan negatievere ziektepercepties (meer 
consequenties en symptomen toegeschreven aan de ziekte, ziekte van langere duur, minder 
controle van de behandeling, minder begrip en sterkere emotionele reactie op ziekte). 
(Ex-)kankerpatiënten die tevreden waren over de informatie die zij kregen, rapporteerden 
minder klachten en negatieve gevolgen die ze toeschreven aan kanker, rapporteerden het 
gevoel te hebben dat de behandeling controle had over de ziekte en dat de kanker van 
kortere duur was, gaven aan minder emotionele problemen en minder zorgen te hebben 
naar aanleiding van de ziekte en hadden een beter begrip van hun ziekte in vergelijking met 
ontevreden (ex-)kankerpatiënten.
In hoofdstuk 6 werden de relaties onderzocht tussen informatievoorziening en patiënt 
gerapporteerde uitkomstmaten (ziekteperceptie, kwaliteit van leven, angst en depressie) 
onder patiënten met uitgezaaide dikkedarmkanker. Uit deze studie bleek dat de 
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informatievoorziening aan deze patiënten vergelijkbaar was met dikkedarmkankerpatiënten 
zonder uitzaaiingen. Patiënten met gemetastaseerde ziekte gaven echter wel aan meer 
informatie te hebben ontvangen over hun behandeling en meer informatie te willen hebben 
over het ziekteverloop en nazorg. Slechts 60% van de patiënten met uitzaaiingen was 
tevreden met de hoeveelheid ontvangen informatie. Het ontvangen van meer informatie 
over de ziekte en nazorg hing samen met slechter functioneren, meer depressieve klachten 
en minder begrip van de ziekte. Terwijl het krijgen van meer behandelinformatie samenhing 
met minder depressieve klachten en een beter begrip van de ziekte. Tevredenheid met de 
hoeveelheid ontvangen informatie was niet gerelateerd aan andere patiënt gerapporteerde 
uitkomstmaten.
De meeste studies beschreven in het literatuuronderzoek van hoofdstuk 4 hadden een cross-
sectioneel studie design. Daarom werd de relatie tussen informatievoorziening en kwaliteit 
van leven, gevoelens van angst en depressie in hoofdstuk 7 longitudinaal onderzocht (twee 
meetmomenten met een tussenliggende periode van twee jaar) onder lymfoom en multipel 
myeloom patiënten. De hoeveelheid ontvangen informatie verminderde licht over tijd (en 
het meest onder korte termijn overlevenden), terwijl kwaliteit van leven en depressieve 
of angstige gevoelens gelijk bleven over de twee meetmomenten. Tevredenheid met de 
hoeveelheid ontvangen informatie op het eerste meetmoment voorspelde kwaliteit van 
leven twee jaar later, echter na correctie voor kwaliteit van leven op het eerste meetmoment 
verdween de gevonden relatie grotendeels. Tevredenheid met de hoeveelheid ontvangen 
informatie op beide meetmomenten was gerelateerd aan betere mentale kwaliteit van 
leven in vergelijking met veranderende tevredenheid of ontevredenheid met de informatie.
Deel II: (Ex-)schildklierkankerpatiënten: een onderbelichte groep
Omdat er nog relatief weinig bekend was over patiënt gerapporteerde uitkomstmaten 
onder (ex-)schildklierkankerpatiënten, lag de focus van deel II van dit proefschrift op de 
(lange termijn) kwaliteit van leven van deze (ex-)patiëntgroep. In hoofdstuk 8 werden trends 
in incidentie, prognose en sterfte van schildklierkanker tussen 1989-2009 in Nederland 
beschreven. Vanaf 1989 is de incidentie van schildklierkanker significant gestegen in 
Nederland, terwijl de sterfte is afgenomen. De prognose (5-jaars relatieve overleving) 
is gelijk gebleven behalve voor (verder) gevorderde tumoren waarvan de incidentie is 
afgenomen. Door de toegenomen incidentie en goede prognose van gedifferentieerd 
schildkliercarcinoom, neemt de prevalentie ook toe. De resultaten van dit hoofdstuk waren 
reden om de lange termijn kwaliteit van leven van (ex-)schildklierkankerpatiënten verder te 
onderzoeken.
In hoofdstuk 9 werd de literatuur met betrekking tot de kwaliteit van leven van 
schildklierkankerpatiënten systematisch doorzocht. Het literatuuronderzoek toonde aan dat 
het ondergaan van een operatie (gehele of gedeeltelijke verwijdering van de schildklier) een 
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direct korte termijn negatief effect heeft op de kwaliteit van leven. Naarmate de tijd verstrijkt, 
keert de kwaliteit van leven weer terug naar het niveau van voor de operatie. Het slikken 
van schildklierhormoon (levothyroxine) kan leiden tot hyperthyreoïdie. Wanneer de patiënt 
moet stoppen met het slikken van schildklierhormoon voor radioactieve jodiumablatie of 
een nacontrole, leidt dit tot hypothyreoïdie, waardoor de kwaliteit van leven ernstig wordt 
aangetast. Het gebruik van recombinant humaan schildklierstimulerend hormoon (rhTSH) 
zorgt ervoor dat een patiënt door kan gaan met het slikken van schildklierhormoon, waardoor 
de kwaliteit van leven gehandhaafd blijft. Studies die hebben gekeken naar de kwaliteit 
van leven van de lange termijn overlevenden van schildklierkanker lieten tegenstrijdige 
resultaten zien, waardoor er over deze groep geen sterke conclusies getrokken konden 
worden. Het voornaamste probleem van de bestaande studies was het ontbreken van een 
valide vragenlijst om de schildklierkanker specifieke kwaliteit van leven te meten. Dat heeft 
er toe geleid dat wij een schildklierkanker specifieke kwaliteit van leven lijst (THYCA-QoL) 
hebben ontwikkeld, beschreven in hoofdstuk 10. Relevante klachten werden geïdentificeerd 
door middel van literatuuronderzoek en een focusgroep. De lijst met klachten die daaruit 
naar voren kwam werd voorgelegd aan 6 artsen en 18 patiënten, die de klachten vervolgens 
beoordeelden op relevantie en de 25 belangrijkste klachten benoemden. Dit resulteerde 
in een lijst van 30 klachten die vervolgens in vragenformaat werden omgezet volgens de 
regels van de European Organisation for Research and Treatment of Cancer – Quality of Life 
Group. Het voortesten van de lijst onder 306 (ex-)schildklierkankerpatiënten leidde tot een 
uiteindelijke vragenlijst van 24 items en zeven conceptuele schalen (neuromusculaire, stem, 
concentratie, sympathische, keel/mond, psychologische en sensorische problemen).
De vragenlijst werd vervolgens gebruikt om de kwaliteit van leven van (ex-)
schildklierkankerpatiënten in kaart te brengen (hoofdstuk 11). De kwaliteit van leven van 
patiënten die 2-20 jaar geleden de diagnose schildklierkanker kregen, bleek lager te zijn 
dan die van de gemiddelde Nederlander met dezelfde leeftijd. Zowel hun lichamelijke als 
mentale gezondheid bleek slechter. Naast een lagere kwaliteit van leven rapporteerden (ex-)
schildklierkankerpatiënten ook meer klachten op het gebied van vermoeidheid, slapeloosheid, 
kortademigheid, gebrek aan eetlust en stofwisselingsklachten. Daarnaast rapporteerden 
(ex-)schildklierkankerpatiënten ook lange tijd na de primaire behandeling (>10 jaar) nog 
medische klachten zoals concentratieproblemen, hormonale problemen, psychologische 
problemen en plotseling invallende vermoeidheid. Vooral deze kankerspecifieke klachten 
verklaarden voor een groot deel (41-58%) de verminderde kwaliteit van leven van (ex-)
schildklierkankerpatiënten in vergelijking met een controlegroep zonder kanker. 
In het voorgaande hoofdstuk kwam vermoeidheid naar boven als een veelvoorkomende klacht 
onder (ex-)schildklierkankerpatiënten. Specifiek onderzoek naar de vermoeidheidsniveaus 
van (ex-)schildklierkankerpatiënten ontbrak, daarom werd er in hoofdstuk 12 onderzocht 
wat de prevalentie van vermoeidheid is onder korte en lange termijn overlevenden van 
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schildklierkanker. De resultaten lieten zien dat 40% van de (ex-)schildklierkankerpati ënten 
hoge niveaus van vermoeidheid rapporteren. Zowel korte als lange termijn overlevenden 
rapporteerden hogere vermoeidheidsniveaus in vergelijking met de gemiddelde Nederlander 
met dezelfde leeft ijd en geslacht. De verschillen waren alleen klinisch relevant voor lange 
termijn overlevenden in vergelijking met de normpopulati e. Schildklierkanker specifi eke 
klachten (neuromusculaire, concentrati e en psychologische klachten) en mentale gezondheid 
(angsti ge/depressieve klachten) waren het sterkst gerelateerd met vermoeidheid.
Concluderende opmerkingen
Het aantal (ex-)kankerpati ënten sti jgt snel in de Westerse wereld. De toenemende incidenti e 
van schildklierkanker kan deels worden toegeschreven aan verbeterde diagnosti ek, mogelijk 
leidend tot overdiagnose en samengaande overbehandeling. 
(Ex-)kankerpati ënten ervaren vaak een verminderde kwaliteit van leven en hogere niveaus 
van angst en depressie als een gevolg van kanker en de behandeling. Herkenning en 
monitoren van de specifi eke klachten waar (ex-)kankerpati ënten mee te maken krijgen 
(bijvoorbeeld door middel van afname van ziektespecifi eke vragenlijsten) is belangrijk 
om opti male nazorg te kunnen bieden. Een ander belangrijk onderdeel van zorg voor 
overlevenden van kanker is informati evoorziening. Tevredenheid met de hoeveelheid 
ontvangen informati e is gerelateerd aan betere pati ënt gerapporteerde uitkomstmaten. 
Echter, verschillende aspecten van de informati evoorziening worden nu nog als onvoldoende 
ervaren. Het achterhalen van de specifi eke informati ebehoeft es van de (ex-)pati ënt kan 
bijdragen aan een pati ëntgerichte benadering. Daarnaast moeten zorgverleners zich 
bewust zijn van de klinische en socio-demografi sche factoren die samenhangen met de 
informati ebehoeft e en de percepti e van de hoeveelheid ontvangen informati e. Een meer 
pati ëntgerichte benadering zal mogelijk bijdragen aan verbetering van de tevredenheid van 
de pati ent en andere meer positi eve pati ënt gerapporteerde uitkomstmaten. De eff ecti viteit 
van strategieën om de informati evoorziening te verbeteren, zoals individuele zorgplannen 
en/of terugkoppeling van pati ënt gerapporteerde uitkomstmaten aan de pati ënten zelf (in 
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